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SUMMARY 
A number of proteins have been identified which are pathologically and/or genetically associated with 
both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). A hexanucleotide repeat 
expansion in the non-coding region of the C9ORF72 gene is the largest genetic factor associated with 
FTD and ALS. Additionally, pathological inclusions of the TDP-43 protein are found in brains of 
approximately 50% of FTD cases and 90% of ALS cases. However, the normal function of these two 
proteins and how this relates to the degeneration of neurons in disease are not yet well understood. 
Accumulating evidence suggests that both proteins may have involvement with the neuronal 
cytoskeleton. The cytoskeleton is of particular interest in FTD/ALS due to significant axon pathology 
and loss observed in post mortem cases. It is known that the cytoskeleton is often a key effector to 
changes in axon integrity in many neurodegenerative diseases. This thesis examined the normal 
functions of TDP-43 and C9ORF72, and their links with the cytoskeleton through use of mouse 
primary cell culture, histological analysis of intact mouse brain, and viral-mediated expression of 
proteins of interest in a retina model in the mouse.  
TDP-43 is a predominantly nuclear protein, with much known about its nuclear roles in DNA and 
RNA binding, and regulation of transcription and translation. Evidence suggests that TDP-43 is also 
important for neurite outgrowth, remodelling and can regulate many components of the neuronal 
cytoskeleton. The effects of overexpression of TDP-43 in primary cortical neurons were examined and 
demonstrated distinct alterations to actin-associated cellular processes including neurite branching and 
growth cone morphology, as well as down-regulation of actin-binding proteins in the proteome of these 
cells. To examine the effect of pathogenic alterations to TDP-43 in vivo AAV2  virus was used to 
mediate the expression of wildtype human TDP-43 and human TDP-43 with a mutation to the nuclear 
localisation signal (NLS) in mouse retinal ganglion cells, through intraocular injection of the virus. 
These changes induced axon pathology in the optic nerve, with indications of perturbed axonal 
transport due to presence of organelle accumulation.  
 x
Several mechanisms for how the non-coding repeat expansion in C9ORF72 may lead to disease have 
been described, however little is known about the normal function and the expression pattern of the 
C9ORF72 protein. This thesis characterized the expression pattern and cellular localisation of the three 
reported mouse isoforms of C9ORF72 in cell culture and in vivo, and demonstrated that C9ORF72 
was present in synaptosomes and within actin-rich structures of neurons.  
In summary, these results indicate that both C9ORF72 and TDP-43 may have links to the neuronal 
cytoskeleton, and in particular the actin cytoskeleton. Modulation of the neuronal cytoskeleton is a 
compelling target for providing therapeutic protection to vulnerable cellular components, such as the 
axon. Studies such as those described in this thesis may provide insight for whether TDP-43- and 
C9ORF72-related FTD/ALS are candidates for these types of interventions.    
 xi
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1 LITERATURE REVIEW 
1.1 FRONTOTEMPORAL DEMENTIA 
1.1.1 Background  
The frontotemporal dementias (FTD) are a group of early-onset diseases that cause dementia 
characterised by progressive changes to behaviour and/or language. Frontotemporal lobar dementia 
(FTLD) is the term routinely used to describe the pathological conditions that clinically present as 
FTD. FTD has a mean age of onset of 52.8 years and, after Alzheimer’s disease (AD), is the second 
most common form of early-onset dementia with a prevalence of 15-22/100,00 (Onyike & Diehl-
Schmid, 2013). FTD is fatal, with death generally occurring within 6 to 11 years after symptom onset 
(De Conti, Borroni, & Baralle, 2017). There are currently no effective treatments (Onyike & Diehl-
Schmid, 2013). Gross examination of post mortem cases of FTD shows atrophy of the frontal and 
temporal lobes, as well as other brain areas depending on the subtype of disease. At the microscopic 
level, there is neuronal loss, protein aggregation, as well as an increase in the number of astrocytes 
(astrocytosis) within atrophied areas of the brain (Sieben et al., 2012). In individual cases, the observed 
pattern of atrophy in FTLD is variable, and clinical symptoms of disease correlate with these patterns 
(Sieben et al., 2012). 
1.2 CLINICAL SUBTYPES OF FTD 
Several different subtypes of FTD have now been described in terms of their key clinical features. 
These include behaviour (behavioural variant FTD, bvFTD), language (semantic variant primary 
progressive aphasia, svPPA; progressive non-fluent aphasia, PNFA), movement disorders (progressive 
supranuclear palsy, PSP; corticobasal syndrome, CBS), neuronal intermediate filament inclusion 
disease (NIFID) and FTD with amyotrophic lateral sclerosis (FTD-ALS, (Roberson, 2012; Sieben et 
al., 2012). 
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1.3 FTD AND ALS AS A CONTINUUM 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND) and 
involves impairment of both upper and lower motor neurons. It usually results in death within three to 
five years of diagnosis, in most cases due to respiratory failure. FTD and ALS are now considered to 
be at opposite ends of a disease spectrum (Burrell et al., 2016). Although physical symptoms of the 
two disorders may differ, many clinical, genetic and pathological characteristics overlap. ALS and 
FTD frequently occur in the same family, with many people living with ALS having impairments in 
frontotemporal functions such as cognition and behaviour, and conversely a large proportion of FTD 
patients with motor neuron dysfunction (Lomen-Hoerth, Anderson, & Miller, 2002; Phukan, Pender, 
& Hardiman, 2007). The close relationship between the disorders was first strengthened when the 
transactive response DNA-binding protein 43 (TDP-43), was determined to be the main protein 
component of the pathology of both ALS and FTD (Neumann et al., 2006). In 2011, the association 
between these two diseases was again confirmed when the repeat expansion of the hexanucleotide 
sequence, GGGGCC, in the C9orf72 gene, was found to be the most common cause of familial ALS 
(37%) and FTD (21%), as well as being associated with sporadic ALS (6%) and FTD (6%; DeJesus-
Hernandez et al., 2011; Rademakers, Neumann, & Mackenzie, 2012; Renton et al., 2011). The 
identified similarities between ALS and FTD have contributed greatly to understanding the 
pathological and genetic mechanisms by which the two disorders operate. 
 
1.4 PATHOLOGICAL SUBTYPES OF FTLD 
Frontotemporal lobar degeneration is similar to many other neurodegenerative diseases in that it is 
characterised by the presence of abnormal intracellular protein aggregates in surviving cells. These 
may consist of genetically mutated protein, but in many disease subtypes, the main aggregated species 
is not the mutant gene product. The pathological inclusions associated with specific gene mutations 
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are illustrated in Figure. 1.1. The accumulations of protein within these aggregates have been used to 
further subcategorise FTLD (Figure 1.1 B). The two major pathological subtypes of FTLD, FTLD-tau 
and FTLD-TDP-43, will be reviewed here. 
1.4.1 FTLD-Tau 
Tau (encoded by the MAPT gene) is a member of the microtubule associated protein (MAP) family 
and stabilises microtubules through tubulin binding (Hirokawa, 1994). FTLD-tau is characterised by 
both neuronal and glial inclusions comprised of hyperphosphorylated tau protein that are immuno-
negative for ubiquitin. Tau-positive inclusions are observed in a range of neurodegenerative diseases, 
collectively described as tauopathies, of which several present as FTD. These include Pick’s disease, 
PSP, CBS, globular glial tauopathy (GGT), and FTD caused by MAPT mutations which accounts for 
approximately 5 to 20% of familial FTD (Rademakers, Cruts, van Broeckhoven, 2004). In these 
conditions, tau has varying degrees of phosphorylation, and different isoforms of tau are present, which 
likely explains the variations in inclusion morphology and cell types affected.  
1.4.2 FTLD-TDP 
TDP-43 protein is encoded by the TARDBP gene and is an RNA binding protein involved in a range 
of RNA processing such as transcription, pre-mRNA splicing, stability, transport and translation 
(Buratti, 2001; 2008). Originally, cases of FTD which were immuno-negative for tau, but had 
ubiquitin-positive inclusions, were termed FTLD-U (Lipton, White, & Bigio, 2004). However, TDP-
43 was later identified as the main protein present in inclusions of most FTLD-U cases (Neumann et 
al., 2006) and this subset was renamed ‘FTLD-TDP’. In FTD, TDP-43 pathology is present in 40 to 
50% of cases (Chare et al., 2014), but in cortical neurons of FTLD-TDP cases, nuclear staining of 
TDP-43 is frequently reduced. 
	A 
B 
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Figure 1.1 Classifications of FTLD (A) FTLD can be classified into disctinct neuropathologic 
subtypes based on proteins found within inclusions: FTLD-Tau, FTLD-TDP, FTLD-FUS, and FTLD-
UPS. (B) The neuropathological subtypes based on proteins within cellular inclusions (colour) and 
known genetic causes (black outlines) of behavioural variant frontotemporal dementia (bvFTD), in 
proportion to frequency. Figure adapted from Halliday et al. (2012) and Roberson (2012)  
 
 
 
 
 
 
 
 
Chapter 1 – Introduction  
    
 
2
TDP-43 and other RNA binding proteins, such as fused in sarcoma (FUS), which is also implicated in 
FTD/ALS, contain a nuclear localisation sequence (NLS) which binds to a transportin receptor to 
regulate transport in and out of the nucleus (Mihevc, Baralle, Buratti, & Rogelj, 2016). In disease, a 
common feature of TDP-43 pathology is mislocalisation of the protein from the nucleus to the 
cytoplasm. In the cytoplasm it becomes abnormally phosphorylated, ubiquitinated and insoluble, and 
can be cleaved to form C-terminal fragments (CTF) (Arai et al., 2006; Neumann et al., 2009; Neumann 
et al., 2006). It is currently unclear if these cytoplasmic protein aggregates are intrinsically toxic or 
whether they have a protective role in the cell by sequestering potential toxic protein species. 
In FTLD-TDP, inclusions are most commonly observed in neurons of the frontotemporal neocortex 
and dentate granule cells of hippocampus, although pathology can also be found more subcortically. 
FTLD-TDP is characterised by neuronal cytoplasmic and intranuclear inclusions, as well as dystrophic 
neurites, which are immunopositive for TDP-43, ubiquitin and p62 (Irwin et al., 2015). Other TDP-43 
pathology includes cytoplasmic inclusions in oligodendrocytes, diffuse neuronal cytoplasmic staining 
inclusions (or pre-inclusions), and wispy neurites (Cairns et al., 2007; Hatanpaa et al., 2008; Neumann 
et al., 2007). FTLD-TDP can be further subcategorised (types A to D, reviewed in (Burrell et al., 
2016)) depending on the location and morphology of inclusions. 
 
1.4.2.1 Familial FTLD-TDP  
In comparison to FTLD-tau, which involves mutations to a single gene (MAPT), TDP-43 pathology in 
FTLD-TDP can be driven by mutations in a range of genes. The hexanucleotide repeat expansion of 
the C9ORF72 gene is associated with brain TDP-43 pathology (FTLD-TDP), most commonly type B, 
although other TDP-43 pathology patterns have emerged (Mackenzie & Neumann, 2016). Mutations 
of GRN, the gene encoding progranulin, are associated with 5 to 20% of familial FTD, and 1 to 5% of 
sporadic FTD (I. Gijselinck et al., 2008) but are not associated with ALS. Progranulin mutations cause 
TDP-43 pathology (Cairns et al., 2007), most commonly presenting as neuronal cytoplasmic and 
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intranuclear inclusions (FTLD-TDP type A). Finally, a small number of cases of FTD are caused by 
mutations to valosin containing protein (VCP; Watts et al., 2004) and TARDBP (Sreedharan et al., 
2008) which both result in TDP-43 pathology.  
 
1.5 CELLULAR CHANGES IN FTD 
Pathological examination of human FTD cases demonstrates that this disease is characterised by 
neurite and synaptic degeneration. Cytoskeletal alterations are a key driver of neuritic abnormalities, 
and are associated with several neurodegenerative diseases involving such alterations (Cairns, Lee, & 
Trojanowski, 2004; Eira, Silva, Sousa, & Liz, 2016; Hur, Saijilafu, & Zhou, 2012; McMurray, 2000; 
Vickers et al., 2009).  
1.5.1 Histopathologic studies of neuritic and synaptic changes 
Previous histopathological studies of FTD brains found swollen presynaptic terminals which were 
immunopositive for tau, high molecular weight neurofilament protein (NFH) and beta tubulin (Zhou 
et al., 1998). A case study of a patient with both FTD and MND revealed reduced dendritic arbours, 
proximal dendritic varicosities, shortened dendrites and a reduction in the number of dendritic spines 
(Ferrer, Roig, Espino, Peiro, & Matias Guiu, 1991). 
Severe loss of axons and white matter is a common feature of FTD, and has been found in both tau- 
and TDP-43-associated FTD (Dickson et al., 1986). Diffusion tensor magnetic resonance imaging (DT 
MRI) of people living with FTD shows alterations to white matter tracts within the brain (Agosta et 
al., 2012; Schofield, 2003) from which cell body death and axon degeneration have been inferred, 
depending on whether correlated grey matter changes are observed. Such axonal alterations followed 
by degeneration are an early feature of FTD (Agosta et al., 2012; Schofield, 2003). Histological 
examination suggests that axon and white matter loss in FTD-tau is distinct from FTD-TDP pathology 
(D. W. Dickson et al., 1986; van Eersel et al., 2015). FTD-tau is associated with large swollen axons 
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(spheroids) filled with neurofilament proteins, whereas these structures are absent from FTD-TDP 
cases (van Eersel et al., 2015). FTD-tau is also associated with “ballooned neurons”, which have 
swollen perikarya filled with neurofilament proteins, and it has been suggested that this results from 
failed transport of neurofilament proteins along the axon (Dickson et al., 1986). Fewer detailed studies 
have examined TDP-43 neurite pathology, although dystrophic neurites are observed in both cortex 
and hippocampus in FTLD-TDP (Hatanpaa et al., 2008). 
1.5.2 Cellular changes in ALS 
Neurite pathology in ALS is well-characterised and axonal alterations within motor neurons are a likely 
cause of the clinical symptoms of disease. Pathological changes in ALS include large swellings of 
axons in the ventral horn of the spinal cord containing accumulations of phosphorylated neurofilament 
proteins, mitochondria and lysosomes (Corbo & Hays, 1992; Hirano, Donnenfeld, Sasaki, & Nakano, 
1984; Hirano, Nakano, et al., 1984) as well as accumulations of kinesin, a key protein involved in 
transport of cargoes in the axon (Toyoshima et al., 1998). In addition, neurofilament proteins including 
NFL and alpha-internexin, and peripherin mRNA are decreased in motor neurons of sporadic ALS 
cases (Wong, 2000).  
Further clues to the involvement of TDP-43 pathology and neurite abnormalities come from ALS 
cases. Alterations to tau proteins are not observed, but TDP-43 pathology is found in most cases of 
ALS (Arai et al., 2006). In addition to cytoplasmic mislocalisation of TDP-43 in ALS, phosphorylated 
TDP-43 accumulates in axons and dendrites of somatomotor neurons as skein-like and dash-like 
aggregates (Braak, Ludolph, Thal, & Del Tredici, 2010). 
These data demonstrate that neurite changes are a common feature of diseases induced by both tau and 
TDP-43 pathology. While tau is an important driver of neurite abnormalities in many FTLD cases, and 
it is likely that tau alterations disrupt the neuronal cytoskeleton, the cause of neurite abnormalities in 
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FTLD-TDP and ALS-TDP-43 are less clear. In these cases, it is possible that TDP-43 may also drive 
neurite abnormalities via alterations to the neuronal cytoskeleton.  
 
1.6 DOES THE PATHOLOGY OF ALS/FTD LINK TO PRIMARY CHANGES IN THE CYTOSKELETON? 
1.6.1 Overview of cytoskeleton 
The cytoskeleton plays a vital role in the maintenance of cellular shape, structural organisation, 
transport, cell division and movement. In highly polarised cells such as neurons, which have complex 
shapes, and sometimes extend processes over a distance of up to one meter, the tight regulation of 
cytoskeletal components is critical. The cytoskeleton is composed of three key elements: microtubules, 
intermediate filaments and microfilaments. Neuronal intermediate filaments include neurofilaments, 
comprised of the subunits NFL, neurofilament medium (NFM), NFH, alpha-internexin (in the CNS) 
and peripherin (in the PNS) (Ge, Volkening, Leystra-Lantz, Jaffe, & Strong, 2007). A substantial 
number of cytoskeleton-associated proteins are also required for linking, regulation and movement.  
1.6.2 ALS/FTD genes associated with the cytoskeleton 
A growing list of cytoskeletal gene mutations is associated with FTLD/ALS, outlined in Table 1.1. As 
mentioned previously, mutations in the microtubule associated protein tau (MAPT) are responsible for 
5 to 20% of familial FTD cases (Hutton et al., 1998; Poorkaj et al., 1998; Rademakers, Cruts, van 
Broeckhoven 2004; Spillantini et al., 1998). In sporadic FTD, tau protein levels are reduced 
(Zhukareva, 2001) due to hyperphosphorylation or protein aggregation. Hyperphosphorylation of tau 
within its repeat domain causes a reduction in microtubule binding, leading to microtubule disassembly 
and hence possible axon transport deficits (reviewed in (Y. Wang & Mandelkow, 2016). Aggregation 
of tau leads to a reduction in available soluble tau, again leading to microtubule disassembly. In mouse 
models of tau loss of function, knockout mice are viable and fertile (Harada et al., 1994; Takei, Teng, 
Harada, & Hirokawa, 2000), likely due in part to compensation by other proteins such as microtubule 
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associated protein 1A (MAP1A). However, motor deficits are present in 12-month-old tau knockout 
mice (Lei et al., 2014), indicating that tau is necessary for normal neuronal functioning; delayed 
developmental maturation of neurons (Dawson et al., 2001) and changes to protein trafficking (Lei et 
al., 2012) are also observed. Therefore, it is likely that tau loss of function is sufficient to cause 
dysfunction and disease through processes involving the cytoskeleton. 
Table 1.1 Cytoskeletal genes associated with ALS and FTD. 
Mutation, Gene (protein) Disease association References 
MAPT (tau) FTLD (Hutton et al., 1998; 
Poorkaj et al., 1998; 
Spillantini et al., 1998) 
NEFH (neurofilament heavy chain) ALS (Al-Chalabi et al., 1999) 
DCTN1 (dynactin) ALS, ALS-FTLD (Puls et al., 2003) 
PFN1 (profilin) ALS (Wu et al., 2012) 
TUBA4a (tubulin alpha, 4A) ALS, atypical FTLD (Smith et al., 2014) 
(Perrone et al., 2017) 
 
ALS/FTD linked mutations within other genes are very rare, with some only described in one to a few 
cases. For example, mutations in the tail region of neurofilament heavy chain (NEFH), important for 
filament stability, were first reported in both sporadic and familial ALS cases in 1999 (Al-Chalabi et 
al., 1999). Additionally, disease-linked mutations within the microtubule-binding domain of DCTN1, 
thought to compromise microtubule-dependent retrograde transport of vesicles and organelles, have 
been identified (Puls et al., 2003) – initially in a patient with slow progressing, autosomal dominant 
ALS, and subsequently in a family with both ALS and FTD (Münch et al., 2005). 
Profilin 1, which converts monomeric to filamentous actin, has also been linked to familial ALS (van 
Blitterswijk et al., 2013; Wu et al., 2012). Cells expressing this mutation show reduced axonal 
outgrowth, smaller growth cones and decreases in bound actin (Wu et al., 2012). More recent studies 
have also identified profilin 1 mutations in sporadic forms of ALS, and although none have been linked 
to FTD, genetic screening of large cohorts would be needed to eliminate the possibility (Tiloca et al., 
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2013).  
Mutations of TUBA4a, one of the proteins making up microtubules, have been found in familial ALS 
cases, and cause destabilisation of the microtubule network (Smith et al., 2014). A recent study found 
a novel mutation in TUBA4a in a patient with atypical FTD, which caused loss of the TUBA4a 
transcript (Perrone et al., 2017).  
These associations underscore the importance of cytoskeletal regulation in maintaining healthy 
neurons, as well as the vulnerability of cells involved in ALS/FTD to cytoskeletal alterations.  
1.6.3 ALS/FTD pathology and the cytoskeleton 
Despite the evidence that cytoskeletal gene mutations can lead to ALS/FTD, the majority of cases are 
not associated with these types of mutations. This raises the question as to whether cytoskeletal 
alterations are involved in the pathogenesis of these other cases. In this regard, there is increasing 
evidence that ALS/FTD pathology, including changes to localisation, post-translational modifications 
and accumulations of proteins associated with FTD, also leads to disruptions to the cytoskeleton.  
NIFID, a type of FTD, is characterised by disruption to the cytoskeleton. This early onset disease 
involves atrophy of the frontal and temporal lobes and symptoms similar to FTD (Cairns et al., 2004). 
Microscopically it presents with intraneuronal cytoplasmic inclusions, axonal swellings and spheroids 
containing NFL, NFM, NFH and a-internexin, which may be ubiquitinated and phosphorylated (Cairns 
et al., 2010). Accumulations of these cytoskeletal proteins may be due to impaired axonal transport.  
Alterations to FUS and progranulin can also cause changes to neurites which could indicate changes 
in the cytoskeleton. In disease models, FUS mutations cause defects including altered axon length and 
branching (Groen et al., 2013; Kabashi et al., 2011), and mutant FUS aggregates, which sequesters 
other proteins important for cytoskeletal maintenance (Groen et al., 2013). Progranulin mutations 
decrease levels of progranulin protein. Under normal conditions, progranulin and its cleaved fragments 
(granulins) promotes neurite outgrowth (Gao et al., 2010). Cell culture and zebrafish models have 
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demonstrated that a decrease in expression of progranulin leads to truncation and aberrant branching 
of neurons (Chitramuthu, Baranowski, Kay, Bateman, & Bennett, 2010; Gao et al., 2010; Gass et al., 
2012) and that adding exogenous progranulin can rescue this phenotype (Chitramuthu et al., 2010; 
Gass et al., 2012) and increase neurite outgrowth (Gao et al., 2010; Van Damme et al., 2008). One of 
these studies also showed that knockdown of progranulin lead to a reduction of GSK-3b 
phosphorylation (Gao et al., 2010), a kinase shown to have a role in axon-dendrite polarity in 
development (Jiang, Guo, Liang, & Rao, 2005). In aged mice with constitutive knockout of progranulin 
(Petkau et al., 2012), similar abnormalities were observed, with altered morphology of apical dendrites 
of hippocampal CA1 pyramidal cells, decreased spine density and altered synaptic activity. Gao et al. 
(2010) suggested that the loss of progranulin expression in FTLD may be responsible for abnormalities 
in axonal repair and neuron loss in these diseases.  
 
While the link between several key pathological proteins in FTD and neurite abnormalities has been 
well investigated, the role of TDP-43 is less clear. Additionally, the way in which C9ORF72 mutations, 
the most common genetic cause of FTD and ALS, lead to neurodegeneration is also not well 
understood.  
1.6.4 Pathological inks between TDP-43 and the cytoskeleton 
Although studies to date are currently limited, there is evidence for cytoskeletal changes in human 
tissue with TDP-43 pathology. A study examining cases of FTLD-U and dementia lacking distinctive 
histopathology demonstrated that dystrophic neurites immuno-positive for TDP-43 are a common 
feature of these two diseases (Hatanpaa et al., 2008). Dystrophic neurites generally consist of swollen 
axons and dendrites, as well as accumulations of the internal cytoskeletal elements such as 
neurofilament proteins and tau (Dickson, King, McCormack & Vickers, 1999). In ALS, TDP-43 
pathology is associated with abnormal neurite accumulations in vulnerable neurons, including 
somatomotor neurons of the lower brainstem and spinal cord (Braak et al., 2010). Additionally, white 
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matter tracts of FTLD-TDP cases undergo degeneration, characterised by vacuolation within the fibre 
tracts (Armstrong, 2017). These studies show that TDP-43 pathology occurs concurrently with 
alterations to neurites.  
1.6.4.1 Cytoskeletal changes in TDP-43 experimental models 
Further evidence from experimental models links cytoskeletal alterations to TDP-43 alterations. In a 
mouse model with cytoplasmic mislocalisation of TDP-43 from the nucleus to the cytoplasm, a 
reduction in the expression of NFL proteins within axons of the corticospinal tract was reported as 
well as axon degeneration and dieback of motor neurons from the neuromuscular junction (Igaz et al., 
2009; Walker et al., 2015). Abnormal neurite morphology can be caused by both knockdown of TDP-
43 and expression of missense mutations (including A315T, Q331K and M337V) in differentiated 
cortical neurons (Han et al., 2013), and by expressing either WT TDP-43 with mutated nuclear 
localisation signal (NLS) or mutant TDP-43 with mutated NLS (Han et al., 2013). Neurite outgrowth, 
branching and maintenance require coordinated structural changes to the cytoskeleton including 
microtubules, neurofilament and actin filaments. In particular, the Rho GTPases are key factors which 
regulate actin cytoskeleton elements (Woo & Gomez, 2006). In line with this, depletion of TDP-43 in 
neuronal cell lines alters neurite outgrowth through deregulation of the Rho family of GTPases (Iguchi 
et al., 2009).  
A recent study by Tripathi and colleagues (2014) demonstrated that expression of mutant forms of 
TDP-43, including the M337V familial ALS mutation and Q331K sporadic mutation, induce cellular 
toxicity and mislocalisation of TDP-43 to the cytoplasm and axons in chick embryo spinal cords and 
primary cultured motor neurons. They also observed defasciculation of motor axons, impairing path-
finding and synaptic targeting (Van Vactor, 1998), leading to truncation and a reduction in neurite 
outgrowth both in vivo and in vitro (Tripathi et al., 2014). Although mechanisms are still unclear, these 
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data provide evidence that changes to TDP-43 lead to dysregulation of the cytoskeleton and altered 
neuron integrity.  
In mouse models with A415T and G348C TDP-43 mutations, the L5 ventral root of 10-month-old 
mice contained more small caliber and fewer larger caliber axons compared to wildtype (Swarup et 
al., 2011), suggestive of neurofilament disruption since these intermediate filaments, NFM in 
particular, are known to regulate axon caliber (Barry et al., 2012; Kirkcaldie & Dwyer, 2017).  
The association of TDP-43 with cytoskeletal function is not limited to mammals. Drosophila lacking 
the TDP-43 homolog, TBPH, have motor dysfunctions, reduced lifespan and structural changes to 
neuromuscular junctions, which can be rescued by expression of human TDP-43 (Feiguin et al., 2009). 
Expression of mutant TDP-43 has been shown to cause altered localisation and aggregation in motor 
neurons, swimming deficits and shorter, excessively branched motor axons in zebrafish (Kabashi et 
al., 2010), rescued by co-expressing WT TDP-43. 
Modulation of TDP-43 expression via the formation of pathological aggregates, mislocalisation from 
the nucleus to the cytoplasm and reduction in expression lead to neurite abnormalities consistent with 
alterations to the neuronal cytoskeleton. In order to understand how TDP-43 may affect neurites and 
the cytoskeleton, it is important to understand the normal function of the protein. 
 
1.7 THE ROLE OF TDP-43 IN CYTOSKELETAL PATHOLOGY AND FUNCTION 
1.7.1 Normal function of TDP-43 
TDP-43 is a highly conserved and ubiquitously expressed protein, located on chromosome 1p36.2 
(Buratti, 2001). Full length TDP-43 protein contains a number of functional domains including two 
RNA recognition motifs (RRM1 and RRM2); an NLS and nuclear export sequence (NES) which allow 
it to shuttle between the nucleus and cytoplasm; and a glycine-rich domain thought to be important for 
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protein-protein interactions (Figure 1.2). TDP-43 is part of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family of nuclear factors, which are highly regulated proteins which 
undergo autoregulation. By binding to its own 3’ untranslated region (UTR) of mRNA, TDP-43 
initiates nonsense-mediated decay and is able to degrade mRNAs with premature translation-
termination codons (Ayala et al., 2011). Tight regulation of TDP-43 expression is important for its 
normal functioning with both increases and decreases causing neurodegeneration. In the healthy brain, 
TDP- 43 is predominantly nuclear in neurons (Fiesel et al., 2010) and is also present at lower levels 
within the cytoplasm. Knockout studies provide information about the normal the role of the protein 
and show that knockout of the Tardbp gene in mice is embryonic lethal within 3.5–7.3 days post-
fertilisation (Kraemer et al., 2010; Sephton et al., 2010; Wu, Cheng, & Shen, 2012), suggesting that 
TDP-43 is critical during early developmental processes such as transcription and/or mRNA splicing 
and processing (Sephton et al., 2010). The protein has distinct nuclear and cytoplasmic functions, 
enabled by its NLS and NES domains. Within the nucleus, TDP-43 plays a variety of roles in the 
splicing of mRNA and processing of microRNAs. Within the cytoplasm it localises to stress granules 
where it is thought to play roles in trafficking and stabilizing mRNA (Colombrita et al., 2009; Dewey 
et al., 2011; McDonald et al., 2011). 
1.7.2 Role of TDP-43 in neurites 
Emerging evidence shows that TDP-43 may also play an important role in the development of neurites. 
TDP-43 is expressed at high levels during development within the mouse cortex and hippocampus 
(embryonic day 18 to postnatal day 7) and then decreases into adulthood (Liu et al., 2015). This timing 
corresponds to the period of maximum neurite outgrowth and branching (Workman et al., 2013) 
providing evidence for a role in the development of neurites. Neurite outgrowth may be regulated by 
TDP-43 in the nucleus (where it is predominately found), or out in the axons and synapses/growth 
cones, where TDP-43 is also present. Fallini and colleagues (2012) demonstrated that TDP-43 particles 
found within neurites are motile and increase in number following treatment with brain-derived  
Location of majority of mutations 
associated with FTD/ALS
RRM1 RRM2
N terminus C terminusNLS NES
Glycine-rich domain
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Figure 1.2 TDP-43 protein structure. TDP-43 protein contains two RNA-cognition motifs (RRM1 
and RRM2), a nuclear localisation signal (NLS), nuclear export signal (NES) and a carboxy-terminal 
glycine-rich domain. The majority of mutations associated with FTD/ALS occur in the glycine-rich 
domain. Figure adapted from Lee, Lee, and Trojanowski (2012).  
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neurotrophic factor (BDNF). In cultured motor neurons, these TDP-43 particles colocalise with other 
mRNA binding proteins (mRBPs) such as FMRP, IMP1 and HuD (Fallini et al., 2012). Subsequent 
studies located TDP-43 within messenger ribonuclear protein particles (mRNPs) which are bi-
directionally transported and deliver mRNAs, such as both mouse and human Nefh/NEFH, down axons 
to their distal targets (Alami et al., 2014). This function may be particularly important for in situ protein 
translation, which TDP-43 may also regulate (Liu-Yesucevitz et al., 2011). Mutations to ALS-related 
genes may impair this TDP-43 function by reducing mRNP trafficking (Alami et al., 2014). Together, 
these studies demonstrate that TDP-43 is expressed in different neuronal compartments, and that it 
plays important roles wherever it is expressed. 
1.7.3 Regulation of the neuronal cytoskeleton by TDP-43 
Aside from its presence in distal neuronal compartments, implying transport-related interactions with 
the cytoskeleton, TDP-43 has also been shown to directly bind to and regulate several cytoskeletal 
elements. For example, it binds to the 3’UTR of Nefl mRNA, stabilising it within the nucleus and 
regulating its translocation to the cytosol, where it may also regulate its translation (Strong et al., 2007; 
Volkening, Leystra-Lantz, Yang, Jaffee, & Strong, 2009). In ALS, affected motor neurons within the 
spinal cord contain neurofilament aggregates with a proportionally lower amount of NFL than usual 
(Strong, Kesavapany, & Pant, 2005). In a NFL knockout mouse model, TDP-43 was abnormally 
increased, without abnormal localisation or aggregate formation (Liu et al., 2015), and age-related 
changes in the phosphorylation state of TDP-43 were also observed. This aberrant TDP-43 
phosphorylation in disease might plausibly alter its binding to NEFL mRNA, which could contribute 
to aggregates by affecting NFL stability and transport. 
TDP-43 may also be involved in microtubule stability. Silencing TDP-43 expression resulted in 
downregulation of histone deacetylase 6 (HDAC6), through a specific interaction between HDAC6 
and the C-terminal and RNA binding domains of TDP-43 (Fiesel, Schurr, Weber, & Kahle, 2011; 
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Fiesel et al., 2010). HDAC6 deacetylates and thus destabilises microtubules (Hubbert et al., 2002) and 
is important in intracellular trafficking and branch formation (Valenzuela-Fernández, Cabrero, 
Serrador, & Sánchez-Madrid, 2008). Several lines of evidence using Drosophila show an interaction 
of the TDP-43 homolog, TBPH, and MAP1b homolog, futsch. Deletion of TBPH altered 
neuromuscular junctions and synaptic boutons which were attributed to cytoskeletal defects caused by 
down-regulating futsch (Godena et al., 2011). Further studies showed that TBPH binds to the 5’UTR 
of futsch mRNA and increases its translation (Romano et al., 2014). TBPH is also important for 
localisation and translation of futsch protein in motor neurons (Coyne et al., 2014).  
These data provide further evidence that TDP-43 is a key regulator of cytoskeletal elements important 
for the health and maintenance of neurites, and that altering its expression (in models and human 
disease) can cause neurite pathology, and impact the integrity of neurons. Alterations to TDP-43 in 
ALS and FTLD cases may lead directly to changes to the neuronal cytoskeleton, ultimately damaging 
neurites and killing neurons. However, it is still not well understood how TDP-43 maintains 
cytoskeletal health, and how that becomes disrupted in disease, particularly in cases of FTLD and ALS 
where TDP-43 itself is not mutated. 
A major genetic cause of TDP-43 pathology in both FTLD and ALS is mutations to C9ORF72. Little 
is known about the normal function of the C9ORF72 protein and it is currently unclear how C9ORF72 
mutations lead to abnormal accumulation and mislocalisation of TDP-43.  
1.8 THE ROLE OF C9ORF72 IN CYTOSKELETAL PATHOLOGY AND FUNCTION 
1.8.1 C9ORF72 and disease 
In 2011, a repeat expansion in a non-coding region of C9orf72 was identified as the most common 
genetic cause of FTD and ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011). The mechanisms 
by which this mutation causes disease are currently unknown, perhaps including RNA toxicity or 
unconventional translation of the nucleotides within the repeat expansion. Alternatively, disease could 
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be due to loss of function of the encoded protein. There are several reports of reduction in C9ORF72 
mRNA from FTD and ALS patient tissue and patient-derived cell lines (Belzil et al., 2013; Ciura et 
al., 2013; Cooper-Knock et al., 2012; DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Xi et al., 
2013) and also reduction of C9ORF72 protein within the affected frontal regions of FTD/ALS brains 
(Waite et al., 2014; Xiao et al., 2015). 
1.8.2 Normal role of C9ORF72 
Currently, little is known about the normal function of the C9ORF72 protein. In humans, the 
C9ORF72 gene codes three alternatively spliced transcripts that are expressed widely, including the 
brain. Alternative splicing of these transcripts produces short and long isoforms (C9-S and C9-L) 
(Renton et al., 2011). Antibodies specific to these two isoforms have demonstrated that within Purkinje 
neurons and spinal motor neurons, C9-L has diffuse cytoplasmic labeling, whereas C9-S localises to 
the nuclear membrane (Xiao et al., 2015). Further descriptions of the expression and localisation of 
C9ORF72 are currently lacking.  
The function of C9ORF72 has been inferred by homology with other proteins containing the 
Differentially Expressed in Normal Neoplasia (DENN) domain, which function as guanosine 
diphosphate/guanosine triphosphate (GDP/GTP) exchange factors (GEFs) for Rab GTPases (Levine, 
Daniels, Gatta, Wong, & Hayes, 2013). Rab proteins mediate membrane trafficking (Marat, Dokainish, 
& McPherson, 2011), implying that C9ORF72 may indirectly regulate this function (Levine et al., 
2013). Farg et al. (2014) confirmed this role by showing C9ORF72 co-localisation with Rabs involved 
in endolysosomal trafficking; furthermore, knockdown of C9ORF72 expression impaired endocytosis 
and autophagy (Farg et al., 2014b). Additional studies have strengthened this association, showing that 
reduced expression of C9ORF72 in culture (Webster et al., 2016) or knockout mice (O'Rourke et al., 
2015; Sullivan et al., 2016) disrupts autophagy.  
1.8.3 C9ORF72 and the neuronal cytoskeleton 
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In line with evidence that other FTD/ALS proteins regulate the cytoskeleton, C9ORF72 has also been 
linked with actin and actin dynamics. Actin is an interacting partner of C9ORF72 and the two proteins 
colocalise in immunocytochemical studies (Farg et al., 2014), as does the cytoskeletal protein cofilin 
(Sivadasan et al., 2016). Cofilin is an actin binding protein which modulates actin organisation and 
dynamics (Bravo-Cordero, Magalhaes, Eddy, Hodgson, & Condeelis, 2013). shRNA knockdown of 
C9ORF72 in cultured motor neurons reduced actin filament production, and truncated axons and 
growth cones, accompanied by enhanced cofilin phosphorylation which is also observed in human 
iPSC-derived motor neurons and post mortem tissue from patients with C9ORF72 expansion 
(Sivadasan et al., 2016). The opposite was observed when C9ORF72 was overexpressed. C9ORF72 
depletion also changed the activity of guanine nucleotide exchange factor protein family members, 
Rac1 and Arf6 (Sivadasan et al., 2016), which the authors suggested indicates that C9ORF72 
modulates small GTPases and thus actin dynamics.  
While the normal functions of the C9ORF72 protein are not yet well described, evidence suggests that 
C9ORF72 may influence the neuronal cytoskeleton.  
 
1.9 SUMMARY AND PROJECT AIMS 
Accumulating evidence suggests that proteins that become dysregulated in FTD and ALS may affect 
the neuronal cytoskeleton, which is of particular interest in these diseases due to the neurite pathology 
and dysfunction observed in post-mortem brains and animal models. Modulation of the neuronal 
cytoskeleton is a compelling target for providing therapeutic protection to vulnerable cellular 
components, such as the axon. The purpose of this thesis was to examine the normal function of TDP-
43 and C9ORF72, and their links to the cytoskeleton.  
Aim 1: Determine the effect of TDP-43 overexpression on neurite development in culture 
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TDP-43 is transported into neurites in an activity-dependent manner, where it regulates neurite growth, 
and is also involved in the transport of mRNA into the neurites for in situ protein translation. The way 
in which TDP-43 controls these processes is still not well understood. The first aim sought to 
investigate global protein changes and alterations to cytoskeleton-dependent processes such as neuron 
morphology and growth cone morphology, using a primary cell culture model from mice 
overexpressing wildtype TDP-43.  
 
Aim 2: Determine the effects of altered TDP-43 on axons within the central nervous system 
Mislocalisation of TDP-43 from the nucleus to the cytoplasm is a key pathological feature of FTD and 
ALS. The consequences of increased cytoplasmic expression of TDP-43 on axons are not well 
understood. This is partly due to the lack of mouse models that allow detailed examination of axon 
structures. The second aim of this thesis was to investigate the cellular effects of overexpression of 
wildtype TDP-43 and mislocalised TDP-43 within the retina ganglion cells and their axons. 
Additionally, this aim was directed at creating and optimizing a novel model to investigate axonal 
alterations in vivo, by using adeno-associated virus to induce altered expression of TDP-43 in retinal 
ganglion cells. 
 
Aim 3: Examine the distribution of C9ORF72 to determine potential roles within neurites  
Several mechanisms for how the non-coding repeat expansion in C9ORF72 may lead to disease have 
been described, however little is known about the normal function and the expression pattern of the 
C9ORF72 protein. This aim sought to characterise the expression pattern and cellular localisation of 
the three reported mouse isoforms of C9orf72 in order to provide insight into the normal function of 
this protein.  
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2 MATERIALS & METHODS 
2.1 ANIMAL CONDITIONS AND CARE 
All experiments involving animals were approved by the University of Tasmania Animal Ethics 
Committee (approvals A12780, A15120, A15121, A14189, A16522), in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (National Health 
and Medical Research Council, 2013). Animals were housed in standard conditions at 20°C, on a 
12/12-hour light/dark cycle with ad libitum access to food and water.  
 
2.2 PRIMARY CELL CULTURE 
2.2.1 Preparation of culture surfaces 
Primary culture cells were plated onto a variety of surfaces. For immunocytochemistry, cells were 
plated onto 13mm coverslips (Menzel-Glaser) etched in 70% nitric acid for four hours, rinsed in 
running water for 30 minutes, then 3 x 10 minutes in MilliQ water, dried, autoclaved and placed singly 
into 24 well trays. For studies involving protein extraction, 12 well culture trays were utilised. All 
surfaces were coated with 10% poly-L-lysine (Sigma-Aldrich) diluted in Hanks Balanced Salt Solution 
(HBSS, Gibco) overnight. Poly-L-lysine was removed and replaced with initial plating media 
consisting of Neurobasal medium (Gibco), 2% B27 supplement, 10% fetal calf serum (Gibco), 0.5mM 
glutamine, 25mM glutamate and 1% antibiotic/antimycotic (Gibco).  
2.2.2 Primary cortical neuron culture 
Primary dissociated cortical cell cultures were prepared from embryonic day (E) 15.5 C57Bl/6 mice 
(unless otherwise stated), which were harvested from pregnant mice euthanised by carbon dioxide 
exposure. Fetuses were removed from their sacs and placed on ice followed by rapid decapitation. 
Brains were exposed by removing skin, skull and meninges, and cortical tissue from both 
hemispheres was collected into 5ml of HBSS. Tissue was dissociated with 0.0125% trypsin for 4 
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minutes, followed by addition of initial plating media described in section 1.2.1 above. Cells then 
underwent gentle trituration with a 1ml pipette. Viable cell numbers were assayed using Trypan Blue 
(Sigma Aldrich) exclusion and cells were plated onto 12mm coverslips (Menzel-Gläser, Germany; 
prepared as in section 2.2.1) in 24 well plates (Corning Inc) at a density of 30,000 (for 24 well plates) 
or 200,000 (for 12 well plates) viable cells per coverslip. Each well contained initial plating medium, 
replaced on the following day with subsequent growth medium (initial medium without the fetal calf 
serum and glutamate), after which half the media was replenished weekly with fresh subsequent 
growth medium. Cultures were grown at 37°C and 5% CO2.  
 
2.3 IMMUNOCYTOCHEMISTRY 
Following removal of media, cells were gently washed with phosphate buffered saline (PBS; 0.01M) 
and fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature on an orbital shaker. 
Coverslips were washed (3 x PBS, 10 minute intervals) and then blocked with blocking solution 
containing 0.01 PBS, 1% BSA (Sigma Aldrich) and 0.3% Triton X-100 (Sigma Aldrich) for 30 
minutes. Coverslips were then placed on wax sheets in a humidity chamber and 50µL of primary 
antibody combinations diluted in 0.6% Triton X-100 in PBS (PBS-T) applied overnight at 4°C. 
Coverslips were returned to 24 well plates and washed to remove unbound antibody (3 x 10 minutes 
PBS). Species-appropriate secondary antibodies (Goat anti-chicken IgY, Thermofisher Scientific, 
reference number A11039, 1:1000; Goat anti-mouse IgG, Thermofisher Scientific, reference number 
A11029, 1:1000; Goat anti-rabbit IgG, Thermofisher Scientific, reference number A11034, 1:1000) 
were diluted in PBS, and applied for 2 hours with agitation in the dark at room temperature. Secondary 
antibodies were removed and coverslips were incubated with DAPI (Molecular Probes, Invitrogen) at 
a concentration of 5µg/ml in dH2O for 5 minutes with agitation in the dark at room temperature. 
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Coverslips underwent final washes (2 x 10 minutes PBS, then milliQ rinse) and then mounted, cell-
side down, onto slides (Livingston International) using fluorescent mounting medium (Dako).  
 
2.4 ANIMAL PERFUSION AND TISSUE PROCESSING 
Animals were euthanised by injection of sodium pentobarbitone (110mg/kg i.p.) and transcardially 
perfused with 4% PFA in PBS for immunohistochemical studies and PBS for biochemical studies. 
Tissue was dissected immediately and post-fixed for 24 hours in 4% PFA in PBS for 
immunohistochemical studies or snap frozen in liquid nitrogen and stored at -80°C for biochemical 
studies.  
 
2.5 IMMUNOHISTOCHEMISTRY 
2.5.1 Cryoprotection and sectioning 
Tissue for immunohistochemistry was cryoprotected in increasing concentrations of sucrose (18% then 
30%) with 0.2% NaN3 in PBS until equilibrated, then embedded in Optimal Cutting Temperature 
(OCT; Tissue-Tek) medium, frozen and sectioned at -25°C using a Leica CM 1850 UV Cryostat. 
2.5.2 Antigen Retrieval 
Paraformaldehyde fixation can mask antigens to the extent that antibodies are unable to bind to their 
epitopes (Leong & Leong 2007), requiring antigen retrieval such as formic acid and citrate buffer 
treatments. Citrate buffer antigen retrieval optimised TDP-43 and C9ORF72 labeling for most tissue, 
and was subsequently used when labeling with these antibodies. Free floating sections were loaded 
into cassettes between two sections of Tally-Ho paper (Imperial Tobacco), or mounted onto charged 
slides (Dako), and were placed in a plastic container containing 5000ml of 0.1M citrate buffer, 
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prepared from citric acid (Sigma Aldrich; pH 6.0). This container was placed in a pressure cooker 
(Russel Hobbs) containing 500ml distilled water, set to maximum temperature for 6 minutes and then 
to moderate-high temperature for 14 minutes. Sections were cooled to 25°C prior to placing in PBS. 
2.5.3 Indirect Fluorescent Immunohistochemistry (IHC) 
Free-floating sections or mounted slides were washed (3 x 10 minute PBS) before non-specific binding 
sites were blocked in serum-free Protein Block solution (Dako) for 20 minutes at room temperature. 
Primary antibodies diluted in PBS-T were added, and incubated with agitation at room temperature 
overnight. Optimum concentrations were determined for each antibody and no-primary controls were 
performed. Sections were washed (3 x 10 min PBS-T) and species-specific secondary antibodies 
diluted in PBS were applied for 2 hours in the dark at room temperature with agitation. Sections were 
incubated with DAPI (Molecular Probes, Invitrogen) at a concentration of 5µg/ml in PBS for 5 minutes 
with agitation in the dark at room temperature. Sections underwent further washes (3 x PBS, 10 minute 
intervals) and were then mounted onto glass slides (Livingston International) and coverslipped 
(Livingston International) using fluorescent mounting medium (Dako). 
 
2.6 WESTERN BLOTTING 
2.6.1 Protein extraction for Western blotting 
For cell culture studies, protein was extracted in 100µL radioimmunoprecipitation assay (RIPA) lysis 
buffer (Sigma Aldrich) containing protease (Complete Mini Protease Inhibitor Cocktail tablets, Roche) 
and phosphatase inhibitors (A.G. Scientific Inc). For tissue studies, 3mg/ml of lysis buffer was added 
to tissue. Samples were homogenised with an Ultra-Turrax homogeniser (IKA TIO basic, IKA Works). 
Protein from both cell culture and tissue studies was then maintained with constant agitation for 30 
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minutes at 4°C and the centrifuged for 20 minutes at 13,000rpm at 4°C. Supernatant was collected and 
frozen at -80°C until needed.  
2.6.2 Nuclear and cytoplasmic fractionation studies 
Nuclear and cytoplasmic fractionation was carried out on cultured cortical neurons (Chapter 3) or 
neocortical tissue (Chapter 5) according to manufacturer’s instructions with some minor adjustments 
(NE-PER Nuclear and Cytoplasmic Extraction Kit, Thermofisher Scientific). Briefly, cultured cells 
were harvested from 12 well culture plates with 100µL of CERI, with protease and phosphatase 
inhibitors, using a cell scraper. Alternatively, neocortical tissue was homogenised in 200µL of CERI, 
with protease and phosphatase inhibitors, with a Ultra-Turrax homogeniser (IKA® TIO basic, IKA 
Works). Subsequent reagent volumes were adjusted accordingly and the protocol was completed using 
manufacturer’s instructions.  
2.6.3 Protein quantification  
Concentrations of extracted protein were determined by performing a Bradford assay (Bio-Rad 
Laboratories) following manufacturer’s instructions. BSA protein standards from 0.125mg/mL to 
4mg/ml were prepared to construct a standard curve. Absorbance was measured on to SpectraMax Plus 
384 Absorbance Reader (Molecular Devices) and subsequent protein concentrations were calculated 
using this standard curve. 
2.6.4 Gel electrophoresis and Western blot 
Bolt 4×lithium dodecyl sulphate (LDS) sample buffer and 10×Bolt sample reducing buffer were added 
to 15µg of protein and denatured at 95°C for 5 minutes. Samples were loaded onto 4-12% Bolt Bis-
TRIS Plus gels and electrophoresed for 20 minutes at 200V in Bolt MES running buffer (all Life 
Technologies). Gel electrophoresis was performed per manufacturer’s protocol (Life Technologies). 
Resolved proteins were then transferred to 0.2µm polyvinylidene fluoride (PVDF) membranes (Bio-
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Rad Laboratories) via electrophoresis in Bolt Transfer buffer for 1 hour at room temperature. 
Following transfer, the membrane was washed in 1x Tris buffered saline with 0.1% Tween-20 (Bio-
Rad Laboratories; TBS-T) and then non-specific binding was blocked via incubation in 5% 
commercial skim powder in TBS-T (blocking solution) for 2 hours at room temperature. The 
membrane was incubated in primary antibody diluted in blocking solution for 2 hours at room 
temperature. Membrane was washed (3 x 10 minutes TBS-T), followed by incubation with species-
appropriate HRP secondary antibody (Dako) diluted in blocking solution for 2 hours at room 
temperature with agitation. Membranes were washed (3 x 10 minutes TBS-T) and then 
immunoreactivity was detected by incubation in Immobilon chemiluminescent HRP substrate 
(Millipore) for 2 minutes, and quantified using the Amersham Imager 600 (GE). If additional antibody 
labelling was required, membranes were stripped with 0.1M glycine, pH 2.9 for 30 minutes at room 
temperature with agitation. Membranes were rinsed in TBS-T and blocked overnight in blocking 
solution at 4°C with agitation. The following day, immunolabeling was carried out as described. 
 
2.7 STATISTICAL ANALYSIS 
All counts and analyses were performed blinded to genotype. Numbers of repeats (n) are detailed in 
each chapter, with a minimum of n=3 biological replicates for quantitation (animals (Chapters 4 and 
5), cultures (Chapters 3 and 5) or embryos (Chapter 3)). For Chapter 3, a minimum of 3 embryos were 
taken from a minimum of 2 mother mice. Western blot analyses also had 3 experimental repeats from 
each sample to account for variation in blotting. Unless otherwise stated, statistical analyses were 
carried out using one-way ANOVA with Tukey’s post hoc test (GraphPad Prism, version 5). Data are 
presented ± standard error of the mean (SEM) and significance set at p<0.05. 
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3 EFFECTS OF OVEREXPRESSION OF TDP-43 ON THE NEURON 
PROTEOME AND MORPHOLOGY  
3.1 INTRODUCTION 
A prominent feature of ALS/FTD tissue are extensive neurite abnormalities, including neuromuscular 
dieback, axonal and dendritic swellings, swollen presynaptic terminals, reduced dendritic 
arbourisation, spine loss and transport deficits, indicated by accumulation of abnormal organelles 
(Brettschneider et al., 2014; Brettschneider et al., 2013; Ferrer et al., 1991;  King, Maekawa, Bodi, 
Troakes, & Al-Sarraj, 2011;  Sasaki & Iwata, 1996; Zhou et al., 1998). Neurite abnormalities are linked 
to cytoskeletal disruption (Vickers et al., 2009).  
TDP-43 pathology is present in 95% of ALS cases and 50% of FTD cases, usually due to 
mislocalisation from the nucleus to the cytoplasm where it forms aggregates. TDP-43 pathology is also 
found within dystrophic neurites in ALS and FTD (Braak et al., 2010; Hatanpaa et al., 2008) and white 
matter tract degeneration is associated with FTLD-TDP (Armstrong, 2017).  The links between TDP-
43 pathology and neurite abnormalities are unclear, however there is accumulating evidence that TDP-
43 plays a normal role in regulating the cytoskeleton, and that disruption to TDP-43 in disease 
conditions is sufficient for neurite abmormalities. 
TDP-43 is essential during neuronal development (Sephton, Cenik, Cenik, Herz, & Yu, 2012) and is 
upregulated during development when circuit formation is occurring (Liu et al., 2015). TDP-43 binds 
directly to NEFL mRNA to stabilize it, and regulates translocation of NEFL mRNA to the cytosol 
(Strong et al., 2007; Volkening et al., 2009). TDP-43 is a predominantly nuclear protein where it exerts 
the majority of its functions (reviewed in Lee et al., 2012)) but is also present in distal neuron 
compartments where it is important for transport of messenger ribonucleoprotein particles down axons 
to their distal targets (Alami et al., 2014). The localisation of TDP-43 expression in neurites and its 
ability to directly regulate cytoskeletal elements suggest that alterations to TDP-43 expression may be 
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a driver of neurite abnormalities in disease. In fact, mutations to TDP-43 can cause cellular toxicity 
and abnormal expression of TDP-43 to axons (Tripathi et al., 2014) as well as impair the transport of 
messenger ribonuclear proteins and reduce axonal outgrowth (Alami et al., 2014; Fallini et al., 2012). 
These data suggest that mutations in TDP-43 relevant to ALS could cause impairment to axonal 
function through a direct role of TDP-43 in the regulation of the integrity of the cytoskeleton.  
This study sought to further investigate how TDP-43 may exert effects on the neuronal cytoskeleton. 
Primary neuronal cultures were prepared from transgenic mouse overexpressing wildtype human TDP-
43 under the control of the prion promoter (hTDP-43Prp). The heterozygous and homozygous hTDP-
43Prp mice express at 1.9 and 2.5 times the rates of endogenous TDP-43 protein, respectively (Xu et 
al., 2010). Postnatal heterozygous mice are viable and lack pathological changes, however 
homozygous mice develop a severe degenerative phenotype by 4 to 6 weeks of age, accompanied by 
TDP-43 aggregates and mislocalisation to the cytoplasm in the brain and spinal cord (Xu et al., 2010). 
Other abnormalities include mitochondrial changes, gliosis and – importantly – axonal and myelin 
degeneration within the spinal cord (Xu et al., 2010).  
Primary neurons cultured from these mice are an ideal way to carry out detailed examination of the 
effect of TDP-43 overexpression, which occurs in disease (Geser, 2008; Mishra et al., 2007), on the 
expression of cytoskeletal proteins and the downstream effects of this on the neurite. Two main 
approaches were taken in this study. Firstly, proteomics, which have previously been used to identify 
interacting partners of TDP-43 (Freibaum, Chitta, High, & Taylor, 2010) allow analysis of global 
changes to proteins following alteration to TDP-43 expression. Secondly, neuron morphology was 
analysed to determine the effect of TDP-43 alterations to developmental processes such as neurite 
outgrowth and branching, which require specific expression and organisation of the cytoskeleton. The 
results from these studies will provide further insight into how alterations in the expression level of 
TDP-43 may cause changes to neurites. 
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3.2 METHODS 
3.2.1 Animals 
TDP-43Prp mice (Xu et al., 2010) (C57BL/6-Tg(Prnp-TARDBP)3cPtrc/J, Jackson Laboratories, stock 
number 016608) were utilised in this study. Due to the phenotype developed by homozygous mice, 
colonies were maintained as heterozygotes for breeding stock. For culture studies, heterozygote mice 
were mated to obtain homozygous, heterozygous and wildtype embryos. All experiments involving 
animals were approved by the University of Tasmania Animal Ethics Committee (A15121) and were 
in accordance with the Australian Guidelines for the Care and Use of Animals for Scientific Purposes 
(National Health and Medical Research Council, 2013). 
3.2.2 Genotyping 
For genotyping of mice from the maintenance colony (heterozygous and wildtype mice), genomic 
DNA from tail clippings was obtained from mice at weaning was extracted according to 
manufacturer’s instructions (Quanta Biosciences). Genotypes (heterozygote and wildtype) were then 
determined by conventional PCR using the MyTaq™ Red Mix (Bioline) using primers specific to 
hTDP-43 and Tcrd internal control (Table 3.1). The PCR conditions are outlined in Table 3.2. Products 
were electrophoresed in a 2% agarose gel, containing 1% SYBR safe DNA gel stain (Invitrogen) at 
125V for 35 minutes. Gels were visualised using the Amersham Imager 600 (GE) with a 400bp band 
for mutant and 200bp band for wildtype. To determine zygosity of embryos cultured from two 
heterozygous parents, quantitative real time PCR (qPCR) was utilised. Genomic DNA was extracted 
from embryonic liver using the Isolate II Genomic DNA Extraction Kit (Bioline), with precaution 
taken to avoid contamination from the mother’s blood. qPCR was carried out using GoTaq® Probe 
qPCR Master Mix with a maximum of 150ng of liver DNA and the following primer sets outlined in 
Table 3.3. qPCR conditions are outlined in Table 3.4. 
Table 3.1 Conventional PCR primer information 
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Primer Sequence 5’-3’ 
hTDP-43 Forward(20µM) GGATGAGCTGCGGGAGTTCT 
hTDP-43 Reverse (20µM) TGCCCATCATACCCCAACTG 
Tcrd internal control forward (20µM) CAAATGTTGCTTGTCTGGTG 
Tcrd internal control reverse(20µM) GTCAGTCGAGTGCACAGTTT 
 
Table 3.2 Conditions for conventional PCR 
Cycle step Incubation times 
Initial 
denaturation 
94°C 2 min  
 10 cycles Step 1: 94°C for 20 sec 
Step 2: 64°C (-0.5°C/cycle) for 15 sec 
Step 3: 68°C for 10 sec 
Amplification 
(28 cycles) 
Step 1: 94°C for 15 sec 
Step 2: 60°C for 15 sec 
Step 3: 72°C for 10 sec 
Final 
extension 
72°C for 2 min 
Hold 11°C infinite 
 
Table 3.3 qPCR primer information 
Primer 5’ label Sequence 5’-3’ 3’ label 
Tg Forward(40µM)  GTACGGGGATGTGATGGATG  
Tg Reverse (40µM)  CGCAATCTGATCATCTGCAA  
Tg probe (40µM) 6-FAM CCAAGCCATTCAGGGCCTTTGC Black Hole 
Quencher 1 
Apob internal control 
forward (100µM) 
 CACGTGGGCTCCAGCATT  
Apob internal control 
reverse(40µM) 
 TCACCAGTCATTTCTGCCTTTG  
Internal control probe 
(5µM) 
Cy5 CCAATGGTCGGGCACTGCTCAA Black Hole 
Quencher 2 
  
 Table 3.4 Conditions for qPCR 
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Cycle step Incubation times 
Initial 
denaturation 
94°C 2 min  
Hot start (10 
cycles) 
Step 1: 94°C for 30 sec 
Step 2: 64°C (-1°C/2 cycles) for 45 sec 
Step 3: 68°C for 30 sec 
Amplification 
(28 cycles) 
Step 1: 94°C for 30 sec 
Step 2: 60°C for 45 sec 
Step 3: 72°C for 30 sec (aquisition) 
Final 
extension 
72°C for 2 min 
 
3.2.3 Primary Cell Culture 
Primary dissociated cortical cultures were prepared as described in Chapter 2.2.2 with slight 
modifications. Heterozygous mice were mated and resulting embryos were harvested at embryonic 
day (E) 15.5. Each embryo was cultured individually and liver tissue was collected for genotyping as 
outlined in section 3.2.2. Following decapitation heads were stored in Hibernate media (Gibco) at 4°C 
until time of culture (10 minutes to 1 hour). Cortical tissue (including both cortex and hippocampus) 
were collected into 1ml HBSS and enzymatically dissociated in 0.0125% trypsin for 4 minutes, prior 
to plating. Cells were plated onto a variety of surfaces, pre-coated with poly L-lysine (Sigma Aldrich; 
details in Chapter 2.2.1). For immunofluorescence and neurite outgrowth assays, cells were plated onto 
12mm coverslips at a concentration of 30,000 viable cells per coverslip. For protein harvest, whole 
cells were plated into 12 well trays at a concentration of 200,000 viable cells per well. Cells were 
grown as described in Chapter 2.2.2.  
3.2.4 Western blotting 
Protein was harvested from whole cells plated in 12 well trays at 3 DIV in 100µL of RIPA buffer 
(Sigma) containing protease (Complete Mini Cocktail, Roche) and phosphatase inhibitors (AG 
Scientific). Protein quantification and Western blotting were carried out as described in Chapter 2.6. 
Following western blotting, membranes were incubated in human TDP-43 (Novus Biologicals, 
reference number H00023435, 1:1000; Zhang, 2008), total TDP-43 (binding to both mouse and human 
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TDP-43; Proteintec Group; reference number 1078-2-AP, 1:1000), GAPDH (Millipore, reference 
number MAB374, 1:5000), Lamin-AC (Santa Cruz, reference number SC-376248, 1:250).  
3.2.5 Nuclear and cytoplasmic distribution 
The distribution of total TDP-43 in the nucleus and cytoplasm was determined by 
immunocytochemistry and nuclear/cytoplasmic fractionation. For immunocytochemistry (outlined in 
Chapter 2.3, and Chapter 3.7.2), careful attention was paid to ensure that coverslips were consistently 
fixed, incubated with antibody, washed and imaged with identical exposures. MAP2 and DAPI were 
used to delineate cytoplasm and nuclei, regions of interest (ROIs) were constructed around these 
cellular compartments and the integrated density of TDP-43 labeling in these areas was measured as 
previously described (Herzog, Deshpande, Shapiro, Rodal, & Paradis, 2017) (Figure 3.1A). For 
cellular fractionation, nuclear and cytoplasmic proteins were extracted from cells at 3 DIV as described 
in Chapter 2.6.2, followed by Western blotting (Chapter 2.6).  
3.2.6 Proteomic mass spectrometry 
3.2.6.1 Protein harvest 
Protein was harvested from wildtype and homozygous neurons which had been plated in 12 well plates 
and grown to 10 DIV. One hundred microliters of lysis buffer (7M urea, 2M thiourea and 30mM tris) 
containing protease (Complete Mini Cocktail, Roche) and phosphatase inhibitors (AG Scientific) was 
used to extract protein. Cells were sonicated (for 1 minute with 15 seconds in the sonicator, 5 second 
out in ice), kept at 4°C for 2 hours, centrifuged at 13,000 rpm for 15 minutes, and supernatant collected. 
Protein concentration was determined by performing a Bradford assay as per manufactures protocol 
(BioRad Protein Assay, BioRad, Chapter 2.6.1). SDS-PAGE followed by silverstaining (BioRad, 
according to manufacterers instructions) was carried out on a sample of each of the extractions to 
verify that approximately equal amounts of protein were digested.  
 
Phalloidin   B3 Tub    Merge
Phalloidin with area ROI  B3 Tub with area ROI
Phalloidin with filopodia
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B
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Figure 3.1 Quantitation of immunocytochemical images. (A) Representative images of cortical 
neurons immunolabelled with MAP2 (green), TDP-43 (red) and stained with DAPI (blue). Dotted lines 
show boundaries of MAP2 labelling (green) and DAPI staining (blue). (B) (I) Representative images 
of cortical neurons immunolabelled with B3 tubulin (green) and stained with phalloidin (red). (II) 
Dotted line (red) used to quantify F-actin area. (III) Dotted line (green) used to quantify tubulin area. 
(IV) Dotted line (red) used to quantify filopodia length. Scale bars: A 10µm, B 5µm.  
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3.2.6.2 Formation of tryptic peptides 
Peptides were prepared from samples according to established methods (Wilson et al., 2010). Briefly, 
samples were reduced by adding 10µL of dithiothreitol (DTT; 100mM; BioRad) to 90µL of protein at 
a concentration of 1mg/ml and incubated overnight at 4°C. Samples were then alkylated by adding 
11µL of iodoacetamide (500mM) and incubated for 2 hours in the dark at room temperature. Proteins 
were digested by adding 1µL of trypsin from porcine pancreas (Sigma-Aldrich, 1mg/ml) to the tube 
containing proteins and flushed into the sample with 1ml of chilled methanol. Samples were incubated 
overnight at -20°C. The resulting peptides were collected by centrifugation at 13,000rpm for 5 minutes. 
Pellets were air-dried and reconstituted in 100µl of ammonium bicarbonate (Sigma-Aldrich; 100 mM) 
for 5 hours at 37°C. After 3 hours of incubation, an additional 1µL of trypsin was added to samples.  
3.2.6.3 Liquid chromatography separation and mass spectrometry 
The resulting tryptic peptides, equivalent to ~ 1µg digested protein, were analysed using nano high 
performance liquid chromatography (HPLC) on an Ultimate 3000 RSLCnano system (Thermo Fisher 
Scientific, MA, USA). Firstly, peptides were concentrated on a 20mm x 75µm PepMap 100 trapping 
column (3µm C18) at a flowrate of 5µL/min, using 98% water, 2% acetonitrile and 0.05% 
trifluoroacetic acid (TFA). Peptides were then separated on a 250mm x 75µm PepMap 100 RSLC 
column (2µm C18) at a flowrate of 300nL/min, held at 40°C. Separation included a 240 minute 
gradient from 98% mobile phase A (0.1% formic acid in water) to 50% mobile phase B (0.08% formic 
acid in 80% acetonitrile and 20% water) and included the following steps: 3-10% B over 10 minutes, 
10-40% B over 180 minutes, 40-50% B over 10 minutes, holding at 95% B for 10 minutes then re-
equilibration in 2% B for 15 minutes. The HPLC system was coupled to an LTQ-Orbitrap mass 
spectrometer, controlled using Xcalibur 2.1 software in data-dependent mode. MS/MS spectra were 
acquired using a Top8 method and 30-second dynamic exclusion of fragmented peptides, as previously 
described (Wilson et al., 2016).  
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3.2.6.4 Protein identification and analysis 
Data files were imported into MaxQuant version 1.5.1.2 (http://maxquant.org/) and MS/MS spectra 
were searched using the Andromeda engine against the complete Mus musculus reference proteome 
(ID 000000589) comprising 44,455 protein entries. Default settings for protein identification by LTQ-
Orbitrap MS/MS and label-free quantitation (LFQ) included a maximum of two missed cleavages, 
mass error tolerances of 20 ppm then 4.5 ppm for initial and main peptide searches, respectively, 0.5 
Da tolerance for fragment ions, variable methionine oxidation and fixed carbamidomethylation. A 
false discovery rate (FDR) of 0.01 was used for peptide-spectrum matches and protein identification. 
The full set of identified peptides and proteins (MaxQuant output files peptides.txt and 
proteinGroups.txt, respectively) are presented in Appendix 3.1. 
The MaxQuant algorithm MaxLFQ was used for peptide intensity determination and normalisation 
(Cox et al., 2014), using pair-wise comparison of unique and razor peptide intensities and a minimum 
ratio count of 2. The MaxQuant proteinGroups output file was processed as follows: The normalised 
label-free quantification (LFQ) intensity values, MS/MS counts and the numbers of razor and unique 
peptides for each of the identified proteins were imported into Perseus software version 1.5.031 
(http://perseus-framework.org/). Protein groups identified as potential contaminants and proteins only 
identified by site or by reverse database matching were removed and LFQ intensity values were log2–
transformed. The proteins were filtered to include only those detected in all three replicates of at least 
one genotype. Missing values were replaced with random intensity values for low-abundance proteins 
based on a normal distribution of protein abundances using default MaxQuant parameters. To 
determine proteins that were significantly altered in abundance between genotypes a two-sided t-test 
was used with a permutation-based FDR of 0.05, using 250 randomisations, and a minimum fold-
change cut-off of 1.3. The data was exported from Perseus into Excel (Appendix 3.2). To extract 
functional information from the proteomic data, proteins that were significantly up- or down-regulated 
in homozygote samples compared to wildtype samples were imported into the online bioinformatics 
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resource DAVID (version 6.8; https://david.ncifcrf.gov/; (Huang, Sherman, & Lempicki, 2009). 
Protein lists were analysed using the mouse genome database, and annotation clusters were ranked 
using the Functional Annotation Clustering tool based on default parameters, with p values < 0.05 after 
adjustment using the Benjamini-Hochberg correction for multiple testing considered significant. The 
complete set of Functional Annotation Clusters is reported in Appendix 3.2.  
3.2.7 Immunocytochemistry 
At 3 and 10DIV coverslips were rinsed, fixed and ICC was carried out as per Chapter 2.3. Primary 
antibodies were diluted in 0.6% Triton-X-100 (Sigma) and included: TDP-43 (mouse and human, 
Proteintec Group, reference number 10782-2-AP, 1:1000); MAP2 (Millipore, reference number 
MAB3418, 1:1000); beta 3 tubulin (Promega, reference number G712A, 1:5000), NFM (Millipore, 
reference number AB1987, 1:1000), SMI312 (Covance, reference number R500, 1:1000). Following 
overnight incubation at 4°C, coverslips were incubated in species-specific secondary antibodies for 
two hours. In some experiments, the f-actin stain phalloidin (1:200, Life Technologies) was applied to 
coverslips for 1 hour following secondary incubation. Nuclei were stained with DAPI (5µg/ml, Life 
Techologies) for 5 minutes. Coverslips were washed 3 x 10 minutes with PBS and mounted. Images 
were captured with a BX-50 Olympus microscope and a Photometrics Coolsnap HQ2 camera.  
3.2.8 Growth cone analysis 
Growth cones were analysed at 3DIV, and immunolabelled with beta 3 tubulin and f-actin. For each 
genotype, two coverslips from three different cultures (from different mothers) were examined. 
Growth cones were classified as filopodial, lamellipodial or blunt (Figure 3.6A), based on the paper 
by Khazaei et al. (2014). For classification, 100 growth cones from each genotype were systematically 
examined across two coverslips per culture (three cultures per genotype) by a researcher blinded to the 
genotype groups. Beta 3 tubulin labeling and f-actin staining were used to examine length and number 
of filopodia; size of growth cone; and ratio of actin to tubulin (Figure 3.1 B). Approximately 30 images 
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from the two coverslips for each culture were obtained, and ImageJ software was used for analysis as 
described previously (Khazaei et al., 2014). 
3.2.9 Neuron morphology analysis 
Phase contrast images of neurons at 3DIV were captured on a Nikon Live Cell microscope (Nikon 
Instruments Inc; NIS-Elements AR 4.00.12 Software, Nikon) by a researcher blinded to genotype 
groups. Approximately 60 individual neurons per genotype (two coverslips from three different 
cultures/mothers) were examined. Images were obtained systematically across each coverslip to 
capture neurons where the whole neurite tree could be visualised. Images were imported into 
Neurolucida (MBF Bioscience) and cell bodies and neurites were traced. Figure 3.7A demonstrates 
the decision-making process for branch points. The longest neurite, normally considered to be the 
axon, was also traced separately. Traced images were imported into Neurolucida Explorer (MBF 
Bioscience) to determine cell body size; length of longest neurite; number of neurite trees; total length 
of neurite tree; number of branches in each order; and total number of branch points.  
3.2.9.1 Mitochondria staining and quantification  
A mitochondrial tracking dye (MitoTracker Red CMXRos, Life Technologies) was added to 3 DIV 
live cortical cultures at a concentration of 100nM. Half the media from wells was removed and kept 
for washing after treatment. MitoTracker was added to culture wells for five minutes and then cells 
were washed using saved media. As MitoTracker was not well-retained after fixation, static counts of 
the number of mitochondria per 100µm of axon (from at least 50 axons from three different cultures 
per genotype) were carried out on two coverslips from three different cultures per genotype. 
3.2.10 Statistical analysis 
Unless otherwise stated, statistical analysis was carried out using a one-way ANOVA with Tukey’s 
post hoc test. Neurolucida tracing data and growth cone morphology data were analysed using mixed 
models with random intercepts to account for clustering within culture batches. The assumptions of 
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normality of residuals and homogeneity of variance were checked using graphical methods (Q-Q and 
residual plots), and where the assumption of normality was violated, data were either log transformed 
or a generalised linear model with appropriate link function (e.g. Poisson link function for count data) 
was fitted to ensure that statistical conclusions were robust. Likelihood ratio tests were used to 
determine statistical significance. To test differences in the distribution of growth cone morphology 
between genotypes, Pearson’s Chi-square test of homogeneity was calculated. Post-hoc comparisons 
were corrected using the Bonferroni method. All statistical analysis was conducted in the R statistical 
language (R Core Team, 2016). Mixed models were fitted using the ‘lme4’ package in R (Bates, 2015). 
Detailed analyses are documented in Appendix 3.3. Data are presented ± standard error of the mean 
(SEM) and significance set at p<0.05. 
 
3.3 RESULTS 
3.3.1 Expression of TDP-43 in development  
Western blot analysis of protein harvested from cultured cortical neurons grown to 3DIV confirmed 
the presence of human TDP-43 in cells from both homozygous and heterozygous embryos, and the 
absence from wild type cells, using a human-specific TDP-43 antibody (Zhang, Tanji, Mori, & 
Wakabayashi, 2008) (Figure 3.2 A). Human TDP-43 was significantly increased in homozygote and 
heterozygote cells compared to wildtype (p<0.05) (Figure 3.2 B). Although there was no difference 
between heterozygote cells and wildtype cells, the blot (Figure 3.2 A) demonstrates the presence of 
the transgene. As TDP-43 is a self-regulating protein, the level of total TDP-43 expression was then 
determined using an antibody that recognizes both mouse and human (total) TDP-43. Total TDP-43 
was significantly increased in both heterozygote and homozygote cells compared to wildtype cells 
(p<0.05) (Figure 3.1 C).  
3.3.2 Cellular localisation of TDP-43 
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In ALS/FTD, there is evidence that mislocalisation of TDP-43 from the nucleus to the cytoplasm may 
cause both gain and loss protein function (Lee et al., 2012). To determine whether increased expression 
of human TDP-43 caused a change in localisation of protein expression, the distribution of TDP-43 
(mouse and human) was analysed in the nucleus and cytoplasm at 3 DIV. Qualitative analysis of 
immunocytochemically labelled neurons suggested that TDP-43 was more abundant in the cytoplasm 
in homozygote cells (Figure 3.3 A). Integrated densitometry of TDP-43 fluorescence demonstrated 
higher levels in both the nucleus and cytoplasm in homozygote cells compared to wildtype cells 
(p<0.05) (Figure 3.3 B, C). These results qualitatively showed that both total TDP-43 and human TDP-
43 were expressed at higher levels in the nuclear and cytoplasmic compartments in homozygote 
samples compared to heterozygote and wildtype samples.  
3.3.3 Global alterations to protein expression following TDP-43 overexpression 
TDP-43 interacts with over 30% of the genome (Sephton et al., 2011) and its effects are likely to be 
broad. A proteomics approach was used to determine global changes to protein expression in 
transgenic cells compared to wildtype. Protein was harvested from homozygous and wildtype neurons 
grown to 3 DIV and 10 DIV, however protein quantity and quality at 3 DIV was insufficient for 
downstream analysis. Principal component analysis of homozygote samples and wildtype samples 
demonstrated a relatively high degree of variability between the three homozygote replicates (Figure 
3.4 A) and therefore statistical analyses were less stringent than would otherwise be used. In the 10 
DIV samples, 85 proteins were downregulated and 94 proteins were upregulated in homozygote 
samples compared to wildtype samples (FDR < 0.05, FC ± 1.3) (Figure 3.4 B). The online 
bioinformatics database tool, DAVID, was used for functional annotation clustering to identify protein 
families that clustered together within up- or down-regulated protein groups (Figure 3.5 A). Functional 
terms associated with downregulated proteins included translation, rRNA binding, and mitochondria, 
whereas upregulated proteins were associated with the COP9 signalosome, proteasome complex and  
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Figure 3.2. Characterisation of total and human TDP-43 expression. (A) Expression of total and 
human TDP-43 were analysed by Western blot from cortical neuron protein from the three genotypes 
at 3 DIV (n=3 cultures per genotype).  Quantification was carried out relative to GAPDH for human 
TDP-43 (B) and total TDP-43 (C). Results are mean and standard error. Statistical significance is 
defined as *p<0.05, **p<0.01.  
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Figure 3.3 Cellular localisation of TDP-43. (A) Cortical neurons from the three genotypes at 3DIV 
(n= 3 cultures per genotype, n= >20 neurons per culture) immunolabelled for TDP-43 (red), MAP2 
(green) and DAPI (blue). MAP2 and DAPI were used to delineate the nucleus (B) and cytoplasm (C) 
within which the integrated density of TDP-43 was determined. Results are mean and standard error. 
Statistical significance is defined as *p<0.05. Scale bar 10µm.  
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Figure 3.4 Proteomic sample characterisation. Proteins extracted at 10 DIV from homozygote and 
wildtype cortical neurons (n= 3 cultures per genotype) were digested into peptides, separated via liquid 
chromatography and identified via mass spectrometry. (A) Principal component analysis was carried 
out. Homozygote samples were compared to wildtype samples. (B) Volcano plot showing –log10 
transformed p-values compared to a log2 transformed fold change of 1.3. Proteins significantly above 
and below this value are demonstrated by red and green, respectively.  
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Figure 3.5 Protein families enriched in homozygote samples compared to wildtype samples. 
Significantly upregulated and downregulated proteins were analysed in functional terms. (A) Pathways 
with the enrichment scores higher than 2.0 (Fisher’s exact test p-values for enriched terms were log 
transformed) are shown, with functional pathways implicated as upregulated (red) or downregulated 
(green). (B) Heat map of actin binding proteins showing the maximum z-score for each sample repeat, 
for each protein.  
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actin binding. These results demonstrated that proteins related to the normal function of TDP-43 were 
disrupted by increased expression, as well as proteins associated with functions known to be altered 
by abnormal TDP-43 (mitochondria and proteasome). Furthermore, increased expression of TDP-43 
upregulated proteins related to actin binding, including Actn1, Arpc4, Capza1, Capza2, Cotl1, 
Marcksl1 and Myh9 (Figure 3.5 B). Many of these proteins are involved in the regulation of growth 
cone dynamics and axon outgrowth.  
3.3.4 Effects of TDP-43 overexpression on growth cones 
Previous studies have suggested that altered TDP-43 affects neurite outgrowth (Fallini et al., 2012; 
Tripathi et al., 2014). This is controlled by growth cones, found at the growing tip of neurites, in which 
attractive or repulsive extracellular guidance cues cause reorganisation of microtubules and actin 
filaments. Since altered TDP-43 expression affects actin-dependent processes, the morphology and 
cytoskeletal composition of growth cones in homozygous, heterozygous and WT TDP-43 cultured 
neurons were examined. Neuronal growth cones were examined at 3 DIV, when cortical neurons are 
actively pathfinding in culture before the majority of synapses form (Dotti, Sullivan, & Banker, 1988). 
Immunolabelling with beta 3 tubulin and staining with the f-actin stain, phalloidin, were used to 
visualize growth cones. Growth cones were classified as filopodial, lamellipodial or blunt (based on 
Khazaei et al. 2014) (Figure 3.6 A). A chi-squared test for homogeneity demonstrated a significant 
difference (χ24 =11, p<0.05) in the distribution of growth cone morphologies between genotypes; 
specifically, heterozygote cultures had fewer lamellipodial growth cones, and more filopodial growth 
cones (Figure 3.6 B). Filopodial growth cones across the genotypes were further analysed for changes 
to the number (Figure 3.6 C) or length (Figure 3.6 D) of growth cone filopodia, however no differences 
were found. The area of phalloidin-stained f-actin (Figure 3.6 E) and beta 3 tubulin (Figure 3.6 F) 
within filopodial growth cones was similar between genotypes, as was the ratio of these areas (Figure 
3.6 G).  
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3.3.5 Effects of overexpression of TDP-43 on neurite morphology 
Initiation of neurites and branching is controlled by expression and reorganisation of cytoskeletal 
proteins. To investigate whether changes to TDP-43 expression cause cytoskeletal alterations, neuron 
morphology across the three different genotypes was examined. Neurons at 3 DIV were traced using 
Neurolucida and several morphological measures were assessed. Axonal outgrowth, quantitated by 
measuring the longest neurite in each cell, and the total length of all neurites showed no significant 
differences between genotypes (Figure 3.7 B, C). Neuritogenesis was examined by looking at the 
number of neurite trees coming from the cell body, the number of branches in each order (primary to 
quaternary) and the length of these branches (branching schematic demonstrated in Figure 3.7 A). 
From these analyses, the only parameter altered was the total number of branches in neurite trees, 
which was increased in heterozygous compared to wildtype cells (p<0.05) (Figure 3.7 E, F).   
3.3.6 Axonal alterations following overexpression of TDP-43 
Next, potential effects of TDP-43 overexpression on axons were characterised. Immunocytochemical 
labelling of neurofilament medium subunit (NFM) and phosphorylated neurofilament triplet protein, 
SMI312 was qualitatively examined. Wildtype cultures demonstrated intact axons with few examples 
of fragmentation or beading. Both homozygote and heterozygote cells at 10DIV demonstrated some 
features of axonal degeneration (Figure 3.8 A). Heterozygote cultures showed examples of ring 
structures that were positive for both NFM and SMI312 were present. These structures have previously 
been described in unhealthy axons in mSOD1 models of ALS (Anna E King, Blizzard, Southam, 
Vickers, & Dickson, 2012) and around beta amyloid plaques in Alzheimer’s disease (Dickson et al., 
2005;  Dickson et al., 1999).  Additionally, homozygote cultures showed examples of neurons with 
fragmentation of SMI312 labelling along axons, and frequent examples of axonal beading with 
accumulations of NFM in chains along the axons. Previous studies in this mouse model have  
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Figure 3.6 Alterations to growth cones. Cortical neurons from the three genotypes at 3DIV (n= 3 
cultures per genotype) were immunolabelled for B3 tubulin (green) and stained with phalloidin (red). 
Growth cones were classified as filopodial, lamellipodial or blunt (A) and counted for each genotype 
(n= 100 growth cones per culture) (B). Filopodial growth cones were analysed further (C-G) (n= >15 
filopodial growth cones per culture). Values are mean and standard error. Statistical significance is 
defined as *p<0.05, scale bar 5µm.  
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demonstrated abnormal clustering of mitochondria and altered expression of proteins which control 
mitochondrial dynamics (Xu et al., 2010). To determine whether there were axonal mitochondrial 
alterations attributable to TDP-43 changes static observations of mitochondria distribution and 
numbers were carried out. There were no significant differences in the number of mitochondria per 
100µm of axon, although there was a trend toward an increase in heterozygote cells compared to 
wildtype cells (Figure 3.8 B, C).  
 
3.4 DISCUSSION 
Following on from reports that TDP-43 plays a role in neurite development, this study focused on 
gaining a better insight into the relationship between TDP-43 and the neuronal cytoskeleton. Due to 
the large number of cytoskeletal proteins, and the known interactions between TDP-43 and a large 
number of proteins, a proteomic approach was taken. This demonstrated a range of proteins that were 
differentially regulated, of which actin-binding proteins were of particular interest. Additionally, non-
pathological TDP-43 overexpression resulted in increased branching and altered growth cone 
morphology (Figure 3.9).  
In the present study, overexpression of wildtype human TDP-43 resulted in increased expression of 
total and human TDP-43 in developing neurons. These results are in line with those from Xu et al. 
(2010) who demonstrated increases in both human and total TDP-43. These authors observed a 
larger increase in human TDP-43 than total TDP-43 when comparing transgenic mice to controls, 
which they attributed to downregulation of endogenous mouse TDP-43. Although TDP-43 is a 
highly regulated protein, capable of autoregulation, the results of the present study suggest that 
overexpressing two copies of human TDP-43 may exceed this regulatory capacity, resulting in higher 
overall levels.  
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Figure 3.7 Alterations of neuron morphology. Cortical neurons were imaged at 3DIV from the 3 
genotypes (n=5 cultures per genotype, n= >20 neurons per culture). Cell bodies, neurites, and the 
longest neurites were traced using Neurolucida and branch points defined (A), yielding measures of 
morphological features (B-E). (F) Example phase contrast images of neurons showing branch 
morphology. Values are mean and standard error. Statistical significance is defined as *p<0.05. Scale 
bar 50µm. 
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Figure 3.8 Alterations to axon structure and function. (A) Cortical neurons from the three 
genotypes at 10DIV (n= 3 cultures per genotype) were immunolabelled with SMI-312 (red) and NFM 
(green) antibodies. In heterozygous cultures, arrowheads show ring-like structures. In homozygous 
cultures, arrows indicate fragmented SMI312 and arrow heads indicate swellings along the axon. (B) 
Cortical neurons from the three genotypes at 4DIV stained with the mitochondrial marker, Mitotracker 
(mitochondria puncta indicated by arrowheads). (C) Static counts of mitochondria per 100µm axon 
were obtained. Results are mean and standard error. Scale bar 10µm. 
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A key pathological feature of FTD/ALS associated with TDP-43 is the mislocalisation of TDP-43 from 
the nucleus to the cytoplasm. The current data shows that homozygous neurons have a modest increase 
in TDP-43 within both cytoplasm and nuclei, which may explain the differences in morphology 
phenotypes between the homozygous and heterozygous neurons. Increased expression of TDP-43 
could alter its role in both compartments, including interactions with DNA and RNA targets, as well 
as transport in mRNA granules (Alami et al., 2014). It was not surprising that a more robust change in 
TDP-43 levels within the nuclear and cytoplasmic compartments was not found between the 
genotypes. Xu et al., (2010) examined brain tissue from postnatal homozygote TDP-43Prp mice and 
also found that mislocalisation of human TDP-43 was only detected occasionally. It is has been 
demonstrated in other models of TDP-43 pathology, such as those expressing TDP-43 mutations, that 
cytoplasmic mislocalisation of TDP-43 is more prominent and that this is toxic to cells (Barmada et 
al., 2010). Results from the current study may indicate that there is a differential effect of increased 
TDP-43 in heterozygotes and TDP-43 with pathologic changes in homozygotes, demonstrated by 
changes to branching and growth cone morphology observed only in heterozygote mice. It is possible 
that the increased cytoplasmic expression of TDP-43 in homozygous neurons may have been 
undergoing early protein oligomerisation or aggregation, which produced toxic effects, negating the 
results observed in heterozygous neurons.  
 
Global changes to protein expression 
This study examined whether altered TDP-43 levels could result in changes to cytoskeletal proteins. 
Due to the vast number of interaction pathways affecting cytoskeletal and associated proteins, a 
proteomic approach was taken to give a global view. Bioinformatic analysis of the proteomes of 
wildtype and homozygous mice demonstrated changes across a range of functional domains, including 
several linked to established TDP-43 roles. For example, proteins related to RNA binding and 
translation were highly down-regulated. TDP-43 is a known RNA binding protein, interacting with 
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over 30% of the genome (Sephton & Yu, 2015), and is likely to regulate the translation of a number 
of mRNAs (Strong et al., 2007). Previous proteomic studies examining interacting partners of TDP-
43 demonstrate strong associations with translation machinery (Freibaum, Chitta, High, & Taylor, 
2010). Alterations to the localisation and therefore function of TDP-43 in homozygote cells would be 
consistent with alterations to these protein families. Other observed changes included the ubiquitin-
proteosome system (UPS), which is highly associated with ALS/FTD. TDP-43 is ubiquitinated in 
aggregates of diseased tissue (Neumann et al., 2006). Mutations in ubiquilin-2, seqestosome-1 and 
valosin-containing protein (VCP) are associated with ALS/FTD with characteristic TDP-43 pathology. 
Levels of TDP-43 protein are regulated by the UPS through degradation of monomeric TDP-43, 
preventing accumulation and aggregation (Scotter et al., 2014), emphasizing the importance of 
regulation to this system. Overexpression of a protein is also consistent with an upregulation of the 
protein degradation system to try and normalise protein levels within the cell, and may be consistent 
with pathological TDP-43 aggregation. 
 
Down regulation of mitochondrial proteins was also observed, in accordance with previous research, 
which demonstrated clustering of mitochondria within axons and dendrites in the same mouse model 
(Xu et al., 2010). In the current study, proteins related to mitochondrial function were downregulated 
in homozygote cells at 10DIV, although there were no alterations to the distribution or number of 
axonal mitochondria in cultures at 3DIV. Mitochondrial dysfunction is a common theme in TDP-43 
mouse models of ALS and FTD, causing aggregation, fragmentation or vacuolation of mitochondria 
(Magrane, Cortez, Gan, & Manfredi, 2014; Wang et al., 2013). Abnormal mitochondria are also a 
feature of human disease with swollen and vacuolated mitochondria observed 
in neurofilamentous axon swellings (Sasako et al., 2007).  
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Figure 3.9 Summary of findings. Schematic summarising differences in TDP-43 localisation, 
branching, growth cone morphology and activation of the proteasome system from neurons cultured 
from the three genotypes. Pink/red colour demonstrates the localisation and level of TDP-43 
expression. 
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The effect of TDP-43 alterations on the cytoskeleton 
Of particular interest to the current study was the finding that actin-binding proteins were among the 
most up-regulated proteins in the proteomic analysis. Actin binding proteins are important for 
controlling the cytoskeletal network through actions such as filament nucleation, severing, 
crosslinking, end capping and monomer sequestering. For cortical neurons during development, these 
processes affect pathfinding, neurite outgrowth and branching. A number of actin binding proteins 
were altered, including non-muscular myosin heavy chain 11B (NMHC11-B), also known as myosin-
9 (MYH9), which was upregulated in homozygote cells. This protein has previously been implicated 
in TDP-43 pathology; SH-SY5Y cells with a TDP-43 knockdown resulted in a cytoplasmic increase 
and a nuclear decrease of MYH9 levels compared to controls (Stalekar et al., 2015), and 
immunoprecipitation of HEK293T cells transfected with FLAG-TDP-43 demonstrated that MYH9 
interacts with TDP-43 (Freibaum, Chitta, High, & Taylor, 2010). In neurons, MYH9 is important for 
driving neurite outgrowth, is involved in growth cone motility (Wylie, 1998) and for NMDA receptor 
trafficking (Amparan et al., 2005). Alterations to NMHC11-B protein expression have been found in 
both ALS patient brains containing TDP-43 aggregates and in transgenic pigs overexpressing the TDP-
43 M337V mutation (Wang et al., 2015). This was hypothesised to be due to the co-mislocalsation of 
TDP-43 and the splicing factor proline-glutamine rich (PSF) and NeuN, which are both responsible 
for regulation of NMHC-11B alternative splicing (Kim, Kim, Adelstein, & Kawamoto, 2011). Mouse 
neurons expressing the M337V mutation had decreased neurite length, which was rescued by 
overexpression of the ‘dominant’ spliced exon (Wang et al., 2015). Although morphological 
differences were not detected in homozygous cells, they were found in heterozygous cells, suggesting 
that actin alterations could have downstream consequences on the neurons that could develop over 
time.  
In more developed neurons, the actin cytoskeleton and actin binding proteins become important for 
supporting synaptic transmission and synaptic plasticity, as the main structural component of synapses 
Chapter 3 – Results  
    
 
29
(Dillon, 2005). Arp2/3, highlighted by the proteomic data, aids the formation of F-actin networks (Dos 
Remedios, 2003). Its putative interaction with TDP-43 and the identified actin-binding proteins is yet 
to be determined. It will be important in future studies to follow up proteomic data with Western blots 
to confirm alterations to proteins identified.  
 
Effects of altered cytoskeleton on neuronal phenotype 
In the current study, morphology was examined at 3DIV because at this developmental stage cortical 
neurons have become polarised and are undergoing dynamic branching and pathfinding (Dotti et al., 
1988). Filopodial growth cones, important for sampling the extracellular environment (Omotade, 
Pollitt, & Zheng, 2017), were also increased. The formation of filopodia and lamellipodia is thought 
to be controlled by rapid polymerisation of the actin cytoskeleton at the leading edge of the growth 
cone, followed by depolymerisation within the growth cone. TDP-43 interacts with members of the 
guanosine triphosphate hydrolase enzyme family (GTPase) involved in these processes. Rac1 is 
important for the formation of lamellipodia while Cdc42 is important for forming filopodia (Nobes, 
2017). Knockdown of TDP-43 inactivated both Rac1 and Cdc42 (Iguchi et al., 2009), plausibly 
explaining alterations to growth cone morphology following TDP-43 overexpression.  
In the current study, total branch number was also increased in heterozygous neurons, although the 
length of the neurite trees was similar across genotypes, implying that neurons became more ramified 
without a change in neurite length. It is known that overexpression of both wildtype and mutant cause 
a decrease in neurite outgrowth (Fallini, Bassell, & Rossoll, 2010; Tripathi et al., 2014) which is 
accompanied with redistribution of TDP-43 to the cytoplasm (Tripathi et al., 2014). Branch formation 
requires coordinated changes in actin and microtubules, and differs in axons and dendrites. Due to the 
early age of the cultures it was difficult to identify the axon, and for this reason branch data was pooled 
from all neurites. A general feature of neurite branching appears to be the protrusion of actin filaments 
from filopodia and/or lamellipodia on the neurite, followed by invasion of microtubules as the branch 
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matures and continues extending (Armijo-Weingart & Gallo, 2017). In line with these findings, Lu 
and colleagues (Lu, Ferris, & Gao, 2009) found that overexpression of Drosophila TDP-43, or human 
TDP-43 in Drosophila, increased dendritic branching of sensory neurons. Conversely, Schwenk and 
colleagues (2016) found that knockdown of TDP-43 in cultured hippocampal neurons reduced the 
complexity of dendrites at both 10 and 19DIV. These alterations were attributed to reduction of 
expression of cell surface receptors important for cell survival and neurite outgrowth (Schwenk et al., 
2016).  
TDP-43 interacts with a myriad of different proteins and mRNAs, and these cytoskeletal changes could 
occur through a range of pathways, such as that involving glycogen synthase kinase 3b (GSK-3b) and 
microtubule associated protein 1b (MAP1b). TDP-43 is known to activate GSK-3b (Stoica et al., 2014) 
and in fact loss of GSK-3b suppresses TDP-43 pathology in drosophila (Sreedharan, Neukomm, 
Brown, & Freeman, 2015). GSK-3b is known to directly phosphorylate MAP1b (Trivedi et al., 2005) 
and the GSK-3b- MAP1b pathway controls neurite branching (Barnat et al., 2016). The slight increase 
in TDP-43 in heterozygote cultures may have increased GSK-3b levels, and thereby MAP1b 
phosphorylation and neurite branching. In contrast, in homozygote cultures, higher levels of TDP-43 
within both the nucleus and the cytoplasm may become toxic and impact on the normal function of 
TDP-43.  
Axon pathology and degeneration are a feature of TDP-43-mediated disease. The TDP-43Prp model 
shows both axon and myelin degeneration in spinal cords. The mechanism of TDP-43-induced axon 
degeneration is thought to be distinct from Wallerian degeneration with evidence that axon degeneration is not 
altered by blocking genes associated with Wallerian degeneration in a Drosophila model with mutant TDP-43 
(Sreedharan et al., 2015). In this study, a small increase in TDP-43 caused neurofilament ring-like 
structures to form, and a large increase caused fragmentation of SMI312 and blebbing of NFM. These 
observations are consistent with features of early axon degeneration.  
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During FTD/ALS cells are known to undergo loss of connectivity, and alterations to dendritic 
arbourisation and dendrite length have been observed in cases of FTD/ALS (Ferrer et al., 1991). During 
disease states, cells may increase their amount of TDP-43 to try and reestablish connectivity. However, 
concomitant stresses on the UPS system may alter the ability to degrade excess TDP-43, leading to 
aggregation and mislocalisation. Synaptic disruption with swollen pre-synaptic terminals is a feature 
of both ALS and FTD (Zhou et al., 1998) and is consistent with alterations to the actin cytoskeleton. 
The results of this study highlight the importance of tight regulation of TDP-43 levels, and suggest 
future studies examining TDP-43’s role in regulation of the cytoskeleton.  
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4 EFFECTS OF ALTERED TDP-43 IN A NOVEL CNS DISEASE MODEL  
4.1 INTRODUCTION 
There is now substantial evidence that TDP-43 plays important roles in regulating the outgrowth of 
neurites and synaptic morphology (Handley et al., 2016; Majumder et al., 2012). However, detailed 
understanding of the effect of TDP-43 alterations on neuronal morphology is still currently lacking. 
While the mSOD1 G93A mouse is a relatively good model of the axon pathology associated with ALS 
(King et al., 2012), axon pathology in models of TDP-43-mediated disease is less prominent, 
potentially due to the complex nature of premature death in many of these models. Select models do 
show features of neurite pathology. For example, overexpressing wildtype human TDP-43 under the 
prion promoter (described in Chapter 3) induces axon degeneration in the spinal cord (Xu et al., 2010), 
and mice expressing the A315T TDP-43 mutation and YFPH under the Thy1 promoter, exhibit altered 
synaptic function and dendritic spine morphology (Handley et al., 2016). Another model, expressing 
TDP-43 with a mutant nuclear localisation sequence (NLS) under the neurofilament heavy (Nefh) 
promoter, shows cytoplasmic accumulation of phosphorylated and ubiquitinated TDP-43 across the 
CNS, accompanied by axonal dieback from neuromuscular junctions then motor neuron loss (Walker 
et al., 2015).  
Examining the cellular changes and mechanisms that induce axon pathology in animal models is 
challenging, due to the fine diameters and anatomical complexity of axon pathways in the CNS. The 
visual system is often used as a model to examine ultrastructural changes in axon degeneration 
following insults such as injury (Knoferle et al., 2010). 
The visual system offers a unique opportunity to examine axonal defects in vivo by providing access 
to the central nervous system (CNS) without invasive surgery. Adeno-associated viruses (AAVs) can 
be used to efficiently transduce retinal ganglion cells (RGCs) with foreign genes (Grant, Ponnazhagan, 
Wang, Srivastava, & Li, 1997) via injection into the eye (Figure 4.1A). The RGCs are 
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Figure 4.1 Eye model and retina layers. (A) Drawing of the eye showing injection into the vitreous 
humour. Green neurons indicate retinal ganglion cells (RGC), passing through the optic nerve (ON) to 
the lateral geniculate nucleus (LGN). (B) Schematic indicating the three substances injected into the 
eye:  AAV2 constructs containing TDP-NLS–-GFP or TDP-WT-GFP, and PBS vehicle. (C) Drawing 
of layers and cell types within the retina (adapted from Swaroop, 2010) and DAPI stained cross-section 
of mouse retina.  
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 a well-characterised population of neurons and their unique location in the retina (as demonstrated in 
Figure 4.1B) allows easy access for transduction of their soma as well as an opportunity for detailed 
analysis of dendrites within the retina, axons within the optic nerve and axon terminals within the 
visual target areas of the brain (including the lateral geniculate nucleus and superior colliculus) (Figure 
4.1A). The functional consequences of foreign gene transduction of RGCs can be assessed by 
measuring the animals’ visual acuity.  
In order to investigate what might lead to the neurite abnormalities observed in FTD-TDP and ALS-
TDP disease, an appropriate model of TDP-43 pathology is needed. Mislocalisation of TDP-43 from 
the nucleus to the cytoplasm is a key pathological feature of TDP-43-mediated disease (Neumann et 
al., 2006) and in cell culture models has been shown to be the most important driver of cellular toxicity 
(Barmada et al., 2010). In disease, TDP-43 is depleted from the nucleus, and this mislocalisation is 
proposed to impair its normal nuclear functions. In the cytoplasm, TDP-43 forms insoluble aggregates, 
positive for ubiquitin and phosphorylated TDP-43 epitopes, which may harm the cell by sequestering 
other RNA binding proteins (Lee et al., 2012). Several groups have manipulated the nuclear export 
sequence (NES) and NLS regions of TDP-43 which has resulted in alterations to neurites. In cultured 
neurons, mutation to the NLS caused cytoplasmic retention of TDP-43, altered neuron morphology 
and decreased length of axons and dendrites (Han et al., 2013); similar expression in vivo leads to axon 
degeneration (Walker et al., 2015). In the current study, TDP-43 with a defective NLS was expressed 
in the visual system to create a new TDP-43 disease model. RGCs of C57Bl/6, wildtype (WT), mice 
were transduced with AAV2 constructs containing the human TDP-43 sequence with a defective NLS, 
fused to GFP (TDP-NLS–-GFP), and human wildtype TDP-43, fused to GFP (TDP-WT-GFP) (Figure 
4.1). Detailed analysis of the cellular changes within the retina and optic nerve were carried out to 
assess the effects of overexpression of WT TDP-43 and mislocalisation of TDP-43 to the cytoplasm.  
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4.2 METHODS 
4.2.1 Animals:  
All experiments involving animals were approved by the University of Tasmania Animal Ethics 
Committee (A14189 and 16522) in accordance with the Australian Guidelines for the Care and Use of 
Animals for Scientific Purposes (National Health and Medical Research Council, 2013).  
4.2.2 Generation of AAV2 viruses: 
Constructs contained human wildtype TDP-43 (TDP-WT, refseq NM_007375) or human TDP-43 with 
a mutated nuclear localisation signal (TDP-NLS–), fused at the C-terminus to mGFP. A commercial 
lentiviral TDP-43 plasmid (RC210639 TARDBP insert, cloned into pLenti-C-mGFP PS100071, 
Origene Technologies) was purchased, and site-directed mutagenesis of the human TDP-43 protein 
sequence was used to create a defective NLS through a missense mutation (ΔNLS1, 
K82A/R83A/K84A, as described in Winton et al. (2008). GFP-tagged TDP-43 inserts (TDP-WT-GFP 
and TDP-NLS–-GFP) were cloned into AAV constructs by Vector Biolabs and AAV with serotype 2 
(AAV2) virus produced. Both TDP-WT-GFP and TDP-NLS–-GFP were under the control of the CAG 
hybrid promoter, consisting of the cytomegalovirus and chicken β-actin promoter (Martin, Klein & 
Quigley 2002). The TDP-WT-GFP virus had a titre of 2.7×1013 GC/ml and TDP-NLS–-GFP virus had 
a titre of 1.2×1013 GC/ml.  
4.2.3 Eye injections 
Mice were anaesthetised with 5% isoflurane (Isothesia, Henry Schein) in oxygen (600 ml/min). Once 
mice were anaesthetised, isoflurane and oxygen were reduced to 2% and 300ml/min respectively. For 
intravitreal injection, a hole was created in the temporal quadrant of the sclera of the left eye with a 
31-gauge needle and 1µL treatment solution was slowly injected into the vitreous humour using a 33-
gauge needle connected to a Hamilton syringe (Intraocular injection kit, World Precision Instruments, 
(Massoll, Mando, & Chintala, 2013). The needle tip was inserted into the superior hemisphere of the 
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eye at the level of the pars plana, at a 45° angle through the sclera and into the vitreous body. This 
route of administration was used to avoid retinal detachment or injury to the eye structures, including 
the lens and iris. The injection was performed over a timecourse of 10 seconds and then the needle was 
held in place for an additional 30 seconds to prevent leakage of the virus/vehicle. Following this, the 
mouse was allowed to recover on a heating pad.  
To determine the optimal injection titre of virus, twelve C57Bl/6 mice (aged 10 to 16 weeks of age) 
were injected with serially diluted TDP-WT-GFP in PBS (virus concentration and animal numbers in 
Table 4.1) and left for 1 month for the virus to be expressed. An additional pilot study was carried out 
to confirm whether similar results were obtained with the TDP-NLS–-GFP AAV2. These mice were 
perfused over a timecourse of 7 (n=2), 14 (n=2) and 28 (n=2) days to determine when induction of 
virus expression could be observed.  
In mice, synaptogenesis occurs within the first to third week of postnatal development (Pfrieger, 2009), 
with synapses subsequently pruned before reaching adult levels at approximately four months of age 
(De Felipe, 1997). Thus, to ensure synaptic maturity six-month-old C57Bl/6 mice were used. Using 
optimal levels determined previously, mice (n=21) were injected with either TDP-WT-GFP (n=7), 
TDP-NLS–-GFP (n=7) or PBS vehicle (n=7). Mice were left for 3 months to allow expression of the 
constructs and development of pathology, based on evidence that an inducible TDP-43 mouse model 
overexpressing the same NLS defect developed axonal changes four weeks post transgene induction, 
and had severe denervation of neuromuscular junctions by 6 weeks post induction (Walker et al., 
2015). 
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Table 4.1 Pilot study animal numbers and virus concentrations 
Virus concentration (GC/ml) Number of mice 
1.35×1013 2 
6.75×1013 1 
3.375×1012 2 
1.69×1012 1 
8.44×1011 2 
4.22×1011 1 
2.11×1011 1 
1.05×1011 1 
5.27×1010 1 
 
4.2.4 Optomotor response 
The optomotor response was used to measure alterations to visual acuity in mice injected with TDP-
43 constructs or controls and was measured as previously described (Heitz et al., 2012) based on 
principles described by Abdeljalil et al. (2005). The testing rig (Figure 4.5 A) consisted of a 10cm 
platform, surrounded by a motorised drum (29 cm in diameter), which rotated clockwise or anti-
clockwise at two rpm, lined with 5mm black and white vertical stripes. Mice were placed on the 
platform and habituated to the experimental setup for 5 minutes every day for 7 days prior to injection. 
The optomotor response (defined as head turning to match the speed of drum rotation) was tested by 
rotating the drum clockwise or anticlockwise. In mice, the left (treated) eye controls the clockwise 
optomotor response, and the right (untreated) eye controls the anticlockwise response (Heitz et al., 
2012). Testing was carried out 1 week pre-injection, 1 week post-injection and then fortnightly for 3 
months.  
4.2.5 Perfusions 
At 9 months of age, 3 months post-treatment, animals were euthanised for immunohistochemistry 
(IHC; n=4 animals/treatment) or transmission electron microscopy (TEM, n=3 animals/treatment). For 
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IHC, perfusions were carried out as per Chapter 2.4.  For TEM, mice were anaesthetised as per Chapter 
2.4, and then perfused with 0.9% saline until the paws and liver blanched. Perfusion with 60ml of 2% 
PFA 2.5% glutaraldehyde in phosphate buffer was then carried out. Brains were immediately 
dissected, severing the optic tract caudally to the optic chiasm. All tissue was post-fixed in perfusion 
solution at 4°C overnight. The following day, the left (injected) and right (uninjected controls) eyes 
were dissected under microscopic guidance to obtain retinas, and optic nerves as depicted in Figure 
4.2. 
4.2.6 Immunohistochemistry 
Transduction efficiency and retina IHC was carried out using an antibody against RNA-binding protein 
with multiple splicing (RBPMS, a retinal ganglion cell marker), on free floating wholemount retina 
with a 48 hour primary antibody incubation as described in Chapter 2.5. Other IHC studies were carried 
out on 16µm cross-sectioned retina mounted on slides (cryopreservation and sectioning as described 
in Chapter 2.5.1), using the primary antibodies in Table 4.2.  
Table 4.2 Primary antibody information  
Name Antigen Species Dilution Supplier Reference 
number 
RBPMS RNA-binding protein with multiple 
splicing (marker of RGCs) 
Rabbit 1:1000 Genetex GTX118619 
GFP Green fluorescent protein Chicken 1:1000 Invitrogen A10262 
GFP Green fluorescent protein – used in 
combination with NFH 
Mouse 1:1000 NeuroMab 75-131 
GFAP Glial fibrillary acidic protein 
(marker of astrocytes) 
Mouse 1:1000 NeuroMab G3893 
Iba1 Ionised calcium binding adaptor 
molecule 1 (marker of microglia) 
Rabbit 1:1000 Wako 019-19741 
NFH Neurofilament heavy chain Chicken 1:1000 Millipore AB5539 
Synaptophysin Pre-synaptic vesicle marker Rabbit 1:500 Millipore AB9272 
 

Chapter 4 – Results  
    
 
9
 
 
 
 
 
 
Figure 4.2 Retina and optic nerve dissection. Schematic of mouse eye indicating anatomical 
features. Retinas were dissected out and cut for immunohistochemistry on wholemount or cross-
sectioned tissue. Optic nerves were removed and the proximal portion, indicated by dotted red line, 
was cross-sectioned for transmission electron microscopy. Figure adapted from Hart, Koronyo, Black, 
and Koronyo-Hamaoui (2016).   
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4.2.7 Analysis of cross sectioned retina:   
4.2.7.1 Inflammatory response 
Iba-1-immunolabelled retina cross sections were imaged and quantitated (n=4 animals/genotype, 4 
images spanning across each retina). For analysis a 28mm2 region of interest (ROI) was constructed 
over all layers of the retina for each image. Images were segmented using ImageSURF, a random forest 
classifier for ImageJ (O’Mara, King, Vickers, & Kirkcaldie, 2017), which was used instead of 
thresholding because it allows for non-biased and reproducible image segmentation based on a 
classifier, which is “trained” to recognise signal from background. The classifier was trained with 
sample Iba-1 labelled images, which were manually annotated for positive labelling or background. 
Based on these training images, the random forest classifier generated automated image segmentation 
rules. The Iba-1 classifier was then used to segment the provided ROI and ImageJ Particle Analysis 
tool was used to quantify the percentage area of labelling, which has previously been used as a proxy 
measure for numbers of microglia (Collins, King, Woodhouse, Kirkcaldie, & Vickers, 2015; 
Fernandez-Martos, King, Atkinson, Woodhouse, & Vickers, 2015). Qualitative analysis of Iba-1-
positive microglia in retina layers was carried out by manual counting.  
4.2.7.2 Retina layer thickness 
ImageJ was used to measure the thickness of total retina and each retinal layer (ganglion cell layer 
(GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer 
nuclear layer (ONL), photoreceptor layer (PL; Figure 4.1 C) using DAPI staining (n=4 
animals/genotype, 4 images spanning across each retina). Due to potential differences in the sectioning 
plane between the retinas, thickness of each layer was divided by the total thickness of the retina (Dysli, 
Enzmann, Sznitman, & Zinkernagel, 2015).  
4.2.7.3 Synapse quantitation 
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Synaptophysin immunolabelling within the IPL was imaged and number of puncta quantitated (n=4 
animals/genotype, 4 images spanning across each retina). For analysis, a 300µm2 ROI was constructed 
over the IPL layer of the retina in each image (demonstrated in Figure 4.9 A). Images were segmented 
using ImageSURF as described above, using sample synaptophysin labelled image to train the 
classifier.  Following segmentation, individual puncta were identified using the segmentation and 
morphological segmentation features of the MorpholibJ plugin for ImageJ (Legland, 2016)) with 
watershed tolerance set to 10, and results displayed as catchment basins. Puncta between 0.15 and 
2µm2 were measured, as described previously (Mitew, Kirkcaldie, Dickson, & Vickers, 2013). The 
number of boutons counted per field (synaptophysin density) and the percentage area covered were 
analysed.  
4.2.8  Transmission electron microscopy 
4.2.8.1 Fixation 
Following primary post-fixation in PFA and glutaraldehyde, the proximal half of the optic nerve (area 
indicated in Figure 4.2) was dissected for transmission electron microscopy (TEM) and stored in 0.1M 
phosphate buffer. Secondary fixation in 1% osmium tetroxide (Electron Microscopy Sciences) was 
carried out for 2 hours at room temperature followed by two washes at room temperature in 0.1M 
phosphate buffer, and a final wash in 4°C 0.1M phosphate buffer. Samples were then washed twice 
with deionised H2O (dH2O), and tertiary fixation was carried out with 1% uranyl acetate (Merck) for 
30 minutes at room temperature. Samples were washed 3 times in dH2O and dehydrated through graded 
acetone solutions  (70% 1 × 8 minutes; 90% 1 × 8 minutes; 95% 1 × 8 minutes; 100% 4 × 5 minutes). 
4.2.8.2 Embedding 
Samples were incubated in propylene oxide (ProSciTech, 2 × 5 minutes) and embedded in resin. 
Embedding consisted of a 2 hour incubation in 1:1 mix of propylene oxide and resin (Procure 812, 
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ProSciTech); 10 minute incubation at 60°C in resin, followed by overnight incubation at room 
temperature in the dark in resin; and finally embedding in resin at 60°C for at least 24 hours.  
4.2.8.3 Sectioning, staining and imaging 
Semi-thin sections (350µm) were cut on a Reichert UltraS ultramicrotome and stained with Toluidine 
Blue (1% borax) for 30 seconds on a hotplate, and rinsed with cold dH2O. Ultra-thin sections (70nm) 
were collected onto copper grids, and stored in a desiccator. Samples on grids were stained with uranyl 
acetate and lead citrate according to Reynolds (1963). Briefly, grids were incubated in saturated uranyl 
acetate solution (5% in 50% EtOH) in the dark for 30 minutes, washed in dH2O and incubated in 
Reynolds’ lead citrate (Sigma Aldrich) for 5 minutes at room temperature, in a CO2 depleted 
environment. Samples were washed with dH2O and stored in a desiccator until imaging on a Hitachi 
7700 transmission electron microscope with a LaB6 filament, at 80kV in high contrast mode.  
4.2.9 Optic nerve analysis 
From each optic nerve (n= 3 animals per genotype), one good quality section was selected and four 
photomicrographs (2000× magnification) across the section were obtained. ImageJ software was used 
to select four 10µm2 ROIs per photomicrograph (n=16 × 10µm2 ROI across each optic nerve section). 
These ROIs were chosen at random, although glial nuclei were avoided as per DeMaman, Melo, 
Homem, Tavares, and Lachat (2010). Axon number and diameter were analysed using the MorphoLibJ 
plugin (Legland, 2016) and MRI g-ratio toolset ("MRI g-ratio Tools ImageJ macro," 2014). The 
number of degenerative profiles were manually counted while blinded to treatment group, and were 
defined as axon profiles with swellings, axonal debris or myelin abnormalities (as described in Joos, 
Li, and Sappington (2010). 
4.2.10 Statistical analysis  
Unless otherwise stated, statistical analysis was carried out using one-way ANOVAs with Tukey 
post hoc tests. Data are presented ± standard error of the mean (SEM), with p<0.05 considered 
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significant. For the optomotor data, linear mixed effects models were used for analysis. Graphical 
methods (Q-Q and residual plots) were used to determine normality of residuals and homogeneity of 
variance to satisfy the assumptions of a linear mixed effects model. Random intercepts and slopes 
were fitted for each animal to account for variance not attributable to the effect of treatment, 
enabling the assumption of independence to be relaxed for this repeated measures experiment. The R 
environment (R Foundation for Statistical Computing) and lme4 package (Bates et al. 2015) were 
used to fit the model using restricted maximum likelihood estimation. F-statistics and denominator 
degrees of freedom were approximated using the Kenward-Roger approximation implemented in the 
pbkrtest package (Halekoh & Hojsgaard, 2014). 95% confidence intervals were calculated and 
adjusted for multiple comparisons using the Tukey method. Detailed analyses are documented in 
Appendix 4.1. 
 
4.3 RESULTS 
4.3.1 Establishment of viral transduction of retina ganglion cells using intraocular injection 
A pilot study was carried out to determine the optimal concentration of AAV2 virus to inject into 
mice. The mice in this cohort underwent serial dilutions of TDP-WT-GFP, and 1µL of virus at 
3.375×1012 GC/ml was determined to be the optimal concentration to ensure transduction efficiency 
above 40% (Figure 4.3). A second pilot study was carried out with TDP-NLS–-GFP AAV2 showing 
similar transduction efficiencies to TDP-WT-GFP AAV2. As these mice were perfused over a time 
course, GFP expression was detected at low levels at 7 days post injection, and robust expression by 
14 days injection (data not shown).  
 
1.35x1013GC/ml
3.375x1012GC/ml
RBPMS           GFP       DAPI             Merge
1.69x1012GC/ml
Tr
an
sd
uc
tio
n 
ef
fic
ie
nc
y 
(%
)
1.3
5x1
01
3
3.3
75x
10
12
1.6
9x1
01
2
Viral titre (GC/ml)
A
B
Chapter 4 – Results  
    
 
1
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Optimisation of RGC transduction with TDP-WT-GFP. (A) Wholemount retina from 
mice injected with TDP-WT-GFP at different concentrations (n= 4 per treatment group) 
immunolabelled for RBPMS (red) GFP (green), and stained with DAPI (blue). (B) The percentage of 
co-localising GFP and RBPMS RGC bodies were quantified to provide an estimate of viral 
transduction efficiency for each concentration. Results are mean and deviation. Scale bar 20µm. 
 
 
 
 
 
 
 
 
 
Chapter 4 – Results  
    
 
2
4.3.2 Transduction efficiency of AAV2 virus was high for TDP-43 inserts 
To study the effect of overexpression of both WT and mislocalised TDP-43, AAV2 viruses were 
injected into the left eye of C57BL6 mice, and the effects analysed after 3 months. Viral transduction 
efficiency of RGCs in the retina was confirmed in wholemount retina. Tissue was labelled with 
antibodies against GFP and RNA-binding protein with multiple splicing (RBPMS), a selective 
marker of RGCs in the mammalian retina (Rodriguez, de Sevilla Muller & Brecha, 2014). GFP and 
RBPMS colocalisation (Figure 4.4 A) demonstrated that 67.6% ± 2.9% of RGCs were transduced in 
TDP-WT-GFP retinas, and 63.1% ± 6.9% of RGCs were transduced in TDP-NLS–-GFP retinas 
(Figure 4.4 B).  
 
4.3.3 Visual acuity was not altered by treatment 
Functional changes to visual acuity following intravitreal injections were determined by the optomotor 
response (Figure 4.5 A), comparing whether treatment (TDP-WT, TDP-NLS–-GFP or vehicle) altered 
the number of head turns over time (Figure 4.5 B I). There was no significant effect of treatment 
(p>0.05).  The number of clockwise head turns (treated eye) decreased for all treatments, potentially 
indicating an effect of the injection itself. Differences between treatment groups with respect to 
direction of head movement were examined, and there was no significant difference in the number of 
head turns between treatment groups for either orientation (Figure 4.5 B II). Data pooled into pre-
injection and 3 weeks post injection (Figure 4.5 C I), when our pilot study showed robust expression 
of GFP (data not shown), showed no effect of treatment on movement direction (Figure 4.5 C II).  
4.3.4 TDP-NLS–-GFP was localised to RGC cytoplasm and proximal neurites  
GFP fluorescence was used to assess the localisation of TDP-WT-GFP and TDP-NLS–-GFP within 
RGCs. Cross-sectioned retinas showed that GFP labelling was restricted to the RGC layer for both 
TDP-WT-GFP and TDP-NLS–-GFP (Figure 4.6 A), with no GFP present in any other layers of the  
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Figure 4.4 Viral transduction efficiency of TDP-WT-GFP and TDP-NLS-GFP. (A) Wholemount 
retina from mice injected with TDP-WT-GFP or TDP-NLS—GFP (n= 4 per treatment group) 
immunolabelled for RBPMS (red) and GFP (green). (B) The percentage of co-localising GFP and 
RBPMS RGC bodies were quantified to provide an estimate of viral transduction efficiency. Results 
are mean and standard error. Scale bar 100µm. 
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Figure 4.5 Optomotor response. (A) Schematic of the rig used to test optomotor response. (B) (I) 
Quantitation of number of head turns in clockwise (treated) and anticlockwise (untreated) for each 
treatment group eyes over time (weeks; n=7 per treatment group). (II) Pairwise comparisons showing 
mean difference in number of head turns between groups for both orientations, with 95% confidence 
intervals. (C) (I) Pooled data comparing the number of head turns pre-injection with 3 weeks post 
injection for clockwise and anticlockwise directions for each treatment group. (II) Pairwise 
comparisons showing mean difference in number of head turns between groups for both orientations, 
with 95% confidence intervals.  
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Figure 4.6 Localisation of GFP in retinal ganglion cells. (A) Sectioned retinas from mice injected 
with TDP-WT-GFP or TDP-NLS–-GFP  (n= 4 per treatment group) immunolabelled for RBPMS (red) 
and GFP (green), showing GFP-positive RGC bodies in the upper ganglion cell layer (arrowheads). 
(B) Wholemount retina from mice injected with TDP-WT-GFP or TDP-NLS–-GFP immunolabelled 
for RBPMS (red) and GFP (green). Upper panels show TDP-WT-GFP in nuclei (arrowheads). Lower 
panels show TDP-NLS–-GFP in cell body (arrow) and in proximal neurites (arrowheads). Scale bar 
(A) 20µm, (B) 10µm. 
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retina. Flat-mount retina preparations showed GFP fluorescence within RGCs labelled with RBPMS 
(Figure 4.6 B). In TDP-WT-GFP retinas, fluorescence was localised to the nuclear portion of RGCs, 
with low expression in the cytoplasm. In TDP-NLS–-GFP retinas, fluorescing cells had high expression 
throughout RGC somas.  In approximately 12% of RGC expressing TDP-NLS–-GFP, fluorescence 
was present in proximal neurites. These cells corresponded to those expressing GFP at a higher level.  
No fluorescent aggregates or inclusions (indicated by increased fluorescence in puncta) were observed 
in either TDP-NLS–-GFP or TDP-WT-GFP. 
 
4.3.5 Altered TDP-43 induced an inflammatory response 
Neuroinflammation, indicated by the presence of activated microglia, is a pathological hallmark of 
many neurodegenerative diseases (Lopez-Valdes, 2016). To determine whether the intraocular 
injection itself, or expression of TDP-WT-GFP or TDP-NLS–-GFP was associated with alterations in 
microglia, the expression of Iba-1 was examined in cross-sectioned retinas (Figure 4.7 A). 
Qualitatively, in vehicle tissue there were sparse numbers of ramified Iba-1 positive microglia across 
the retina, with the majority of cells located within the GCL, INL and ONL layers (Figure 4.7 A, 
arrowheads, B). In both TDP-WT-GFP and TDP-NLS–-GFP transduced retinas, Iba-1 positive 
microglia were more highly ramified, indicative of a change in activation. These hyper-ramified 
microglia were found within the GCL, INL and ONL layers, as well as in the plexiform layers (Figure 
4.7 A, arrowheads, B). As a proxy for the number of microglia in the sections (Collins et al., 2015; 
Fernandez-Martos et al., 2015), the area occupied by Iba-1 immunoreactivity across all layers of the 
retina was assessed. Significant differences were detected in the amount of Iba-1 labelling in TDP-
NLS–-GFP compared to vehicle retinas (Figure 4.7 C). Although morphology of microglia appeared 
changed in the TDP-WT-GFP retinas, there were no difference to area occupied by Iba-1  
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Figure 4.7 Microglial alterations associated with transduction with TDP-WT-GFP and TDP-
NLS–-GFP. (A) Sectioned retinas from mice injected with vehicle (PBS), TDP-WT-GFP or TDP-
NLS–-GFP (n= 4 per treatment group) immunolabelled with Iba1 (green) and GFAP (red). Arrow 
heads indicate the GCL, INL and ONL. (B) Counts of the number of Iba-1 positive microglia in each 
retina layer. (C) The percentage area occupied by Iba1-positive microglia was quantified. Values are 
mean and standard error. Statistical significance is defined as *p<0.05. Scale bar 25µm.  
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immunoreactivity. Qualitatively, GFAP-labelled astrocytes also appeared to have more intense 
labelling in the GCL in both TDP-WT-GFP and TDP-NLS–-GFP retinas.   
 
4.3.6 Laminar structure of the retina was not altered by treatment 
Layers of the retina are known to undergo thinning in some neurodegenerative diseases affecting the 
eye, due to loss of cells, or loss of connectivity between layers of the retina (Abegg et al., 2014; Garcia-
Martin, 2014; Syc et al., 2012). In order to determine whether TDP-43 expression in RGCs had 
downstream effects on the cells providing their inputs, the underlying layers of the retina were 
examined. The thickness of each of the retinal layers with respect to the total thickness were 
determined (Figure 4.8 A), and no differences were detected (Figure 4.8 B-H). 
 
4.3.7 Synaptic density was increased in TDP-WT-GFP treated mice 
To further determine the effect of TDP-43 expression on the connectivity of RGCs, alterations to 
presynaptic inputs were examined. Cross-sectioned retinas were immunolabelled with the presynaptic 
marker synaptophysin and puncta quantitated in the IPL (Figure 4.9). Images were processed using 
random forest segmentation (O’Mara et al., 2017) and synapses within a 300µm2 ROI of the IPL were 
analysed. There was a significant increase (approximately 14%) in the number of synaptophysin 
immunoreactive puncta per 300µm2 (synaptic density) in TDP-WT-GFP retinas compared to vehicle 
and TDP-NLS–-GFP treatments (p<0.001) (Figure 4.9 C). There were no differences in synaptic 
bouton size or the percentage area covered by synaptophysin-positive synapses (Figure 4.9 D, E). 
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Figure 4.8 Thickness of retinal layers. (A) Representative images of sectioned retina from mice 
injected with vehicle (PBS), TDP-WT-GFP or TDP-NLS–-GFP (n= 4 per treatment group) stained 
with DAPI showing retinal layers: ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear 
layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), and photoreceptor layer (PRL). 
(B-H) Thickness of each layer with respect to total thickness was quantified, yielding measures of each 
layer. Values are mean and standard error. Scale bar 20µm. 
 
 
 
 
 
 
 
 

Chapter 4 – Results  
    
 
10
 
 
 
 
 
 
Figure 4.9 Synaptic alterations in inner plexiform layer of retina.  (A) Representative image of 
sectioned retina immunolabelled with synaptophysin indicating ganglion cell layer (GL), inner 
plexiform layer (IPL) and inner nuclear layer (INL). (B) Representative image showing segmentation 
of synaptophysin immunolabelling. Red box indicates 300µm2 region of interest (ROI) constructed 
over IPL. (C-E) Quantitation of segmented puncta per 300µm2 ROI yielded measurements of synaptic 
density, average size and percentage area occupied by synaptophysin-positive synaptic boutons (n= 4 
per treatment group). Values are mean and standard error. Statistical significance is defined as 
**p<0.01. Scale bar 25µm. 
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4.3.8 Neurofilament localisation was altered in TDP-NLS–-GFP retinas 
Retinal ganglion cells extend a single axon along the surface of the retina to the optic disk, where it 
enters the optic nerve and becomes myelinated. The health of the RGC axons were qualitatively 
examined in the retina for morphological changes following overexpression of TDP-43. Wholemount 
retinas were labelled with a polyclonal antibody that detects both phosphorylated and non-
phosphorylated NFH. This cytoskeletal protein is abundant in a subset of retinal axons, and alterations 
to NFH have been observed following injury (Mikucki, 1991; Moss, 1983). In axon bundles close to 
the optic disk, there was strong, continuous NFH immunolabelling along axonal structures, with no 
qualitative differences between treatment groups (Figure 4.10 A). In more peripheral portions of the 
retinas from all treatment groups, NFH labelling was also strongly expressed in axons. However, in 
TDP-NLS–-GFP expressing tissue, NFH labelling was also localised to cell bodies. This phenomenon 
was not observed in TDP-WT-GFP or vehicle treated tissue (Figure 4.10 B).  
 
4.3.9 Ultrastructural alterations to RGC axons 
In order to determine whether alterations to TDP-43 caused ultrastructural changes to the RGC axons, 
analysis of optic nerves was carried out using TEM (Figure 4.11 A). For this study, the optic nerve 
proximal to the optic nerve head was sectioned. Qualitative analysis of EM sections in vehicle treated 
mice demonstrated the presence of regularly spaced axons, each surrounded by a myelin sheath, and 
containing clearly visible cytoskeletal elements such as microtubules and neurofilaments. Occasional 
mitochondria were also observed. For more detailed analysis, sixteen 10µm2 ROIs per optic nerve 
were used. There was a significant increase in the mean number of RGC axons per  
 
 
 
NFH                       GFP                  Merge
TDP-WT-GFP
TDP-NLS--GFP
PBS
PBS                       TDP-WT-GFP          TDP-NLS--GFP
A
B
Chapter 4 – Results  
    
 
12
 
 
 
 
 
 
 
 
Figure 4.10 Neurofilament heavy immunolabelling of the retina. (A) Representative images taken 
close to the optic disk of wholemount retina from mice injected with vehicle, (PBS), TDP-WT-GFP 
or TDP-NLS–-GFP (n= 4 per treatment group)  immunolabelled for NFH. (B) Representative images 
taken in the peripheral portions of wholemount retina from mice treated as above immunolabelled for 
NFH (red) or GFP (green). Arrowheads show increased NFH labeling in cell bodies which also have 
high GFP labeling in TDP-NLS--GFP injected tissue. Scale bar 20µm.  
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Figure 4.11 Ultrastructural changes in cross-sectioned optic nerve. (A) Representative 
electronmicrographs demonstrating 10µm2 regions of interest of optic nerves from mice injected with 
vehicle, (PBS), TDP-WT-GFP or TDP-NLS–-GFP (n= 3 per treatment group). (B) Representative 
electronmicrographs showing examples of degenerative profiles. (I) Arrowheads indicate myelin 
disruption. (II) Arrowheads indicate degenerating mitochondria, arrows indicate putative 
autophagosomes. (III) Arrowhead shows myelin disruption and membranous whorls. (C-D) 
Quantitation of axon profiles per 10µm2 yielded measurements of axon diameter and number of 
degenerative profiles. Values are mean and standard error. Statistical significance is defined as 
*p<0.05. Scale bars: (A) 2µm, (BI-II) 1µm, (BIII) 300nm.  
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10µm2 ROI from eyes treated with TDP-WT-GFP compared to both vehicle and TDP-NLS–-GFP 
(p<0.05) (Figure 4.11 C), which corresponded with a significantly smaller diameter of axons in TDP- 
WT-GFP compared to both vehicle and TDP-NLS–-GFP (p<0.05) (Figure 4.11 D). Qualitative analysis 
of the morphology of axons within the optic nerve suggested the presence of a number of degenerative 
profiles, identified by myelin breakage or disruption (Figure 4.11 B i, arrowheads), organelle 
accumulation (Figure 4.11 B ii), and/or membranous whorls (Figure 4.11 B iii). The number of 
degenerative profilesper 10µm2 ROI were manually counted and demonstrated that while degenerative 
profiles were present in all genotypes, there was a significant increase in degenerative profiles in 
animals treated with TDP-NLS–-GFP compared to vehicle or TDP-WT. It is possible that some 
degenerative profiles, such as myelin defects, were artefacts due to processing for EM, however the 
abnormal accumulation of organelles was specific to the TDP-NLS–-GFP tissue. Accumulated 
organelles appeared to include degenerating mitochondria (similar to those observed by (Ferreirinha 
et al., 2004); Figure 4.11 B ii, white arrow heads) and autophagosomes (similar to those observed by 
(Komatsu et al., 2007); Figure 4.11 B ii, white arrows), however more detailed analysis would be 
required to definitively identify these structures.  
 
4.4 DISCUSSION 
Mislocalisation of TDP-43 from the nucleus to the cytoplasm is thought to be an important driver of 
cellular alterations in FTD and ALS. This study has established a new in vivo model for examining 
whether alterations to expression level and localisation of TDP-43 has downstream effects on cellular 
morphology, connectivity and cell health, and whether these alterations result in the development of 
pathological features similar to those found in neurodegenerative diseases with TDP-43 pathology. 
The visual system allows relatively less invasive access to the CNS and is a valuable model for 
examining axonal changes as it allows for axons to be traced into the optic nerve and the laminar 
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structure of the retina allows for examination of connectivity. High transduction efficiency rates for 
both of TDP-WT-GFP and TDP-NLS–-GFP under the CAG promoter were demonstrated in this study, 
allowing downstream changes in the optic nerve to be more reliably attributed to overexpression of 
the transgene. The main findings were that TDP-WT-GFP expression caused an increase in pre-
synaptic input into the RGC and was associated with a decrease in RGC axon diameter within the optic 
nerve. Mislocalisation of TDP-43 (TDP-NLS–-GFP) induced increased density of microglia in the 
retina, caused mislocalisation of neurofilament proteins and led to axonal alterations in RGC axons. 
RGCs transmit visual information from the outer retina layers to the visual areas of the brain. To assess 
visual function following RGC transduction, the well-established optomotor response test of visual 
acuity was used (Abdeljalil et al., 2005); RGC loss has been shown to reduce acuity (Ellouze et al., 
2008). However, in the current study, there was no significant effect of treatment on this visual 
parameter despite alterations to RGCs observed in TDP-WT-GFP and TDP-NLS–-GFP treated mice. 
There was a decrease in the number of head turns in the clockwise direction for all treatments, 
potentially indicating an effect of the injection itself. More sensitive tests of visual function such as an 
electroretinogram would be valuable in looking for more subtle changes to visual function caused by 
overexpression of TDP-43.  
This study modeled both overexpression of wildtype TDP-43 and mislocalised TDP-43 due to their 
associations with disease processes in ALS/FTD. Eyes injected with TDP-WT-GFP demonstrated 
nuclear localisation within RGCs, with no mislocalisation to the cytoplasm, which was free of both 
diffuse or GFP-positive aggregates. Multiple studies suggest that mislocalisation of overexpressed WT 
TDP-43 depends on the rate of overexpression. In cell culture studies by Barmada et al. (2010), 
transfection with low levels of WT TDP-43 did not result in cytoplasmic localisation and there was no 
effect on cell survival, whereas higher concentrations of WT TDP-43 resulted in variable 
mislocalisation to the cytoplasm and a reduction in cell survival (Barmada et al., 2010). Similarly, 
overexpressing WT TDP-43 on the mouse prion promoter in mice at a rate 2.5x endogenous TDP-43 
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expression results in cytoplasmic mislocalisation accompanied by severe neurodegeneration (Xu et al., 
2010). In contrast, overexpression at of TDP-43 at both 1.5x (Arnold et al., 2013) and 1.9x (Xu et al., 
2010) the endogenous rate, results in phenotypically normal mice. In the current study, it is likely that 
the amount of TDP-43 that was overexpressed in the TDP-WT-GFP treated retinas was insufficient to 
cause degenerative features.  
Expression of TDP-WT-GFP did however lead to an increase in the number of synapses in the IPL of 
the retina, which contains cell processes and synapses of RGC, amacrine cells and bipolar cells. This 
suggests that there may be an increase number of pre-synaptic inputs into the RGC. TDP-43 has 
previously been linked to synapse formation, and is expressed at synapses (Fallini et al., 2012), 
consistent with a role in regulation of synaptic plasticity by controlling transport of synaptic mRNAs 
(Wang, Wu, Chang, & Shen, 2008) which could occur in situ at the synapse (Liu-Yesucevitz et al., 
2011). Both WT and mutant TDP-43 have been shown to reduce the number of synaptic vesicles at 
the neuromuscular junction (NMJ; Estes et al., 2011). Majumder et al. (2012) found that depletion of 
TDP-43 leads to an increase in hippocampal dendritic spines. This is consistent with a loss-of-function 
of TDP-43, suggested by a reduction of in cortical layer 5 pyramidal dendritic spines in an A315T 
TDP-43 transgenic mouse model (Handley et al., 2016). Together these two studies suggest that 
synaptic dysfunction may be related to the mislocalisation of TDP-43 to the cytoplasm, which is 
accompanied by ubiquitin aggregates. In contrast, findings of the current study were that 
overexpression of WT TDP-43 increased the number of synapses within the IPL of the retina. It is 
likely that these differences are due to upregulation of TDP-43 in the nucleus in the current study 
(normal localisation of the protein in healthy cells), possibly enhancing normal function, and the fact 
that RGCs are not spiny. TDP-43 is upregulated during periods of synaptogenesis in C56Bl/6 mice 
(Liu et al., 2015), which together with the results of the current study, may suggest that TDP-43 plays 
a role in the development of synapses. In light of increased branching following overexpression of 
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TDP-43 in Chapter 3, it would be interesting to examine dendritic abourisation in the retina in future 
studies.  
In contrast to TDP-WT-GFP mice, transduction of RGC with TDP-NLS–-GFP resulted in strong GFP 
fluorescence in the cytoplasm and the primary neurites in a subset of cells. This cytoplasmic expression 
may cause the axonal alterations observed within the optic nerve. Other studies, where cultured cells 
have been transfected with TDP-NLS– constructs, have demonstrated high neuritic expression 
(Barmada et al., 2010) and axonal accumulation of exogenous TDP-43 (Winton et al., 2008), which 
has also been recapitulated in vivo (Tripathi et al., 2014).  
ALS and FTD are characterised by severe white matter loss and axon degeneration, including axon 
swellings containing neurofilament proteins (Hirano, Donnenfeld, et al., 1984; Hirano, Nakano, et al., 
1984). Previous studies using transgenic mice expressing TDP-43 with a mutated NLS recapitulate 
some features of axon degeneration (Igaz et al., 2011; Walker et al., 2015). Transduction of RGCs with 
TDP-NLS–-GFP in the current study also led to increased numbers of degenerative profiles in the optic 
nerve, including accumulations of abnormal organelles, myelin disruption, vacuoles and membranous 
whorls. The organelles were similar to degenerating mitochondria and autophagosomes found in 
previous studies examining axon degeneration (Ferreirinha et al., 2004; Komatsu et al., 2007) and 
further studies will need to be carried out to positively identify the nature of these organelles. Organelle 
accumulation is an indicator of axon transport defects, which are an important feature of human ALS 
and mSOD1 models of ALS (reviewed in De Vos & Hafezparast, 2017). 
In the peripheral portion of retinas, NFH was increased within cell bodies, which did not occur in TDP-
WT-GFP or vehicle treated tissue. It is known that alterations to neurofilament proteins within the cell 
body are observed following injury. For example, following axotomy, neurons often demonstrate a 
decreased expression of neurofilament proteins within the cell body (Mikucki, 1991), and after nerve 
crush injury phosphorylated epitopes of neurofilaments, which are normally localised to axons, can be 
Chapter 4 – Results  
    
 
18
observed in the cell body (Moss, 1983). There is tight topographical regulation of expression and 
phosphorylation of neurofilament proteins, but abnormal accumulation in the cell body may occur if 
filament assembly is abnormal (Liu et al., 2004). Phosphorylation of the N-terminus of neurofilaments 
governs their localisation to the soma or axon (Yates et al., 2009) suggesting a dysfunction of this 
process following transduction with TDP-NLS–-GFP. Accumulation of neurofilament in the cell body 
could also be related to axon transport defects, characterised by axonal swellings of abnormal 
organelles, which were observed in the current study. Axonal accumulation of neurofilament is 
thought to be due to altered stoichiometry of the subunits (Strong et al., 2005; Strong et al. 2001), 
which may be affected by TDP-43 alterations, since it is known to stabilise NFL mRNA within the 
nucleus and may regulate its translation in the cytoplasm (Strong et al., 2007). In ALS, NFL mRNA is 
sequestered to stress granules and its expression is suppressed (Strong et al., 2007; Volkening et al., 
2009), reducing the availability of this subunit. Alterations to the location of TDP-43 induced by TDP-
NLS–-GFP expression could cause changes to NFL expression and possibly promote the formation of 
stress granules, leading to altered stoichiometry of neurofilament polymers.  
Axon calibre was significantly changed in TDP-WT-GFP optic nerves. This too could be related to 
alterations in neurofilament stoichiometry as NFM is a key regulator of establishing and maintaining 
axon calibre (Kirkcaldie & Dwyer, 2017). A major question raised by these results whether TDP-NLS–
-GFP leads to cell body changes, followed by axon pathology, or whether the axon pathology precedes 
cell body changes. Future studies will examine tissue from mice injected over a timecourse to 
determine if one change is observed before the other.  
Inflammation is an important aspect of ALS and FTD, with alterations to microglia, the resident 
immune cells of the CNS, being a pathological hallmark of these diseases (Lopez-Valdes, 2016; Piguet, 
2013). The current study shows increased microglia density within the retina of TDP-NLS–-GFP 
treated tissue only, with no differences in TDP-WT-GFP or vehicle treated tissue, and qualitative 
changes to microglia distribution and morphology in TDP-43 transduced retinas. Microglial activation 
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and migration is observed following CNS injury (Kreutzberg, 1996), and also occurs in areas of protein 
inclusion pathology in ALS and FTD (Brettschneider et al., 2012). The latter study demonstrated 
microglial activation in brain regions with high TDP-43 pathology, and mouse models with an 
inducible form of TDP-NLS–-GFP showed activated astrocytes and microglia in the cortex and 
hippocampus within one month of expressing the transgene (Igaz et al., 2011). Future studies further 
investigating the interaction between microglia in normal TDP-43 function, and in TDP-43-induced 
degeneration would be of interest.   
This is the first study to characterize the effect of altered expression and localisation of TDP-43 within 
a retinal model. Although preliminary, it has provided important data to suggest that the visual system 
can be used to investigate the downstream effects of TDP-43 alterations on neuronal morphology and 
ultrastructural changes within axons. Future studies are needed to examine the downstream effects of 
TDP-43 expression on RGC presynaptic terminals in visual target areas, including the superior 
colliculus and lateral geniculate nucleus, as well as a more detailed examination of cytoskeletal 
alterations in the optic nerve and the characterisation of accumulated organelles in the optic nerve. 
Development of TDP-43 bicistronic constructs, which allow for both the localised expression of TDP-
43 and GFP labelling throughout the cells, would be valuable for synaptic studies, and also for 
examining alterations in transduced axons in the optic nerve. The morphology and dendritic 
arbourisation of transduced RGS in the retina could also be examined using these constructs.  
The current study has developed a new model allowing detailed examination of alterations caused by 
TDP-43 overexpression and mislocalisation of TDP-43. The eye presents as an ideal model for trialing 
therapeutic intervention due to the ease of access to the RGC and also the downstream analysis that 
can be carried out, exemplified in this chapter. While a virtue of the eye model, its simplicity means 
that results obtained would need to be tested further in models of degenerative disease that can more 
fully recapitulate disease complexities. Such models for ALS and FTD are currently lacking, 
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suggesting that more work in this area in required. The results from this chapter will contribute to the 
knowledge of TDP-43-mediated disease.  
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5 C9ORF72 EXPRESSION AND CELLULAR LOCALISATION OVER 
MOUSE DEVELOPMENT 
5.1 INTRODUCTION 
Following on from studies of TDP-43 and how changes to this disease-related protein may cause 
changes to the neuronal cytoskeleton, the current study was also interested in characterising one of the 
most recently discovered proteins in FTD and ALS, C9ORF72. In 2011, two independent groups 
identified the repeat expansion of the hexanucleotide sequence GGGGCC in the C9ORF72 gene as the 
largest genetic cause of ALS/FTLD (DeJesus-Hernandez et al., 2011; Renton et al., 2011). This 
expansion occurs in a non-coding region of chromosome 9. It is currently unknown how the repeat 
expansion contributes to FTLD and ALS, although several mechanisms have been proposed, including 
unconventional translation of the repeated sequence (repeat-associated non-ATG initiated translation) 
leading to intracellular accumulations of dipeptide repeat proteins (Ash et al., 2013; Mori et al., 2013), 
and the sequestration of RNA binding proteins into RNA foci, causing RNA dysfunction (DeJesus-
Hernandez et al., 2011; Simón-Sánchez et al., 2012). An additional possibility is haploinsufficiency 
due to reduced expression of C9ORF72 transcripts (Ciura et al., 2013; DeJesus-Hernandez et al., 2011; 
Donnelly et al., 2013; Therrien, Rouleau, Dion, & Parker, 2013; Waite et al., 2014; Xiao et al., 2015).  
While pathological features of C9ORF72-associated disease, such as TDP-43 aggregates, dipeptide 
repeat protein expression and RNA foci, are under intense investigation regarding their role in disease, 
to date, less attention has been paid to the normal expression and function of the encoded protein, 
C9ORF72. Elucidating the expression, localisation and function of this protein in neural cells may 
contribute further to knowledge regarding how the repeat expansion is associated with 
neurodegenerative changes.  
In humans, alternative splicing of three RNA transcript variants from the C9ORF72 gene produces 
two different isoforms of the C9ORF72 protein (Renton et al., 2011). Transcript variants 1 and 3 
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encode a 481 amino acid protein and variant 2 encodes a 222 amino acid protein (DeJesus-Hernandez 
et al., 2011) (Figure 5.1 A). In mice, there are 3 protein-coding regions reported of 481 (isoform 1), 
420 (isoform 2) and 317 (isoform 3) amino acids, hence, likely encoding at least 3 different protein 
isoforms (Figure 5.1 B). However, the roles of the encoded proteins have not been well characterised. 
A role for C9ORF72 in trafficking has previously been demonstrated (Farg et al., 2014a), which was 
in line with earlier studies (Levine, Daniels, Gatta, Wong, & Hayes, 2013). Farg et al. (2014b) showed 
that C9ORF72 is involved in endosomal trafficking via Rab-dependent pathways. Rab proteins are 
part of the Rab-GDP/GTP exchange factor family (Rab-GEF) (as reviewed in Stenmark, 2009) that 
mediate all membrane trafficking events between organelles. Farg et al. (2014) provided the first 
experimental evidence that C9ORF72 regulates endocytosis and autophagy  and recent studies have 
also added to this (Webster et al., 2016). 
Other studies have examined the expression of the C9orf72 gene using a transgenic mouse model 
harboring a targeted LacZ insertion (Suzuki et al., 2013). This study observed C9orf72 in neuronal and 
non-neuronal cells within the central nervous system (CNS). Recently, the effect of ablating the 3 
isoforms of C9ORF72 protein from neurons and glia has been examined, demonstrating a reduction in 
body weight but no motor neuron degeneration or motor deficits (Koppers et al., 2015). This suggests 
that complete lack of C9ORF72 throughout development and adulthood is not sufficient to cause a 
motor neuron disease phenotype in mice.   
Several studies have examined the expression of C9ORF72 in human tissue (Cooper-Knock et al., 
2012; DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Hsiung et al., 2012; Snowden et al., 
2012; Stewart et al., 2012) and cell lines (Gijselinck et al., 2012; Renton et al., 2011) using a variety 
of commercial antibodies. However, there has been a lack of consensus about the localisation of 
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Figure 5.1 Schematic overview of human and mouse C9ORF72 transcripts and encoded proteins. 
Protein coding regions for transcript variants (V1 to 3) are indicated in light blue for human (A) and 
dark blue for mouse (B) as well as size of encoded proteins. Non-coding regions are indicated in red 
and location of the G4C2 repeat expansion in yellow. 
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 C9ORF72 across these studies. Some investigations have described coarse punctate expression within 
the hippocampus, suggestive of synaptic terminals (Cooper-Knock et al., 2012; Hsiung et al., 2012; 
Satoh, Tabunoki, Ishida, Saito, & Arima, 2012; Snowden et al., 2012). Recently,  Xiao et al. (2015) 
generated antibodies specific to the two human C9orf72 isoforms. They demonstrated diffuse 
cytoplasmic and ‘speckled’ localisation of the long isoform, as well as localisation of the short isoform 
to the nuclear membrane. This is in line with previous investigations which demonstrated a nuclear 
and punctate pattern of expression of C9ORF72 in vitro in both SH-SY5Y cells, typical of vesicles, as 
well as in primary cultured cortical neurons (Farg et al., 2014).  
The current study examined the expression of C9ORF72 in the mouse CNS over development in vivo 
and in vitro in order to provide information about its expression and cellular localisation during neurite 
outgrowth, neuron maturation and synapse formation. This investigation demonstrated that C9ORF72 
mRNA and protein have differential expression over a developmental time course, is expressed in both 
nuclear and cytoplasmic fractions in an isoform specific manner, and that the large isoform may be 
present in synaptic fractions. 
 
5.2 METHODS 
5.2.1 Animals 
C57BL/6 mice were utilised in this study. All experiments involving animals were approved by the 
University of Tasmania Animal Ethics Committee (A12780) and were in accordance with the 
Australian Guidelines for the Care and Use of Animals for Scientific Purposes. 
5.2.2 Tissue preparation 
For molecular biology analysis, combined neocortical and hippocampal tissue were harvested from 
mice at embryonic day (E) 18, postnatal (P) 1, P7, P14, P28 and P56 (for Western blot) (n= 4 mice per 
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time-point) and P1, P7 and P56 (for real time qPCR) (n= 4 mice per time-point). Tissue was processed 
as previously per Chapter 2.6.  
For immunohistochemical analysis, animals were terminally anaesthetised with sodium 
pentobarbitone (140 mg/kg) and transcardially perfused with 4% PFA. Brains were immediately 
dissected, post-fixed overnight in paraformaldehyde and then cryoprotected (Chapter 2.5). Serial 40µm 
coronal sections were cut on a cryostat (Leica CM 1850). For each mouse at each time point, four 
regularly spaced sections were examined from the rostral to caudal cortex corresponding to bregma 
0.98 mm to -1.82 mm (in adult tissue) according to the stereotaxic mice atlas of Franklin and Paxinos 
(2008). Antigen retrieval was carried out prior to immunohistochemistry using citric acid, pH 6.0, in a 
pressure cooker for 14 mins (Chapter 2.5.2). 
5.2.3 Protein extraction and Western blot analysis 
Protein from combined cerebral cortex and hippocampus was extracted as described in Chapter 2.6.1. 
Denatured proteins samples (15 µg) from each time-point were used for western blotting (Chapter 2.6). 
A corresponding anti-rabbit or anti-mouse horseradish peroxidase (HRP)-conjugated secondary 
antibody (1:7000; Amersham) was used, as described previously (Liu et al., 2014). GAPDH (1:7000, 
Millipore) was used as a loading control and band intensity was measured as the integrated intensity 
using ImageJ software (v1.4; NIH), and normalised with respect to the loading controls. 
5.2.4 Nuclear and cytoplasmic fractionation 
Nuclear and cytoplasmic protein extractions were prepared from right hemispheres (excluding 
olfactory bulbs and cerebellum) of fresh E18, P1, P7, P56 brains using the NE-PER kit (Life 
Technologies; Chapter 2.6.2). Denatured protein samples were electrophoresed as described above. 
Fraction purity was confirmed by labelling with HDAC2 (1:700; Abcam) for nuclear fractions and 
GAPDH (as above) for cytoplasmic fractions. Membranes were also incubated with C9ORF72 (as 
above). Densitometry of bands was carried out using ImageJ. Results were normalised to total protein. 
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5.2.5 Synaptosome preparation 
Synaptosomes were prepared as described previously (Dunkley, Jarvie, & Robinson, 2008; Mitew et 
al., 2013) with some modifications. Briefly, P56 mice (n= 4) were anaesthetised and perfused with 
sucrose buffer (0.32 M sucrose, 1 mM ethylenediaminetetraacetic acid, 5 mM dithiothreitol, pH 7.4). 
Whole brains were harvested and homogenised at 4 °C with a teflon-glass homogenizer using 12 
strokes with 9:1 ratio of sucrose buffer supplemented with a protease cocktail inhibitor (Roche) to 1 g 
of tissue. Homogenate was centrifuged at 1000 g for 10 mins at 4 °C. The resulting pellet containing 
mostly nuclei was removed and the supernatant was layered onto a discontinuous gradient consisting 
of 3 %, 10 %, 15 % and 23 % (vol/vol) Percoll (GE Healthcare). Tubes were then centrifuged at 31,000 
g for 8 mins at 4 °C in a Sorvall WX Ultra90 (70.I TI rotor).  
The contents of the resulting fractions have been characterised previously (Dunkley et al., 2008; 
Stigliani et al., 2006). The resulting purified fractions were collected and protein was extracted in RIPA 
buffer for Western blotting. Denatured protein samples (15 µg) were electrophoresed as described 
above. Membranes were probed with C9ORF72 antibody, along with synaptic markers: synaptophysin 
(1:5000, Millipore), PSD-95 (1:1000, Abcam), GAD67 (1:2500, Millipore); and GFAP (1:1000, 
NeuroMAB) as a marker of glia.  
5.2.6 RNA isolation and RT-PCR analysis  
Total RNA from combined cerebral cortex and hippocampus tissue at the time-points P1, P7 and P56 
(n = 4/group) was isolated using the RNeasy Mini Kit (Qiagen), according to the manufacturer’s 
instructions and complementary DNA (cDNA) was synthesised from DNase-treated RNA (1µg) as 
described previously by Fernandez-Martos et al. (2009).  
To semi-quantitatively analyse C9orf72 gene expression, real time PCR analysis was conducted as 
previously described (Fernandez-Martos et al., 2011). Before relative quantification, C9orf72 gene 
was subjected to a serial dilution assay to determine the optimum detection range of Ct values, with a 
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Ct threshold of 35 for undetectable mRNA levels of expression. Relative quantitation of C9orf72 
mRNA isoforms per time point was performed using 25 ng of reverse-transcribed total RNA, 20 
pmol/ml of both sense and antisense primers and the SYBR Green PCR Master Mix (Applied 
Biosystems) in a final reaction volume of 10 µl. The reactions were run on an LightCycler® 480 System 
(Roche) according to the manufacturer's instructions. To standardize the amount of sample cDNA 
added to the reaction, amplification of endogenous control β-Actin (primer sequence obtained from 
Gonzalez-Fernandez et al., 2013) were included in a separate well as a real-time reporter. Primer 
efficiency was calculated (Figure 5.2 A) and at the end of each run, melting curve profiles were 
performed to confirm amplification of specific transcripts (Figure 5.2 B). Relative quantification for 
each gene was performed by the ∆∆Ct method (Livak & Schmittgen, 2001).  
All primers were designed using NCBI/ Primer-BLAST software (Table 1). Primers were designed to 
amplify the different isoforms of the C9ORF72 mouse ortholog (3111004O21Rik). As C9ORF72 
isoforms 2 and 3 are contained within isoform 1, fold change in the mRNA expression of isoform 2 
and 3 were calculated as the increment with respect to the expression levels of isoform 1. 
Table 5.1 List of qPCR primers 
Gene name Forward Primer Reverse Primer Accession 
Number 
C9orf72 isoform 1 5’- 
CCCACCATCTCC
TGCTGTTG-3’ 
5’-
GTAAGCAAAGGTAGCCGC
CA-3’ 
NM_001081343.1 
C9orf72 isoform 2 5’-
CTTTCCTTGCAC
AGTTCCTCC-3’ 
5’- 
TCATCCTCGATGTACTTGA
TTAGTG-3’ 
XM_006538293.2 
C9orf72 isoform 3 5’- 
TGGAAGATCAG
GGTCAGAGT-3’ 
5’- 
GCAAGCAGCTCCATTACA
GG-3’ 
XM_006538294.1 
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Figure 5.2 Primer efficiency and melting curve analysis. (A). The efficiency of the primer pairs for 
C9orf72 isoforms was assessed by plotting the cycle threshold value (Ct) at each concentration against 
the logarithm of the fold dilution of the sample. The slope of a linear-regression trendline is indicative 
of primer efficiency. Primer efficiencies were 1.86 for isoform 1 (a i), 1.94 for isoform 2 (a ii) and 
1.97 for isoform 3 (a iii). (B) Representative melting curve analysis showing the specific amplification 
of the C9orf72 isoform products. Melting peaks (plotted as the negative derivative of fluorescence) 
revealed peaks at three different temperatures which indicate the identity of amplified C9orf72 
isoforms. (TIFF 24326 kb) 
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Primers used for qPCR analysis of the 3 C9orf72 isoforms including primer sequence (forward and 
reverse sequence respectively) and GenBank accession number. 
5.2.7 Primary cell culture 
Primary dissociated cortical cultures were prepared as described in Chapter 2.2 using standard culture 
techniques with slight modifications. Dissociated cells were plated onto 12mm coverslips in 24 well 
plates. Neurons were fixed with 4% PFA (Sigma Aldrich) at 1, 3, 7, 14 and 21 DIV (n > 5 cultures per 
time-point). 
5.2.8 Immunofluorescence 
Cultured cells and brain sections were incubated 3 x 10 mins in 0.01 M PBS followed by Dako serum-
free protein block for 15 min at room temperature (RT). Immunofluorescence labeling was carried out 
for both cultured cells and brain tissue following standard procedures using C9ORF72 (1:1000 Santa 
Cruz),  β-III Tubulin (1:5000, Promega) and MAP2 (1:1000, Millipore) diluted in 0.01 M PBS with 
0.6% Triton-X-100 and incubated at room temperature (RT) overnight. Samples were incubated in 
secondary antibodies (AlexaFluor, Invitrogen Probes) for 2 hrs at RT, followed by incubation with the 
nuclear stain DAPI (5µg/ml; Molecular Probes®, Life Technologies), for 5 mins at RT. 
Immunoreactivity was visualised and captured using a Leica (Germany) DM BL2 upright fluorescence 
microscope. For the purpose of illustration, images were then adjusted for brightness and contrast using 
Adobe Photoshop CS6 (v 13).  
Specificity of immunoreactivity was confirmed by two methods. Both brain sections and cultured cells 
were examined for non-specific labelling after processing without primary antibody. Additionally, 
tissue from P56 brain and 7 DIV cultures were incubated with C9ORF72 antibody combined with 7 
times excess of C9ORF72 peptide (sc-138763 P; Santa Cruz).  
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5.2.9 Statistical analyses 
Data from real time PCR studies were compared using a one-way ANOVA followed by a Tukey post-
hoc and t-tests for a point-to-point comparison. Data from Western blots were compared using a two-
way ANOVA followed by Tukey or Sidak post-hoc comparisons. All statistical analysis was 
performed using GraphPad Prism software (version 6.0) and p-values with p<0.05 (CI 95 %) 
considered significant. Values were reported as the mean ± standard error (SEM).  
 
5.3 RESULTS 
5.3.1 Cellular pattern of C9ORF72 protein changes over development of mouse cortex 
This study utilised the commercially available anti-human C9ORF72 antibody (Santa Cruz) raised 
against amino acid residues 165 to 215 of C9ORF72 protein, which is contained within the sequence 
of all 3 mouse C9ORF72 isoforms. Previous data has shown a decrease in labeling in a Western blot 
with the antibody following treatment with C9ORF72 short interfering RNA (siRNA) (Farg et al., 
2014). To further characterise the specificity of immunolabelling, the C9ORF72 antibody was 
preadsorped with recombinant peptide. Immunolabelling of tissue sections from P56 mice (8 5.3 A) 
and cultured cortical neurons at 7 DIV (Figure 5.3 B) with preadsorped C9ORF72 demonstrated that, 
relative to non-adsorbed antibody, there was a large reduction in immunolabelling. 
Expression or localisation of C9ORF72 over a developmental time-course from E18 to P56 in mice 
was determined, which covers periods of neurite outgrowth and synapse development (Pfrieger, 2009; 
Workman et al., 2013). To determine potential alterations in the localisation of C9ORF72 over 
development, 40 µm coronal tissue sections from mice at ages E18, P1, P14, P28 and P56 were 
immunolabeled with C9ORF72 antibody along with the neuronal somatodendritic marker, MAP2. At 
both E18 (data not shown) and P1, there was strong labeling for C9ORF72 in discrete puncta 
throughout the neuropil (Figure 5.4 A) but little somal immunoreactivity was present. At P7, there 
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Figure 5.3 Preadsorbtion with C9ORF72 peptide. (a) P56 tissue from C57/Bl6 mice or (b) 7 DIV 
cortical neurons cultured from C57/Bl6 mice were labeled with C9ORF72 (sc-138763) antibody or 
C9ORF72 (sc-138763) antibody preadsorbed with the C9ORF72 peptide (sc-138763 P) (n= 4). 
Labeling was decreased in both preadsorbed samples. Labeling of puncta (arrows) and nuclei 
(arrowheads) with C9ORF72 antibody was present in brain tissue and cultured neurons (panel 1, a, b). 
In contrast, when labeled with preadsorbed C9ORF72 peptide, there was no nuclei labeling and non-
specific puncta present in brain samples (arrows, panel 2, a), and in cultured samples there was faint 
non-specific nuclear labeling and an absence of puncta (arrowhead, panel 2, b). Scale bar: a, 12 µm; 
b, 10 µm. 
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Figure 5.4 Localisation of C9ORF72 during development in vivo. (A) At P1, C9ORF72 (red) had 
punctate localization throughout the neuropil (arrows). (B) At P7, C9ORF72 labeling was present 
within nuclei (arrowheads) of neuronal cells (MAP2, green) and as strong puncta within cytoplasm 
and neuropil (arrows). (C) At P56, C9ORF72 labeling was present in the neuropil as puncta (arrows) 
and was localized to the cytoplasm surrounding nuclei (DAPI, arrowheads). N= 4 animals per 
timepoint. Scale bar: 10 µm 
 
 
 
 
 
 
 
 
Chapter 5 – Results  
    
 
14
 was distinct somal and nuclear expression, which was both diffuse and punctate in many MAP2-
immunoreactive cells throughout the cortex and hippocampus (Figure 5.4 B) confirming the presence 
of C9ORF72 in neurons. At P14, P28 and P56, cytoplasmic labeling continued with apparent lower 
expression in nuclei (Figure 5.4 C) Punctate labeling was less distinct than at P1 and P7 (Figure 5.4 A, 
B).  
 
5.3.2 Temporal expression of C9ORF72 isoforms over development 
The temporal mRNA expression pattern of C9ORF72 isoforms (C9orf72- 1, 2 and 3) were then 
evaluated. As shown in Figure 5.5 A, the mRNA encoding for all C9orf72 isoforms were detected in 
combined cerebral cortex and hippocampus tissue at all time-points P1, P7 and P56. Isoform 1 was 
significantly higher (p<0.05) at P1 compared to P7 and P56 (Figure 5.5 A) and, similarly, the 
expression of isoform 2 was significantly higher (p<0.05) at P56 relative to the other time points tested 
(Figure 5.5 A). There were no changes in the mRNA expression levels of isoform 2 over development 
(Figure 5.5 A). Next, by Western blot analysis, the temporal protein expression of C9ORF72 protein-
coding regions (481, 420 and 317 amino acids) were evaluated, which correspond to predicted protein 
size isoforms of approximately 55, 50 and 35 kDa. Western blots of combined cerebral cortex and 
hippocampus tissue demonstrated that the Santa Cruz C9ORF72 antibody labelled the 3 predicted 
protein isoforms (Figure 5.5 B) C9ORF72 protein isoforms at 55, 50 and 35 kDa were detected in 
combined cerebral cortex and hippocampus tissue at all the time-points. Moreover, additional bands 
at 110 kDa were also detected.  The identity of this band remains unknown. 
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Figure 5.5 Expression of C9ORF72 isoforms over development. (A) Relative expression of 
C9orf72 isoforms 1, 2 and 3 mRNA in combined cerebral cortex and hippocampus of C57Bl/6 mice 
(n= 4 per timepoint). Isoform 1 was significantly (p < 0.05) higher at P1 compared to P7 and P56 and 
isoform 2 was significantly (p < 0.05) higher at P56 compared to P1 and P7. (B) Western blot of 
C9ORF72 expression in mouse tissue over development. Bands corresponding to reported isoforms of 
C9ORF72 were present at 55, 50 and 35 kDa. Additional bands at 110 and 50 kDa were also present. 
GAPDH was used as a loading control. Values represent mean ± standard error. *p < 0.05 P1 and P7 
vs. P56 
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5.3.3 Subcellular localisation of C9ORF72 over development 
To further investigate the differential nuclear and cytoplasmic localisation of C9ORF72 over 
development in vivo, nuclear and cytoplasmic protein extractions were performed at E18, P1, P7 and 
P56. Purity of the nuclear and cytoplasmic extractions was confirmed with HDAC 2 and GAPDH 
proteins with HDAC2 being higher in the nuclear samples and GAPDH being higher in the cytoplasmic 
samples (Figure 5.6 A) As in non-fractionated samples, Western blot analysis of C9ORF72 showed 
protein bands at approximately 55, 50 and 35 kDa. The 55 kDa protein was significantly higher in the 
nuclear fractions compared to cytoplasmic fractions (p<0.05) (Figure 5.6 B). Post hoc tests showed 
that at E18 and P1 there was significantly (p<0.05) more of the 55 kDa protein in nuclear fractions 
compared to cytoplasmic. Post hoc tests also showed that within nuclear fractions, there was 
significantly more (p<0.05) of the 55 kDa protein at E18 compared to P56. There were no significant 
differences in cytoplasmic expression of the 55 kDa protein over the time course. There were also no 
significant differences in localisation of the 50 kDa protein over the time course (Figure 5.6 B). The 
35 kDa protein was significantly higher in the cytoplasmic fractions compared to nuclear fractions 
(p<0.05) (Figure 5.6 B). Post hoc tests showed that, at E18 and P1, there was significantly (p<0.05) 
more of the 55 kDa protein in cytoplasmic fractions compared to nuclear. Post hoc tests also showed 
that within cytoplasmic fractions there was significantly more (p<0.05) of the 35 kDa protein at E18, 
P1 and P7 compared to P56. There were no significant differences in nuclear expression of the 35 kDa 
protein over the time course. These results suggest that C9ORF72 protein isoforms were differentially 
expressed in cellular compartments over development 
5.3.4 C9ORF72 is present in synaptosome preparations 
The results showed that C9ORF72 has punctate localisation in the neuropil, however, it is unclear if it 
is present in synapses. To address this, subcellular fractionation on P56 mouse brain tissue was 
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Figure 5.6 Expression of C9ORF72 in nuclear and cytoplasmic protein fractions over 
development. (A) Representative western blot of C9ORF72 in nuclear and cytoplasmic fractions from 
E18, P1, P7, and P56 mouse brain (n= 4 per timepoint). HDAC2 and GAPDH were used to demonstrate 
nuclear and cytoplasmic fractions respectively. C9ORF72 isoforms were present at differing levels 
and in specific fractions throughout the time course. (B) Relative quantitation of C9ORF72 isoform 
expression in nuclear and cytoplasmic fractions over the time course. Overall, the 55 kDa protein was 
significantly (p < 0.05) increased within nuclear fractions compared to cytoplasmic fractions and 
specifically at E18 and P1 compared to P56 (p < 0.05). Within nuclear fractions, the 55 kDa protein 
was significantly (p < 0.05) increased at P1 compared to P56. There were no significant differences in 
nuclear and cytoplasmic expression for the 50 kDa band. Overall, the 35 kDa band was significantly 
(p < 0.05) increased within cytoplasmic fractions compared to nuclear fractions and specifically at E18 
compared to P56 (p< 0.05). Within cytoplasmic fractions, the 35 kDa protein was significantly 
increased (p < 0.05) at E18, P1 and P7 compared to P56. Values represent mean ± standard error. *p 
< 0.05 nuclear vs. cytoplasmic at E18 and P1. + p < 0.05 E18 vs. P56 (nuclear for 55 kDa bad, 
cytoplasmic for 35 kDa band). # p < 0.05 P1 vs. P56 (nuclear for 55 kDa band, cytoplasmic for 35 kDa 
band) 
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carried out to isolate synaptosome fractions according to the methods of Dunkley and colleagues 
(2008). The content of each resulting fraction have been characterised previously (Dunkley et al., 2008; 
Stigliani et al., 2006). F1 contains unidentified membranous material (Dunkley et al., 2008), F2 
contains predominantly re-sealed plasma membranes from glial cells (Stigliani et al., 2006). F3 and 
F4 contain purified synaptosomes and these fractions were combined (Dunkley et al., 2008). To 
confirm the purity of the fractions, Western blotting was carried out with a range of antibodies. GFAP 
was used as a glia marker and was most abundant in F2 (Figure 5.7). As expected, synaptophysin, 
PSD95 and GAD67 were most abundant within the F3/F4 fraction (Figure 5.7). PSD-95 and 
synaptophysin were also present in F2, possibly binding to synaptic proteins within axonal transport 
vesicles. Only the 55 kDa protein band of C9ORF72 was observed within C9ORF72-positive fractions, 
and was most abundant within F3/F4 fractions where other synaptic proteins were found. It was also 
present at low levels in F2.  
 
5.3.5 C9ORF72 is expressed in nuclei and neurites of cultured cortical neurons 
For a more detailed examination of the localisation of C9ORF72 in neuronal soma and neurites, 
immunocytochemistry was performed in cultured cortical neurons fixed at 1, 3 and 7 DIV (during 
neurite outgrowth) and 14 and 21 DIV (during synaptogenesis and maturity). Cells were labeled with 
C9ORF72 along with neuronal cytoskeletal markers βIII-tubulin and MAP2 and the F-actin stain, 
phalloidin. At 1 and 3 DIV, C9ORF72 labeling was present in the cell soma, excluding the nucleus, 
and throughout the neurites as demonstrated by co-labeling with βIII-tubulin (Figure 5.8). C9ORF72 
also extended into the actin cytoskeleton, including within growth cones and filopodia extending from 
the soma and down the length of neurites, as demonstrated by co-labeling with phalloidin (Figure 5.8). 
From 7 DIV, immunolabelling for C9ORF72 increased in the soma and a large proportion of cells had 
high nuclear expression of the protein, accompanied by bright puncta in the soma (data not 
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Figure 5.7 Expression of C9ORF72 in synaptosome preparations from mouse brains. Figure 
shows representative western blots with results from 2 animals for each marker (indicated by 1 and 2 
on figure). The 55 kDa isoform of C9ORF72 was present in the combined F3/F4 fractions which 
contain synaptosomes. C9ORF72 expression was low in fraction F1, containing membranes, and F2 
containing myelin, membranes and glia. Unfractionated brain at P56 was also included. Purity of 
fractions was determined by labeling with GFAP (F2) and synaptic markers, synaptophysin, PSD-95 
and GAD67 (F3/F4). 
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Figure 5.8 Localization of C9ORF72 over development in vitro. Immunofluorescence was carried 
out on primary cultured cortical neurons (n= >5 cultures per timepoint). (A) At 1 DIV, C9ORF72 (red) 
labeling was present within cell bodies, excluding nuclei (DAPI, blue) and punctate localization was 
present in neurites and growth cones (β-III tubulin, green). (B) Co-staining with phalloidin (green) at 
3 DIV confirmed localization of C9ORF72 (red) labeling to growth cones and to filopodia (arrows). 
(C) At 14 DIV, C9ORF72 (red) was localized to nuclei of a population of neurons (arrows) but was 
less intensely expressed in nuclei of other neurons (arrowhead). Neurons indicated by MAP2 (green). 
Neurons with nuclear immunolabeling for C9ORF72 frequently had punctate somal localization of 
this protein. Inset (c) shows C9ORF72 labeling in nuclei and in puncta in surrounding cytoplasm. Scale 
bar: A, 2.5 µm; B, C, 10 µm 
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 shown). Similar cellular localisation was observed at 14 DIV with bright vesicular labeled puncta 
more prominent in, but not restricted to, neurons with nuclear expression of C9ORF72 (Figure 5.8). A 
smaller proportion of neurons had more diffuse immunolabelling which was present in less intensely 
stained puncta in the cytoplasm and neurites (axons and dendrites, demonstrated by MAP2 co-labeling) 
in cells with nuclear and non-nuclear labeling. Immunolabelling of C9ORF72 was similar at 21DIV. 
These results show that C9ORF72 was present throughout the microtubule cytoskeleton including 
throughout the axon, soma and dendritic arbor as well as within actin-rich structures such as growth 
cones and filopodia. 
 
5.4 DISCUSSION 
In this study, the expression of C9ORF72 was examined by multiple biochemical and molecular 
biological analyses conducted both in vivo and in vitro. Results from these investigations demonstrated 
that C9ORF72 undergoes alterations in cellular expression and localisation throughout the time-course 
analysed, which may reflect differential expression of isoforms that are present in specific locations. 
Furthermore C9ORF72 is found in synaptic-rich cellular fractions.  
In order to gain some insight into the function of C9ORF72 protein, the expression level was examined 
over development. Neuronal development involves a number of different processes and therefore 
alterations in the expression or localisation of proteins during development may indicate a role in these 
processes. The results of the current study suggest that there are alterations in the cellular localisation 
of C9ORF72 protein as well as in the expression pattern of the isoforms over time. C9ORF72 was 
detected prenatally, consistent with previous studies looking at the protein in mouse tissue (Koppers 
et al., 2015). C9ORF72 was also observed in adult as well as in embryonic and larval stages in 
Chapter 5 – Results  
    
 
22
zebrafish (Ciura et al., 2013; Koppers et al., 2015). A transcription expression study of the mouse 
ortholog of C9orf72 found that it was only detectable from P1 in the CNS where it increased gradually 
until P60 (Suzuki et al., 2013). Koppers and colleagues (2015) suggested these differences could be 
explained by a failure of the heterozygous LacZ reporter mice used in this study to detect the low levels 
of gene expression present prenatally.    
C9ORF72 isoforms were differentially expressed between the nucleus and cytoplasm. Western blot 
analysis of nuclear and cytoplasmic protein fractions showed that the 55 kDa band was predominantly 
nuclear, the 35 kDa band was predominantly cytoplasmic and the 50 kDa band was expressed similarly 
in both fractions. The expression of mRNA for isoform 1 was higher at P1 than in adult tissue 
corresponding with higher protein expression of isoform 1 at P1. The higher expression of isoform 1 
during these developmental timepoints is consistent with the strong immunohistochemical labeling of 
C9ORF72 in mouse tissue in postnatal tissue and the localisation of C9ORF72 to nuclei at P7. At P56 
there was an increase in isoform 3 mRNA compared to P1 and P7. However, this increase in mRNA 
content was not reflected at the protein level, where isoform 3 protein was significantly higher at early 
timepoints. These discrepancies may be explained by differences in mechanisms involved in the post-
transcriptional regulation, or repression of translation of isoform 3 mRNA in adulthood. A recent study 
by Xiao et al. (2015) found differential localisation of human C9orf72 isoforms. The human short 
isoform (approximately 25 kDa) was localised to the nuclear membrane and the long isoform 
(approximately 55 kDa) was localised to cytoplasm with diffuse and punctate expression. 
The identity of the 110 kDa labeled by C9ORF72 is unknown. These bands have been observed in 
previous studies (Renton et al., 2011) and also in Western blots from primary cell culture in the current 
study (data not shown). As the characteristic labeling of C9ORF72 was reduced following 
preadsorption, it is possible that it may be a dimer of the 55 kDa band resistant to the reducing agents 
used in the Western blot protocol. Further studies are required to further investigate these bands. 
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Throughout all time-points in the current study, C9ORF72 had a punctate pattern of 
immunolocalisation, which is consistent with other studies describing expression of this protein. In 
mice, synaptogenesis ranges from the first to third weeks of postnatal life (Pfrieger, 2009). It is 
therefore plausible that, in the current study, the presence of strongly labeled puncta during this time 
and reports of diffuse cytoplasmic and punctate labeling from other studies (Cooper-Knock et al., 
2012; Hsiung et al., 2012; Satoh et al., 2012; Snowden et al., 2012; Xiao et al., 2015) suggest 
involvement of C9ORF72 at the synapse. Only the 55 kDa form of C9ORF72 was in synaptic-rich 
fractions in the synaptosome preparations, perhaps indicating a specific role of isoform 1 at synapses. 
This is also consistent with higher expression of isoform 1 at early postnatal timepoints.  
It is unknown why specific populations of cells are vulnerable to degeneration in diseases such as 
FTLD and ALS. This study showed C9ORF72 expression in neurites and the neuropil. Previous studies 
have found C9ORF72 within dystrophic neurites within plaques of AD brains and within swollen 
neurites in the hippocampus of both AD and non-AD brains (Satoh et al., 2012), suggesting that it is 
present in neurites. Additionally, the protein is observed within swollen axons in the spinal cord ventral 
grey matter (Stewart et al., 2012). Motor deficits and abnormal motor neuron axons have been 
described following knockdown of C9orf72 in zebrafish (Ciura et al., 2013), although more recent 
studies in mice have found no effect of complete lack of C9ORF72 on motor function (Koppers et al., 
2015). The results of the current study demonstrate the presence of C9ORF72 as puncta throughout 
the actin cytoskeleton, and the presence of the protein in synaptic-rich fractions. There are a number 
of vesicles known to be present in axons including those supplying the synapse, those involved in 
membrane trafficking and axon outgrowth, and vesicles containing RNA molecules and signaling 
vesicles (Millecamps & Julien, 2013). Membrane trafficking is critical for cell survival and defects in 
transport to the membrane are common hallmarks of neurodegenerative diseases, including FTLD (D. 
Wang, Chan, Cherry, & Hiesinger, 2013). In a similar line, it was recently demonstrated that C9ORF72 
is involved in endosomal trafficking via Rab-dependent pathways (Farg et al., 2014). When C9ORF72 
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expression was knocked down, endocytosis and autophagy-related trafficking were inhibited. Human 
C9orf72 isoforms have also been shown to interact with nuclear pore complex components, suggesting 
a possible role in nucleocytoplasmic shuttling (Xiao et al., 2015). These studies, in combination with 
the results of the current study related to synaptosome preparations and differential nuclear and 
cytoplasmic localisation, may suggest that C9ORF72 plays a role in trafficking and raises the 
possibility that failure in such neuronal cellular transport during ageing may be linked to 
neurodegeneration.  
Like many other genetic causes of neurodegenerative disorders, the repeat expansion found in the 
C9ORF72 gene is present at birth but does not cause disease until later in life. If haploinsufficiency of 
the encoded protein, C9ORF72, does contribute to disease then this suggests that it is due to 
vulnerability caused by altered isoform expression in ageing. 
This study has been the first to give a detailed description of the expression of C9ORF72 in mice, 
including expression over development, and lays a foundation for future studies examining the effects 
of altering C9ORF72 expression in rodent models, potentially providing insights into how abnormal 
repeat expansion may be associated with FTLD and ALS. The presence of C9ORF72 within vesicular 
puncta also warrants further study. Identification of these vesicles could be key to determining the role 
of this protein within cells. 
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6 FINAL DISCUSSION 
FTD and ALS are two neurodegenerative diseases, which often occur during mid- to latter-life. 
Currently, neither have effective therapeutics available. ALS has two approved drugs, neither of which 
offers substantial help: Edaravone has only recently been approved by the US Food and Drug 
Administration (The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group, 
2017) and its therapeutic benefits are yet to be described, and Riluzole only increases patient life-
expectancy by 2 to 3 months (Bensimon, 1994; Miller, Mitchell, & Moore, 2012). For FTD, while 
there are drugs to alleviate some of the behavioural and psychiatric symptoms, there are no disease-
modifying treatments available. 
The most important step in developing effective therapeutics for these diseases is understanding their 
causes. ALS and FTD are likely on a continuum, due to their overlapping features. Both conditions 
often arise from mutations to the C9orf72 gene, which can cause abnormal accumulation of TDP-43 
in surviving cells of the brain and spinal cord. Accumulation and mislocalisation of TDP-43 also occur 
in other familial and sporadic forms of the FTD and ALS. In addition to gross brain and spinal cord 
atrophy, both diseases are characterised by significant neurite pathology including white matter loss, 
loss of dendrite arbours, synaptic dysfunction and axon swelling and degeneration. These 
abnormalities are likely to stem from cytoskeletal disruption, but the involvement of TDP-43 
pathology in driving these abnormalities, and whether the C9ORF72 protein also plays a role in 
regulating the cytoskeleton, remain key questions. The main aim of this thesis was to characterise the 
roles of TDP-43 and C9ORF72 in the development of cytoskeletal pathology by examining their effect 
on neurites.  
 
6.1 ALTERATIONS TO NEURON MORPHOLOGY 
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Neurons require tight regulation of processes like pathfinding, neurite outgrowth, branching, growth 
cone formation and synapse formation, which must be adequately maintained across the entire lifespan 
to preserve connectivity of the brain. In the intact CNS, connectivity via synapses depends upon 
arbourisation of both dendrites and axons, and thus remodeling of these structures may disrupt 
function. Dendrite arbourisation is damaged in both ALS and FTD, (Ferrer et al., 1991). The finding 
in chapter 3, that overexpression of WT TDP-43 alters cortical neurite branching, suggests a direct 
pathogenic role for TDP-43 when considered along with several studies linking TDP-43 to neurite 
branching (Herzog et al., 2017; Lu et al., 2009; Schwenk et al., 2016). Models of ALS, including the 
G93A SOD1 mouse model, exhibit reduced dendritic arbourisation associated with excitability 
changes (Fogarty, Noakes, & Bellingham, 2015; van Zundert, Izaurieta, Fritz, & Alvarez, 2012). In 
human ALS, hyper-excitability occurs in both upper and lower motor neurons (Kiernan, 2012; Vucic, 
2006), and may leave them more susceptible to additional insults (Bae, Simon, Menon, Vucic, & 
Kiernan, 2013). Increased synapse numbers following overexpression of WT TDP-43 in vivo (Chapter 
4) further imply a relationship between TDP-43 and neuronal connectivity. Although the origin of 
disease processes in both ALS and FTD remains unknown, alterations to TDP-43 may mediate changes 
in morphology and perhaps ultimately changes to connectivity.  
When retinal ganglion cells (RGCs) were used as a model of TDP-43 axonal effects, overexpression 
of TDP-WT caused a decrease in axon caliber in optic nerves in vivo, further supporting a role for 
TDP-43 in regulating cytoskeletal composition in these axons. Specifically, neurofilament proteins, 
particularly NFM, are important for establishing and maintaining axon caliber (Barry et al., 2012), and 
changes to neurofilament composition may account for the decreased axon diameter. This range of 
evidence associating altered TDP-43 expression with changes to neurite morphology pinpoint this as 
a vulnerable pathway through which TDP-43 pathology may act.  
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6.2 ACTIN CYTOSKELETON 
This thesis demonstrated a potentially significant relationship between TDP-43 and C9ORF72 and the 
actin cytoskeleton. Within neurons, actin plays several roles including support of membranes, 
regulating axonal transport, motility of the developing growth cone and pre- and post-synapse 
formation, and is the substrate for myosin motor proteins (e.g. myosin Va) which link cytoskeletal 
elements. Disruption to the actin cytoskeleton can perturb synapse formation and neuronal integrity 
(W. B. Zhang, D. L., 2001, reviewed in Eira et al., 2016), and it is closely regulated by a number of 
signalling pathways, particularly the Rho GTPase family, which act upstream of actin binding proteins 
(Nobes, 1995).  In chapter 3, proteomic analysis identified actin binding proteins as one of the most 
upregulated groups in response to TDP-43 overexpression in culture, including Myh9 in agreement 
with previous work (Freibaum et al., 2010; Stalekar et al., 2015) but also including actin binding 
proteins not previously linked to TDP-43 changes. Consequent disruptions to the actin cytoskeletal 
network included changes to neurite branching and growth cone morphology, which could be 
attributed to interactions with Rac1 and Cdc42, key Rho GTPases which TDP-43 has previously been 
shown to modulate (Iguchi et al., 2009).  
This thesis further identified novel potential links between C9ORF72 and the actin cytoskeleton. In 
chapter 5, C9ORF72 expression in cultured cortical neurons extended beyond the microtubule 
cytoskeleton and into actin-rich filopodia and growth cones. One subsequently published study found 
that C9ORF72 interacts with cofilin 1 (Sivadasan et al., 2016), an actin binding protein important for 
modulating organisation and dynamics of the actin cytoskeleton (Bravo-Cordero et al., 2013). It is 
currently not known how mutations in C9orf72 lead to both ALS and FTD, but it is likely due to a 
combination of RNA toxicity, translation of the repeat expansion into harmful dipeptide repeat 
proteins, and a reduction in the amount of C9ORF72 protein. If C9ORF72 significantly interacts with 
the actin cytoskeleton and synapses, a reduction in the level of this protein is likely to have a 
detrimental effect. Mutations to C9ORF72 cause TDP-43 pathology, and it is currently unclear if 
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alterations to C9ORF72 at the transcriptional or translational level cause TDP-43 to become 
mislocalised and aggregate in the cytoplasm. The results indicate that actin associated processes need 
more investigation in ALS/FTD.  
Actin is enriched in dendritic spines, and is important for synapse formation and maintenance 
(Jaworski et al., 2009). Altered synaptic terminals are observed in ALS/FTD (Zhou et al., 1998) and 
also feature in a range of other neurodegenerative diseases (reviewed in Vickers et al., 2009). In this 
thesis, C9ORF72 protein was enriched within synapses in adult mouse brains, further strengthening 
the association between this protein and the actin cytoskeleton. When RGCs were used to model 
synaptic alterations following transduction with altered TDP-43, transducing them with TDP-WT 
resulted in increased synapses in the IPL, which is pre-synaptic to the RGCs, and perhaps attributable 
to increased dendrite branching of RGCs and an increase in the number of dendritic spines available 
for IPL neurons to connect to. This phenomenon would need to be examined in a more disease-relevant 
model to determine whether it is significant for ALS/FTD, although previous work in primary 
hippocampal neurons (Majumder et al., 2012) and in the cortex of A315T TDP-43 transgenic mice 
(Handley et al., 2016) have also demonstrated that altered TDP-43 impacts dendritic spines. 
 
6.3 AXON DEGENERATION 
Axonal changes have been hypothesised to initiate pathological processes causing cell dysfunction and 
degeneration in a range of diseases (Vickers et al., 2009). In ALS and FTD, white matter tracts are 
lost, and axons swell and degenerate. Many clinical symptoms in ALS are thought to arise from axon 
degeneration, especially in peripheral motor pathways; axon degeneration is implied by the observed 
loss of motor neuron axons without corresponding cell body loss (Fischer et al., 2004; Gould et al., 
2006; King et al., 2012). These diseases share axon-specific pathology, since neurofilament alterations 
are common in ALS and in the FTD variant NIFID. In in vitro studies in this thesis, neurofilament-
Chapter 6 – Discussion 
    
 
6
labelled axons were observed undergoing early alterations to their integrity, exhibiting ‘beads on a 
string’ labelling and neurofilament-labelled ring-like structures. Similarly, in an earlier study of an 
mSOD1 mouse model of ALS, axons expressing GFP showed axon blebbing in chains along white 
matter tracts (Anna E King et al., 2012). Neurofilament-labelled rings have also been observed in 
several pathological contexts, including around beta amyloid plaques in pre-clinical (Dickson et al., 
1999) and end-stage AD cases (Dickson et al., 2005); and may represent microtubule dissolution and 
axonal collapse (Vickers et al., 2009). Slowing of axonal transport of neurofilaments is observed 
following glutamate excitotoxicity (Ackerley et al., 2000), and excitotoxic mechanisms are an 
important pathological feature of ALS (King et al., 2016). In vivo, NFH became abnormally localised 
to cell bodies of RGCs following transduction with TDP-NLS–-GFP tissue, suggesting that TDP-43 
may alter neurofilament stoichiometry and/or its transport into axons. TDP-43 has previously been 
shown to regulate NFL by stabilising its mRNA and thus its translation in the cytoplasm (Strong et al., 
2007; Volkening et al., 2009), providing a plausible link between TDP-43 and neurofilament 
alterations.  
Under ultrastructural examination of transduced RGC axons, TDP-NLS–-GFP increased the number 
of degenerative profiles and the accumulation of abnormal organelles, resembling the disrupted axons 
observed in the ventral horn of human ALS spinal cords. Ultrastructural and neuropathological 
analyses show that these swellings contain accumulations of phosphorylated neurofilament proteins, 
mitochondria and lysosomes (Corbo & Hays, 1992; Hirano, Donnenfeld, et al., 1984; Hirano, Nakano, 
et al., 1984; Rouleau et al., 1996) and importantly, accumulations of kinesin, a key protein involved in 
transport of cargoes in the axon (Toyoshima et al., 1998). Determining the composition of the 
organelles accumulated in the RGC model will be an important future investigation. 
 
6.4 LIMITATIONS AND FUTURE DIRECTIONS 
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Primary cell culture models were utilised in this thesis to allow for the examination of developmental 
processes, and detailed characterisations of individual cells and their connections. However, ALS and 
FTD are older adult-onset diseases. Although there are parallels between developmental and ageing 
processes, including plastic remodelling of synapses and branches, primary culture models present 
limitations in their ability to reproduce features of ageing-related diseases. However, these types of 
models are crucial in gaining mechanistic insights into diseases like ALS and FTD. 
It has been particularly challenging to create models of TDP-43 pathology to recapitulate degenerative 
features observed in TDP-43-mediated disease. The TDP-43Prp transgenic mouse model, 
overexpressing human TDP-43, was chosen for in vitro studies, but its two month postnatal onset of 
severe neurodegeneration does not resemble adult-onset ALS/FTD.  
Future studies will further extend the in vivo eye model, introduced in chapter 4, to further investigate 
TDP-43 pathological and normal function. Transduction with bicistronic vectors allowing independent 
expression of TDP-43 and cell-wide fluorescent protein will enable tracing of transduced RGC through 
the optic nerve and into the brain, as well as analysis of neuron arborisation within the retina, to further 
extend in vitro findings.  
To extend the key proteomic findings of Chapter 3, the effects of TDP-43 overexpression on different 
neuronal compartments could be investigated using microfluidic devices that allow separation of the 
somatodendritic and axonal compartments. Additionally, due to limitations with sample preparation, 
replication of whole cell proteomics at 3 DIV may allow stronger associations between neuron 
morphology changes and global protein alterations to be determined.  
The interactions between both TDP-43 and C9ORF72 with the actin cytoskeleton represent the key 
findings of this thesis. Future studies to further elucidate the normal function of C9ORF72 will help 
determine its role in disease; specifically, knockdown studies will be of value to determine whether 
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reduction of C9ORF72 alters the functions suggested in this thesis, such as growth cone 
morphology/motility and synapse development. 
 
6.5 THERAPEUTIC IMPLICATIONS 
In both ALS and FTD, extensive pathology of neurites and synapses are present. Evidence from this 
thesis and other studies suggests that TDP-43 is a key regulator of cytoskeletal elements that are vital 
for maintaining healthy neurites. If the disruptive effects of altered TDP-43 on the neuronal 
cytoskeleton could be ameliorated, then it may be possible to protect vulnerable neurons from 
developing neurite and synaptic pathology and degenerating.  
The neuronal cytoskeleton presents as an attractive target for therapeutic intervention. Currently, 
animal and human clinical trials of drugs targeting the neuronal cytoskeleton in other 
neurodegenerative diseases are underway, and show promising results (Eira et al., 2016). These include 
drugs that target microtubules and their stability, as well as regulators of cytoskeletal dynamics such 
as RhoA and GSK3b (Eira et al., 2016). There is accumulating model-based and clinical evidence that 
neurite abnormalities are an important consequence of altered TDP-43, and this thesis has provided 
further evidence that alterations to TDP-43 can alter neurite morphology, including induction of axon 
degeneration (Chapter 4), and changes in synapse numbers. Chapter 3 highlights actin-binding proteins 
as potential mediators of these changes, and chapter 5 adds to the growing body of evidence that 
C9ORF72 is also a regulator of the actin cytoskeleton. Further understanding how actin is involved in 
neuritic alterations, and what modulates these processes is an essential step to identify targets for 
therapeutic intervention. Currently, there are few trials targeting actin dynamics because actin is so 
widely expressed. However, a number of laboratories are working towards targeting drugs to specific 
cell types, and therefore a thorough understanding of the role of actin alterations in ALS/FTD could 
lead to directed future interventions. 
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6.6 CONCLUSIONS  
An improved understanding of the pathological roles of genes and proteins implicated in ALS and 
FTD is an important step for developing therapeutic strategies. Based on the literature to date, it is 
reasonable to propose that neurite abnormalities observed in human post-mortem tissue may occur 
through altered TDP-43 modulation of the cytoskeleton, and that genetic mutations to C9ORF72 may 
also impact these pathological alterations. This thesis has added to a growing body of evidence that 
TDP-43 and possibly C9ORF72 play important roles in interacting with the neuronal cytoskeleton, 
particularly the actin and neurofilament cytoskeletons, and that alterations to TDP-43 levels may be a 
driver of axon degeneration. Future studies will help to unravel these interactions further. Modulation 
of the neuronal cytoskeleton is a compelling target for providing therapeutic protection to vulnerable 
cellular components, such as the axon, as well as potentially preventing neuritic changes that could 
lead to functional disruption and altered excitability. Studies such as those described in this thesis may 
provide insight for whether TDP-43- and C9ORF72-related FTD/ALS are candidates for these types 
of interventions. 
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8 APPENDICES 
8.1 COMMON LABORATORY REAGENTS 
0.01M Phosphate Buffered Saline (PBS) – 1.0L 
850mL MilliQ® water 
100mL 90.0g/L Sodium chloride (NaCl; BDH, USA) 
40mL 28.0g/L Di-sodium hydrogen orthophosphate (Na2HPO; BDH, USA) 
10mL 31.2g/L Sodium di-hydrogen orthophosphate (NaH2PO4.2H2O; Ajax, Australia) 
4% Paraformaldehyde – 1.0L 
40g granulated paraformaldehyde (PFA) 
500mL MilliQ® water 
400mL 28.0g/L Na2HPO 
100mL 31.2g/L NaH2PO4.2H2O 
1.0M NaOH & 1.0M HCl to pH 
Heat MilliQ® to 80oC, add granulated PFA and 5 drops of NaOH. Stir until PFA dissolved, 
add NaH2PO4.H2O and Na2HPO. Filter and pH to 7.4. 
 
0.4M phosphate buffer – 1.0L  
 45.42 g NaH2PO4  
 12.48g Na2HPO4 
 Dissolve in 900ml of distilled water 
 pH to 7.4 with NaOH or HCl 
 Make up to 1L with distilled water 
 
2% PFA/ 2.5% glutaraldehyde – 0.1L  
 250ml 0.4M phosphate buffer 
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 20g PFA powder 
 700ml distilled water (pre-heated in microwave to reduce dissolving time) 
 Dissolve PFA on heat stirrer 
 Filter with whatman paper 
 Add 50ml 50% glutaraldehyde (defrost at room temp for 1hr prior to adding) 
 
Tissue Storage Solution – 500mL 
500mL 0.01M PBS 
0.5g sodium azide 
Cryoprotectant Solution (30% sucrose) – 500mL 
500mL 0.01M PBS 
150g sucrose 
0.02% sodium azide 
8.2 CHAPTER 3 APPENDIX 
Appendix 3.1 Proteomic MS peptide and protein group counts and intensities 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this thesis.  
Appendix 3.2 Proteomic data set after filtering, imputation of missing values, calculation of 
differential expression and calculation of FDR, and Complete DAVID functional annotation 
clustering analysis of proteins up and down regulated greater than 1.3-fold by wildtype TDP-43 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this thesis.  
Appendix 3.3 Statistical appendix for growth cone morphology and Neurolucida analysis  
8.2.1 Growth-cone morphology 
Data were loaded from Excel files and collated into tables. Boxplots suggest tg-het genotypes had a 
different distribution of growth cone morphologies than tg-hom and wt mice, with fewer 
lamelopodial cones and more filopodial cones observed. 
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Data were collapsed into a 3 x 3 contingency table and a Pearson's Chi-squared test of homogeneity 
was calculated. 
##     collapsed filopodial lamelopodial 
## wt        127        196           92 
## hom       122        193           90 
## het       122        219           58 
##  
##  Pearson's Chi-squared test 
##  
## data:  df1 
## X-squared = 11.009, df = 4, p-value = 0.02647 
The chi-squared test shows that one genotype has a different distribution of growth cone 
morphologies to the other two. We can safely assume from the plot that this is the tg-het 
genotype. 
8.2.1.1 Filopodia length 
## Data: df 
## Models: 
## fit3a_null: log(length.filo) ~ 1 + (1 | embryo) 
## fit3a: log(length.filo) ~ geno + (1 | embryo) 
##            Df    AIC    BIC  logLik deviance  Chisq Chi Df Pr(>Chisq) 
## fit3a_null  3 1174.5 1188.7 -584.26   1168.5                          
## fit3a       5 1178.5 1202.0 -584.23   1168.5 0.0563      2     0.9722 
8.2.1.2 Actin : !-tubulin ratio 
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## Data: na.omit(df) 
## Models: 
## fit3a_log_null: log(actin.tubulin.ratio) ~ 1 + (1 | embryo) 
## fit3a_log: log(actin.tubulin.ratio) ~ geno + (1 | embryo) 
##                Df     AIC     BIC logLik deviance  Chisq Chi Df Pr(>Chisq) 
## fit3a_log_null  3 -47.275 -40.019 26.638  -53.275                          
## fit3a_log       5 -45.360 -33.266 27.680  -55.360 2.0845      2     0.3527 
## Analysis of Variance Table 
##      Df  Sum Sq Mean Sq F value 
## geno  2 0.34742 0.17371  0.6634 
## Analysis of Variance Table 
##      Df  Sum Sq Mean Sq F value 
## geno  2 0.26581  0.1329  0.6751 
 
8.2.2 Neuorolucida analysis of neuron morphology 
Number of branch points 
 
## Generalized linear mixed model fit by maximum likelihood (Laplace 
##   Approximation) [glmerMod] 
##  Family: poisson  ( log ) 
## Formula: num.branch.points ~ geno + (1 | embryo) 
##    Data: bp 
##  
##      AIC      BIC   logLik deviance df.resid  
##    831.7    844.4   -411.8    823.7      173  
##  
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## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -2.1064 -0.9799 -0.2971  0.7409  3.4814  
##  
## Random effects: 
##  Groups Name        Variance Std.Dev. 
##  embryo (Intercept) 0.03354  0.1832   
## Number of obs: 177, groups:  embryo, 9 
##  
## Fixed effects: 
##             Estimate Std. Error z value Pr(>|z|)     
## (Intercept)   1.6690     0.1193  13.985  < 2e-16 *** 
## genohom      -0.2806     0.1733  -1.620  0.10532     
## genowt       -0.5603     0.1758  -3.188  0.00143 **  
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##         (Intr) genohm 
## genohom -0.688        
## genowt  -0.677  0.467 
## Single term deletions 
##  
## Model: 
## num.branch.points ~ geno + (1 | embryo) 
##        Df    AIC    LRT Pr(Chi)   
## <none>    831.67                  
## geno    2 834.46 6.7952 0.03345 * 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
## # A tibble: 3 x 3 
##    geno     MEAN        SE 
##   <chr>    <dbl>     <dbl> 
## 1   het 5.396825 0.4326295 
## 2   hom 4.055556 0.3491196 
## 3    wt 3.083333 0.2507522 
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8.3 CHAPTER 4 APPENDIX 
Appendix 4.1 Statistical appendix for optomotor data  
 
A main effect of direction (t >= 1) or direction x time (for all t) would convincingly show an effect of 
injection. Differences in treatment groups can be detected by direction x treatment (t >= 1). 
We note that the response variable is count data, and thus " ∼ $%&'()), but inspection of the density 
plots (below) suggests the variable may be better modelled assuming " ∼ +(,, ./). We will fit models 
both ways to determine the best using AIC (where the model with the smaller AIC is considered a 
better fit). 
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m1 <- glmer(value ~ movdir*time + movdir*treatment*time + (time|id), family = "p
oisson", df) 
m2 <- lmer(value ~ movdir*time + movdir*treatment*time + (time|id),  df) 
anova(m1, m2) 
## Data: df 
## Models: 
## m1: value ~ movdir * time + movdir * treatment * time + (time | id) 
## m2: value ~ movdir * time + movdir * treatment * time + (time | id) 
##    Df    AIC    BIC  logLik deviance  Chisq Chi Df Pr(>Chisq)     
## m1 15 3607.0 3669.6 -1788.5   3577.0                              
## m2 16 3201.8 3268.5 -1584.9   3169.8 407.26      1  < 2.2e-16 *** 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
A general linear model provides the best fit. Now we test whether the 3-way interaction is 
significant using a likelihood ratio test (LRT). 
m3 <- lmer(value ~ time + movdir + treatment + time:movdir + time:treatment + mo
vdir:treatment + (time|id),  df) 
anova(m2, m3) 
## Data: df 
## Models: 
## ..1: value ~ time + movdir + treatment + time:movdir + time:treatment +  
## ..1:     movdir:treatment + (time | id) 
## object: value ~ movdir * time + movdir * treatment * time + (time | id) 
##        Df    AIC    BIC  logLik deviance  Chisq Chi Df Pr(>Chisq) 
## ..1    14 3199.2 3257.6 -1585.6   3171.2                          
## object 16 3201.8 3268.5 -1584.9   3169.8 1.4385      2     0.4871 
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The model with 2-way interactions is equivalent to the model with 3-way interactions, so unless the 
3-way interaction is significant, there is no convincing argument to include it. 
## Analysis of Variance Table of type III  with  Satterthwaite  
## approximation for degrees of freedom 
##                       Sum Sq Mean Sq NumDF DenDF F.value    Pr(>F)     
## movdir                791.86  791.86     1   414 20.5074 7.778e-06 *** 
## time                   28.83   28.83     1    27  0.7466   0.39516     
## treatment             108.78   54.39     2    27  1.4086   0.26188     
## movdir:time           170.25  170.25     1   414  4.4091   0.03635 *   
## movdir:treatment       43.58   21.79     2   414  0.5643   0.56919     
## time:treatment        107.54   53.77     2    27  1.3925   0.26573     
## movdir:time:treatment  54.84   27.42     2   414  0.7102   0.49216     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
We can exclude the 3-way interaction (p = .49) 
ANOVA table for two-way interaction model, 
anova(m3, ddf = "Kenward-Roger") 
## Analysis of Variance Table of type III  with  Kenward-Roger  
## approximation for degrees of freedom 
##                  Sum Sq Mean Sq NumDF  DenDF F.value    Pr(>F)     
## time              28.79   28.79     1  32.91  0.7466   0.39381     
## movdir           791.86  791.86     1 416.00 20.5360 7.659e-06 *** 
## treatment        108.63   54.32     2  38.15  1.4086   0.25690     
## time:movdir      170.25  170.25     1 416.00  4.4152   0.03622 *   
## time:treatment   107.39   53.69     2  32.91  1.3925   0.26271     
## movdir:treatment 172.62   86.31     2 416.00  2.2383   0.10792     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
Use standard graphical methods to test the assumption of normality (qq-plot) of residuals and 
homogeneity of variance (plot of residuals) 
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The 2-way interaction time x treatment is not significant, but it may still be important to report this 
result if it evidences a hypothesis that was formed a-priori (i.e "there were no significant differences 
between treatment groups over time"). Similarly, there is no differences between treatment groups with 
respect to movement direction (movdir x treatment interaction). 
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Tukey contrasts and 95% CIs: 
## $lsmeans 
## movdir = Clockwise: 
##  treatment  lsmean       SE    df lower.CL upper.CL 
##  PBS       17.4625 1.301929 36.63 14.82363 20.10137 
##  TDP-NLS   18.7750 1.301929 36.63 16.13613 21.41387 
##  TDP-WT    20.8375 1.301929 36.63 18.19863 23.47637 
##  
## movdir = Anti-clockwise: 
##  treatment  lsmean       SE    df lower.CL upper.CL 
##  PBS       24.6375 1.301929 36.63 21.99863 27.27637 
##  TDP-NLS   24.7250 1.301929 36.63 22.08613 27.36387 
##  TDP-WT    25.0875 1.301929 36.63 22.44863 27.72637 
##  
## Degrees-of-freedom method: satterthwaite  
## Confidence level used: 0.95  
##  
## $contrasts 
## movdir = Clockwise: 
##  contrast         estimate       SE    df t.ratio p.value 
##  PBS - TDP-NLS     -1.3125 1.841205 36.63  -0.713  0.7575 
##  PBS - TDP-WT      -3.3750 1.841205 36.63  -1.833  0.1731 
##  TDP-NLS - TDP-WT  -2.0625 1.841205 36.63  -1.120  0.5080 
##  
## movdir = Anti-clockwise: 
##  contrast         estimate       SE    df t.ratio p.value 
##  PBS - TDP-NLS     -0.0875 1.841205 36.63  -0.048  0.9988 
##  PBS - TDP-WT      -0.4500 1.841205 36.63  -0.244  0.9676 
##  TDP-NLS - TDP-WT  -0.3625 1.841205 36.63  -0.197  0.9789 
##  
## P value adjustment: tukey method for comparing a family of 3 estimates 
 
Difference in number of head turns with 95% CI 
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Reducing time to two levels, pre-test and the first observation post-treatment (14 days post treatment) 
 
## Analysis of Variance Table of type III  with  Kenward-Roger  
## approximation for degrees of freedom 
##                   Sum Sq Mean Sq NumDF  DenDF F.value   Pr(>F)    
## time_f           298.629 298.629     1 27.304 11.0600 0.002525 ** 
## movdir           170.408 170.408     1 56.000  6.3112 0.014906 *  
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## treatment        125.256  62.628     2 27.113  2.3195 0.117522    
## time_f:movdir    221.408 221.408     1 56.000  8.2001 0.005885 ** 
## time_f:treatment  13.376   6.688     2 27.304  0.2477 0.782336    
## movdir:treatment  16.217   8.108     2 56.000  0.3003 0.741781    
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
## $lsmeans 
## movdir = Clockwise: 
##  treatment lsmean       SE    df lower.CL upper.CL 
##  PBS        20.20 1.341172 62.15 17.51916 22.88084 
##  TDP-NLS    18.35 1.341172 62.15 15.66916 21.03084 
##  TDP-WT     22.40 1.341172 62.15 19.71916 25.08084 
##  
## movdir = Anti-clockwise: 
##  treatment lsmean       SE    df lower.CL upper.CL 
##  PBS        23.00 1.341172 62.15 20.31916 25.68084 
##  TDP-NLS    21.35 1.341172 62.15 18.66916 24.03084 
##  TDP-WT     23.75 1.341172 62.15 21.06916 26.43084 
##  
## Results are averaged over the levels of: time_f  
## Degrees-of-freedom method: satterthwaite  
## Confidence level used: 0.95  
##  
## $contrasts 
## movdir = Clockwise: 
##  contrast         estimate       SE    df t.ratio p.value 
##  PBS - TDP-NLS        1.85 1.896704 62.15   0.975  0.5951 
##  PBS - TDP-WT        -2.20 1.896704 62.15  -1.160  0.4814 
##  TDP-NLS - TDP-WT    -4.05 1.896704 62.15  -2.135  0.0910 
##  
## movdir = Anti-clockwise: 
##  contrast         estimate       SE    df t.ratio p.value 
##  PBS - TDP-NLS        1.65 1.896704 62.15   0.870  0.6611 
##  PBS - TDP-WT        -0.75 1.896704 62.15  -0.395  0.9175 
##  TDP-NLS - TDP-WT    -2.40 1.896704 62.15  -1.265  0.4200 
##  
## Results are averaged over the levels of: time_f  
## P value adjustment: tukey method for comparing a family of 3 estimates 
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Reducing time to two levels, pre-test and post-treatment (all observations post-treatment) 
 
## Analysis of Variance Table of type III  with  Kenward-Roger  
## approximation for degrees of freedom 
##                     Sum Sq Mean Sq NumDF  DenDF F.value    Pr(>F)     
## t2                   79.64   79.64     1  34.77  2.0526    0.1609     
## movdir                1.67    1.67     1 414.00  0.0430    0.8359     
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## treatment           112.27   56.13     2  32.84  1.4467    0.2500     
## t2:movdir           643.13  643.13     1 414.00 16.5745 5.605e-05 *** 
## t2:treatment        105.61   52.81     2  34.77  1.3609    0.2698     
## movdir:treatment      1.23    0.62     2 414.00  0.0159    0.9842     
## t2:movdir:treatment  18.48    9.24     2 414.00  0.2381    0.7882     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
## Analysis of Variance Table of type III  with  Kenward-Roger  
## approximation for degrees of freedom 
##                  Sum Sq Mean Sq NumDF  DenDF F.value    Pr(>F)     
## t2                78.88   78.88     1  37.15  2.0373    0.1618     
## movdir             1.67    1.67     1 416.00  0.0430    0.8357     
## treatment         62.20   31.10     2  35.33  0.8033    0.4559     
## t2:movdir        643.13  643.13     1 416.00 16.6107 5.498e-05 *** 
## movdir:treatment 172.62   86.31     2 416.00  2.2292    0.1089     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
## $lsmeans 
## movdir = Clockwise: 
##  treatment   lsmean       SE   df lower.CL upper.CL 
##  PBS       17.91814 1.250189 41.2 15.39370 20.44257 
##  TDP-NLS   18.18842 1.250189 41.2 15.66398 20.71285 
##  TDP-WT    20.96845 1.250189 41.2 18.44401 23.49288 
##  
## movdir = Anti-clockwise: 
##  treatment   lsmean       SE   df lower.CL upper.CL 
##  PBS       25.09314 1.250189 41.2 22.56870 27.61757 
##  TDP-NLS   24.13842 1.250189 41.2 21.61398 26.66285 
##  TDP-WT    25.21845 1.250189 41.2 22.69401 27.74288 
##  
## Degrees-of-freedom method: satterthwaite  
## Confidence level used: 0.95  
##  
## $contrasts 
## movdir = Clockwise: 
##  contrast           estimate       SE    df t.ratio p.value 
##  PBS - TDP-NLS    -0.2702804 1.727882 40.27  -0.156  0.9866 
##  PBS - TDP-WT     -3.0503085 1.727882 40.27  -1.765  0.1942 
##  TDP-NLS - TDP-WT -2.7800281 1.727882 40.27  -1.609  0.2536 
##  
## movdir = Anti-clockwise: 
##  contrast           estimate       SE    df t.ratio p.value 
##  PBS - TDP-NLS     0.9547196 1.727882 40.27   0.553  0.8458 
##  PBS - TDP-WT     -0.1253085 1.727882 40.27  -0.073  0.9971 
##  TDP-NLS - TDP-WT -1.0800281 1.727882 40.27  -0.625  0.8073 
##  
## P value adjustment: tukey method for comparing a family of 3 estimates 
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DEVELOPMENT 
 
 
 
 
 
 
 
 
 
  
RESEARCH Open Access
C9ORF72 expression and cellular
localization over mouse development
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Abstract
Introduction: A majority of familial frontotemporal lobar dementia and amyotrophic lateral sclerosis cases are
associated with a large repeat expansion in a non-coding region of the C9ORF72 gene. Currently, little is known about
the normal function and the expression pattern of the C9ORF72 protein. The aims of this study were to characterize
the expression pattern and cellular localization of the three reported mouse isoforms of C9orf72, over a developmental
time-course in primary cultured cortical neurons and brain tissue from C57BL/6 mice.
Results: We demonstrated that the different isoforms of C9ORF72 at the mRNA and protein level undergo alterations in
expression during development and into adulthood. Cellular fractionation and immunofluorescence demonstrated that
levels of nuclear and cytoplasmic expression of isoforms changed significantly over the time course. Additionally,
immunofluorescence studies showed C9ORF72 labeling as puncta throughout neurons, extending beyond the
microtubule cytoskeleton into actin-rich structures such as filopodia and growth cones. Finally, synaptosome preparations
demonstrated the presence of C9ORF72 isoform 1 in synaptic-rich fractions from adult mouse brain.
Conclusion: In summary, the presence of C9ORF72 as puncta and within synaptic-rich fractions may indicate
involvement at the synapse and differential expression of isoforms in nuclei and cytoplasm may suggest distinct roles for
the isoforms. Determining the physiological role of C9ORF72 protein may help to determine the role it plays in disease.
Keywords: C9ORF72, FTLD, ALS
Introduction
Frontotemporal lobar dementia (FTLD) and amyo-
trophic lateral sclerosis (ALS) are progressive neurode-
generative disorders, which due to their overlapping
features, are now thought to represent two ends of a dis-
ease spectrum [17]. In 2011, two independent groups
identified the largest genetic cause of FTLD and ALS as a
repeat expansion of the hexanucleotide sequence
GGGGCC in the C9ORF72 gene [4, 25]. This expansion
occurs in a non-coding region of chromosome 9. It is cur-
rently unknown how the repeat expansion contributes to
FTLD and ALS, although several mechanisms have been
proposed, including potential unconventional translation
of the repeated sequence (repeat-associated non-ATG ini-
tiated translation) leading to intracellular accumulations
of dipeptide repeat proteins [1, 23], and the sequestration
of RNA binding proteins into RNA foci, causing RNA
dysfunction [4, 27]. Alternatively, the hexanucleotide ex-
pansion may result in haploinsufficiency due to reduced
expression of C9ORF72 transcripts [2, 4, 5, 33, 34, 37].
While pathological features of C9ORF72-associated
disease, such as TDP-43 aggregates, dipeptide repeat
protein expression and RNA foci, are under intense in-
vestigation regarding their role in disease, to date, less
attention has been paid to the normal expression and
function of the encoded protein, C9ORF72. Elucidating
the expression, localization and function of this protein
in neural cells may contribute further to knowledge re-
garding how the repeat expansion is associated with
neurodegenerative changes.
In humans, alternative splicing of three RNA tran-
script variants from the C9ORF72 gene produces two
different isoforms of the C9ORF72 protein (Fig. 1a) [25].
Transcript variants 1 and 3 encode a 481 amino acid
protein and variant 2 encodes a 222 amino acid protein
[4]. In mice, there are 3 protein-coding regions reported
of 481 (isoform 1), 420 (isoform 2) and 317 (isoform 3)
amino acids, likely encoding at least 3 different protein
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isoforms (Fig. 1b). However, the roles of the encoded pro-
teins have not been well characterized. We have previ-
ously demonstrated a role for C9ORF72 in trafficking [7]
which was in line with previous studies [16]. C9ORF72 is
involved in endosomal trafficking via Rab-dependent
pathways. Rab proteins are part of the Rab-GDP/GTP ex-
change factor family (Rab-GEF) (as reviewed in [29]) that
mediate all membrane trafficking events between organ-
elles. We provided the first experimental evidence for this,
when we established that C9ORF72 regulates endocytosis
and autophagy [7].
Other studies have examined the expression of the
C9orf72 gene using a transgenic mouse model harboring a
targeted LacZ insertion [32]. This study observed C9orf72
in neuronal and non-neuronal cells within the central
nervous system (CNS). Recently, the effect of ablating the
3 isoforms of C9ORF72 protein from neurons and glia has
been examined, demonstrating a reduction in body weight
but no motor neuron degeneration or motor deficits [15].
This suggests that complete lack of C9ORF72 throughout
development and adulthood is not sufficient to cause a
motor neuron disease phenotype in mice.
Several studies have examined the expression of
C9ORF72 in human tissue [3, 4, 11, 13, 28, 30] and cell
lines [11, 25] using a variety of commercial antibodies.
However, there has been a lack of consensus about the
localization of C9ORF72 across these studies. Some in-
vestigations have described coarse punctate expression
within the hippocampus, suggestive of synaptic termi-
nals [3, 13, 26, 28]. Recently, Xiao and colleagues [37]
generated antibodies specific to the two human C9ORF72
isoforms. They demonstrated diffuse cytoplasmic and
‘speckled’ localization of the long isoform, as well as
localization of the short isoform to the nuclear membrane.
This is in line with our previous investigation which dem-
onstrated a nuclear and punctate pattern of expres-
sion (typical of vesicles) of C9ORF72 in vitro in both SH-
SY5Y cells and in primary cultured cortical neurons [7].
The current study examined the expression of
C9ORF72 in the mouse CNS over development in vivo
and in vitro in order to provide information about its ex-
pression and cellular localization during neurite out-
growth, neuron maturation and synapse formation. This
investigation demonstrated that expression of C9ORF72
mRNA and protein differ over a developmental time
course, are expressed in both nuclear and cytoplasmic
fractions in an isoform specific manner, and that the large
isoform may be present in synaptic fractions.
Materials and methods
Animals
C57BL/6 mice were utilized in this study. All experiments
involving animals were approved by the University of
Tasmania Animal Ethics Committee (A12780) and were in
accordance with the Australian Guidelines for the Care and
Use of Animals for Scientific Purposes.
Tissue preparation
For molecular biology analysis, combined neocortical
and hippocampal tissue was harvested from mice at em-
bryonic day (E) 18, postnatal day (P) 1, P7, P14, P28 and
P56 (for western blot) (n = 4 mice per time-point) and
P1, P7 and P56 (for real time qPCR) (n = 4 mice per time-
point). Tissue was processed as previously described [18].
Fig. 1 Schematic overview of human and mouse C9ORF72 transcripts and encoded proteins. Protein coding regions for transcript variants
(V1 to 3) are indicated in light blue for human (a) and dark blue for mouse (b) as well as size of encoded proteins. Non-coding regions are
indicated in red and location of the G4C2 repeat expansion in yellow.
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For immunohistochemical analysis, animals were termin-
ally anaesthetized with sodium pentobarbitone (140 mg/kg)
and transcardially perfused with 4 % paraformaldehyde.
Brains were immediately dissected, post-fixed overnight in
paraformaldehyde and then cryoprotected as previously de-
scribed [19]. Serial 40 μm coronal sections were cut on a
cryostat (Leica CM 1850). For each mouse at each time
point, four regularly spaced sections were examined from
the rostral to caudal cortex corresponding to bregma
0.98 mm to −1.82 mm (in adult tissue) according to the
stereotaxic mice atlas [10]. Antigen retrieval was carried
out prior to immunohistochemistry using citric acid,
pH 6.0, in a pressure cooker for 14 min.
Protein extraction and western blot analysis
Protein from combined cerebral cortex and hippocampus
was extracted with RIPA Buffer (Sigma Aldrich) contain-
ing a cocktail of protease inhibitors (Roche). Protein ex-
tract was then placed at 4 °C for 30 min, centrifuged at
13,000 rpm for 20 min and supernatant stored at −80 °C.
Denatured proteins samples (15 μg) from each time-
point were electrophoresed into 10 % SDS-PAGE gels
(BioRad), transferred to PVDF membranes (BioRad) and in-
cubated in primary antibodies overnight (Table 1). A corre-
sponding anti-rabbit or anti-mouse horseradish peroxidase
(HRP)-conjugated secondary antibody (1:7000; Amersham)
was used, as described previously [18]. GAPDH (1:7000,
Millipore) was used as a loading control and band intensity
was measured as the integrated intensity using ImageJ soft-
ware (v1.4; NIH), and normalized with respect to the load-
ing controls. Three experimental repeats were carried out.
Nuclear and cytoplasmic fractionation
Nuclear and cytoplasmic protein extractions were pre-
pared from right hemispheres (excluding olfactory bulbs
and cerebellum) of fresh P1, P7, P56 brains using the NE-
PER kit (Thermo Fisher Scientific) according to manufac-
turer instructions. Denatured protein samples were elec-
trophoresed as described above. Fraction purity was
confirmed by labeling with HDAC2 (1:700; Abcam) for
nuclear fractions and GAPDH (as above) for cytoplasmic
fractions. Membranes were also incubated with C9ORF72
antibody (as above). Densitometry analysis of bands was
carried out using ImageJ. Results were normalized to total
protein. Three experimental repeats were carried out.
Synaptosome preparation
Synaptosomes were prepared as described previously
[6, 22] with some modifications. Briefly, P56 mice (n = 4)
were anaesthetized and perfused with sucrose buffer
(0.32 M sucrose, 1 mM ethylenediaminetetraacetic acid,
5 mM dithiothreitol, pH 7.4). Whole brains were harvested
and homogenized at 4 °C with a teflon-glass homogenizer
using 12 strokes with 9:1 ratio of sucrose buffer supple-
mented with a protease cocktail inhibitor (Roche) to 1 g of
tissue. Homogenate was centrifuged at 1000xg for 10 min
at 4 °C. The resulting pellet containing mostly nuclei was
removed and the supernatant was layered onto a discon-
tinuous gradient consisting of 3, 10, 15 and 23 % (vol/vol)
Percoll (GE Healthcare). Tubes were then centrifuged at
31,000xg for 8 min at 4 °C in a Sorvall WX Ultra90
(70.I TI rotor).
The contents of the resulting fractions have been char-
acterized previously [6, 31]. The resulting purified frac-
tions were collected and protein was extracted in RIPA
buffer for western blotting. Denatured protein samples
(15 μg) were electrophoresed as described above. Mem-
branes were probed with C9ORF72 antibody, along with
synaptic markers: synaptophysin (1:5000, Millipore),
PSD-95 (1:1000, Abcam), GAD67 (1:2500, Millipore);
and GFAP (1:1000, NeuroMAB) as a marker of glia.
RNA isolation and RT-PCR analysis
Total RNA from combined cerebral cortex and hippocam-
pus tissue at the time-points P1, P7 and P56 (n = 4 mice
per time point) was isolated using the RNeasy Mini Kit
(Qiagen), according to the manufacturer’s instructions
and complementary DNA (cDNA) was synthesized from
DNase-treated RNA (1 μg) as described previously [8].
To semi-quantitatively analyse C9orf72 gene expres-
sion, quantitative PCR (qPCR) analysis was conducted as
previously described [9]. Before relative quantification,
C9orf72 gene was subjected to a serial dilution assay to
determine the optimum detection range of Ct values,
with a Ct threshold of 35 for undetectable mRNA levels
of expression. Relative quantitation of C9orf72 mRNA
isoforms per time point was performed using 25 ng of
reverse-transcribed total RNA, 20 pmol/ml of both sense
and antisense primers and the SYBR Green PCR master
mix (Applied Biosystems) in a final reaction volume of
10 μl. The reactions were run on an LightCycler® 480 Sys-
tem (Roche) according to the manufacturer’s instructions.
Table 1 List of qPCR primers
Gene name Forward primer Reverse primer Accession number
C9orf72 isoform 1 5’- CCCACCATCTCCTGCTGTTG-3’ 5’-GTAAGCAAAGGTAGCCGCCA-3’ NM_001081343.1
C9orf72 isoform 2 5’- TGGAAGATCAGGGTCAGAGT-3’ 5’- GCAAGCAGCTCCATTACAGG-3’ XM_006538294.1
C9orf72 isoform 3 5’-CTTTCCTTGCACAGTTCCTCC-3’ 5’- TCATCCTCGATGTACTTGATTAGTG-3’ XM_006538292.2
Primers used for qPCR analysis of the 3 C9orf72 isoforms including primer sequence (forward and reverse sequence respectively) and GenBank accession number
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To standardize the amount of sample cDNA added to
the reaction, amplification of endogenous control β-
Actin (primer sequence obtained from Gonzalez-
Fernandez and colleagues [12]) were included in a sep-
arate well as a real-time reporter. Primer efficiency was
calculated (Additional file 1: Figure S1a), and at the
end of each run, melting curve profiles were performed to
confirm amplification of specific transcripts (Additional
file 1: Figure S1b). Relative quantification for each gene
was performed by the ∆∆Ct method [20].
All primers were designed using NCBI/Primer-
BLAST software (Table 1). Primers were designed to
amplify the different isoforms of the C9orf72 mouse
ortholog (3111004O21Rik). As C9orf72 isoforms 2 and
3 are contained within isoform 1, fold change in the
mRNA expression of isoform 2 and 3 were calculated
as the increment with respect to the expression levels
of isoform 1.
Cell culture
Primary dissociated cortical cultures were prepared as
previously described [14] using standard culture tech-
niques with slight modifications. Briefly, neocortical tis-
sue was harvested from E15.5 C57BL/6 mice and
enzymatically dissociated in 0.0125 % trypsin for 4 min,
prior to plating. Cells were plated onto poly L-lysine
(Sigma Aldrich) coated 12 mm coverslips in 24 well plates
at a density of 30,000 viable cells per coverslip. Cells were
grown in an initial plating media consisting of Neuroba-
sal™ medium (Gibco), 2 % B27 supplement, 10 % fetal calf
serum (Gibco), 0.5 mM glutamine, 25 mM glutamate and
1 % antibiotic/antimycotic (Gibco). Medium was replaced
on the following day with subsequent growth media con-
sisting of initial media without the fetal calf serum and
glutamate, and half the media was replenished weekly with
fresh subsequent growth medium. Cultures were grown at
37 °C and 5 % CO2. Neurons were fixed with 4 % para-
formaldehyde (Sigma Aldrich) at 1, 3, 7, 14 and 21 days
in vitro (DIV) (n > 5 cultures per time-point).
Immunofluorescence
Cultured cells and brain sections were washed 3x10 mi-
nutes in 0.01 M PBS followed by serum-free protein
block (Dako) for 15 min at room temperature (RT). Im-
munofluorescence labeling was carried out for both
cultured cells and brain tissue following standard pro-
cedures using antibodies against C9ORF72 (as above),
β-III Tubulin (1:5000, Promega) and MAP2 (1:1000,
Millipore) diluted in PBS with 0.6 % Triton-X-100 and
incubated at RT overnight. Samples were incubated in
secondary antibodies (AlexaFluor, Invitrogen Probes) for
2 h at RT, followed by incubation with the nuclear stain
DAPI (5 μg/ml; Molecular Probes®, Life Technologies), for
5 min at RT. Immunoreactivity was visualized and
captured using a Leica (Germany) DM BL2 upright fluor-
escence microscope. For the purpose of illustration, im-
ages were then adjusted for brightness and contrast using
Adobe Photoshop CS6 (v 13).
Specificity of immunoreactivity was confirmed by two
methods. Both brain sections and cultured cells were ex-
amined for non-specific labeling after processing without
primary antibody. Additionally, tissue from P56 brain
and seven DIV cultures were incubated with C9ORF72
antibody combined with seven times excess of C9ORF72
peptide (sc-138763 P; Santa Cruz).
Statistical analyses
All statistical analysis was performed using GraphPad
Prism software (version 6.0) and p-values with p < 0.05
(CI 95 %) considered significant. Values were reported as
the mean ± standard error (SEM). Data from real time
PCR studies were compared using a one-way ANOVA
followed by a Tukey post-hoc and t-tests for a point-to-
point comparison. Data from western blots were com-
pared using a two-way ANOVA followed by Tukey or
Sidak post-hoc comparisons.
Results
Cellular pattern of C9ORF72 protein changes over
development of mouse cortex
This study utilized the commercially available anti-
human C9ORF72 antibody raised against amino acid
residues 165 to 215 of C9ORF72 protein, which is con-
tained within the sequence of all three mouse C9ORF72
isoforms. We have previously shown a decrease in label-
ing in a western blot with the antibody following treat-
ment with C9ORF72 short interfering RNA (siRNA) [7].
To further characterize the specificity of immunolabel-
ing, the C9ORF72 antibody was preadsorbed with re-
combinant peptide. Immunolabeling of tissue sections
from P56 mice (Additional file 2: Figure S2a) and cul-
tured cortical neurons at 7 DIV (Additional file 2: Figure
S2b) with preadsorbed C9ORF72 demonstrated that,
relative to non-adsorbed antibody, there was a large re-
duction in immunolabeling (Additional file 2: Figure
S2).
We next determined the expression or localization of
C9ORF72 over a developmental time course from E18
to P56 in mice, which covers periods of neurite out-
growth and synapse development [24, 36]. To determine
how C9ORF72 localization changes over development,
40 μm coronal tissue sections from mice at ages E18, P1,
P14, P28 and P56 were immunolabeled with C9ORF72
antibody along with the neuronal somatodendritic
marker, MAP2. At both E18 (data not shown) and P1,
there was strong labeling for C9ORF72 in discrete
puncta throughout the neuropil (Fig. 2a) but little somal
immunoreactivity was present. At P7, there was distinct
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somal and nuclear expression, which was both diffuse
and punctate in many MAP2-immunoreactive cells
throughout the cortex and hippocampus (Fig. 2b), con-
firming the presence of C9ORF72 in neurons. At P14,
P28 and P56, cytoplasmic labeling continued with appar-
ent lower expression in nuclei (Fig. 2c). Punctate labeling
was less distinct than at P1 and P7 (Fig. 2a and b).
Temporal expression of C9ORF72 isoforms over
development
We evaluated the temporal mRNA expression pattern of
C9orf72 isoforms (C9orf72- 1, 2 and 3; Fig. 1). As shown
in Fig. 3a, the mRNA encoding for all C9orf72 isoforms
were detected in combined cerebral cortex and hippo-
campus tissue at all time-points P1, P7 and P56. Isoform
1 was significantly (p < 0.05) higher at P1 compared to
P7 and P56 (Fig. 3a) and, similarly, the expression of iso-
form 2 was significantly (p < 0.05) higher at P56 relative
to the other time points tested (Fig. 3a). There were no
changes in the mRNA expression levels of isoform 3
over development (Fig. 3a). Next, by western blot ana-
lysis, we evaluated the temporal protein expression of
C9ORF72 protein-coding regions (481, 420 and 317
amino acids), which correspond to predicted protein size
isoforms of approximately 55, 50 and 35 kDa. Western
blots of combined cerebral cortex and hippocampus tis-
sue demonstrated that the Santa Cruz C9ORF72 anti-
body labeled the three predicted protein isoforms at 55,
50 and 35 kDa at all the time points (Fig. 3b). Moreover,
we also detected additional bands at 110 kDa. The iden-
tity of this band remains unknown.
Subcellular localization of C9ORF72 over development
To further investigate the differential nuclear and cyto-
plasmic localization of C9ORF72 over development in
vivo, nuclear and cytoplasmic protein extractions were
performed at E18, P1, P7 and P56. Purity of the nuclear
Fig. 2 Localization of C9ORF72 during development in vivo. a At P1, C9ORF72 (red) had punctate localization throughout the neuropil (arrows).
b At P7, C9ORF72 labeling was present within nuclei (arrowheads) of neuronal cells (MAP2, green) and as strong puncta within cytoplasm and
neuropil (arrows). c At P56, C9ORF72 labeling was present in the neuropil as puncta (arrows) and was localized to the cytoplasm surrounding
nuclei (DAPI, arrowheads) Scale bar: 10 μm
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and cytoplasmic extractions was confirmed with HDAC
2 and GAPDH antibodies with HDAC2 being higher in
the nuclear samples and GAPDH being higher in the
cytoplasmic samples (Fig. 4a). As in non-fractionated
samples, western blot analysis of C9ORF72 showed pro-
tein bands at approximately 55, 50 and 35 kDa. The
55 kDa protein was significantly (p < 0.05) higher in the
nuclear fractions compared to cytoplasmic fractions
(Fig. 4b). Post hoc tests showed that at E18 and P1 there
was significantly (p < 0.05) more of the 55 kDa protein
in nuclear fractions compared to cytoplasmic fractions.
Post hoc tests also showed that within nuclear fractions,
there was significantly (p< 0.05) more 5 kDa protein at
E18 compared to P56. There were no significant differ-
ences in cytoplasmic expression of the 55 kDa protein
over the time course. There were also no differences in
localization of the 50 kDa protein over the time course
(Fig. 4b). The 35 kDa protein was significantly higher in
the cytoplasmic fractions compared to nuclear fractions
(p < 0.05) (Fig. 4b). Post hoc tests showed that, at E18
and P1, there was significantly (p < 0.05) more of the
55 kDa protein in cytoplasmic fractions compared to
nuclear. Post hoc tests also showed that within cytoplas-
mic fractions there was significantly (p < 0.05) more
35 kDa protein at E18, P1 and P7 compared to P56.
There were no significant differences in nuclear expres-
sion of the 35 kDa protein over the time course. These
results suggest that C9ORF72 protein isoforms were dif-
ferentially expressed in cellular compartments over
development.
C9ORF72 is present in synaptosome preparations
Our results showed that C9ORF72 has punctate
localization in the neuropil, however, it is unclear if it is
present in synapses. To address this, we performed sub-
cellular fractionation on P56 mouse brain tissue to iso-
late synaptosome fractions according to the methods of
Dunkley, Jarvie and Robinson [6]. The content of each
resulting fraction have been characterized previously
[6, 31]. F1 contains unidentified membranous material
[6], F2 contains predominantly re-sealed plasma mem-
branes from glial cells [31]. F3 and F4 contain purified
synaptosomes and these fractions were combined [6].
To confirm the purity of the fractions, western blotting
Fig. 3 Expression of C9ORF72 isoforms over development. a Relative expression of C9orf72 isoforms 1, 2 and 3 mRNA in combined cerebral
cortex and hippocampus of C57Bl/6 mice. Isoform 1 was significantly (p < 0.05) higher at P1 compared to P7 and P56 and isoform 2 was
significantly (p < 0.05) higher at P56 compared to P1 and P7. b Western blot of C9ORF72 expression in mouse tissue over development. Bands
corresponding to reported isoforms of C9ORF72 were present at 55, 50 and 35 kDa (b). Additional bands at 110 and 50 kDa were also present.
GAPDH was used as a loading control. Values represent mean ± standard error. *p < 0.05 P1 and P7 vs. P56
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was carried out with a range of antibodies. GFAP was used
as a glia marker and was most abundant in F2 (Fig. 5). As
expected, synaptophysin, PSD95 and GAD67 were most
abundant within the F3/F4 fraction (Fig. 5). Only the
55 kDa protein band of C9ORF72 was observed within
C9ORF72-positive fractions, and was most abundant
within F3/F4 fractions where other synaptic proteins were
found. It was also present at low levels in F2.
C9ORF72 is expressed in nuclei and neurites of cultured
cortical neurons
For a more detailed examination of the localization of
C9ORF72 in neuronal soma and neurites, immunocyto-
chemistry was performed in cultured cortical neurons
fixed at 1, 3 and 7 DIV (during neurite outgrowth) and
14 and 21 DIV (during synaptogenesis and maturity).
Neurons were labeled with C9ORF72 along with neur-
onal cytoskeletal markers βIII-tubulin and MAP2 and
the F-actin stain, phalloidin. At 1 and 3 DIV, C9ORF72
labeling was present in the cell soma, excluding the nu-
cleus, and throughout the neurites as demonstrated by
co-labeling with βIII-tubulin (Fig. 6a). C9ORF72 also ex-
tended into the actin cytoskeleton, including within
growth cones and filopodia extending from the soma
and down the length of neurites, as demonstrated by co-
labeling with phalloidin (Fig. 6b).
From 7 DIV, immunolabeling for C9ORF72 increased
in the soma and a large proportion of cells had high nu-
clear expression of the protein, accompanied by bright
puncta in the soma (data not shown). Similar cellular
localization was observed at 14 DIV with bright vesicular
labeled puncta more prominent in, but not restricted to,
neurons with nuclear expression of C9ORF72 (Fig. 6c). A
smaller proportion of neurons had more diffuse immunola-
beling which was present in less intensely stained puncta in
the cytoplasm and neurites (axons and dendrites, demon-
strated by MAP2 co-labeling) in cells with nuclear and
non-nuclear labeling. Immunolabeling of C9ORF72 was
similar at 21 DIV. These results show that C9ORF72 was
present throughout the microtubule cytoskeleton including
throughout the axon, soma and dendritic arbor as well as
within actin-rich structures such as growth cones and
filopodia.
Discussion and conclusions
In this study, we have examined the expression of
C9ORF72 by multiple biochemical and molecular bio-
logical analyses conducted both in vivo and in vitro.
Results from these investigations demonstrated that
C9ORF72 undergoes alterations in cellular expression
and localization throughout the time course analyzed,
which may reflect differential expression of isoforms
that are present in specific locations. Furthermore
C9ORF72 is found in synaptic-rich cellular fractions.
In order to gain some insight into the function of
C9ORF72 protein, we examined whether the expression
level was altered throughout development. Neuronal de-
velopment involves a number of different processes and
therefore alterations in the expression or localization of
proteins during development may indicate a role in
these processes. Our results suggest that there are alter-
ations in the cellular localization of C9ORF72 protein as
well as in the expression pattern of the isoforms over
Fig. 4 Expression of C9ORF72 in nuclear and cytoplasmic protein
fractions over development. a Representative western blot of C9ORF72
in nuclear and cytoplasmic fractions from E18, P1, P7, and P56 mouse
brain. HDAC2 and GAPDH were used to demonstrate nuclear and
cytoplasmic fractions respectively. C9ORF72 isoforms were present at
differing levels and in specific fractions throughout the time course.
b Relative quantitation of C9ORF72 isoform expression in nuclear and
cytoplasmic fractions over the time course. Overall, the 55 kDa protein
was significantly (p < 0.05) increased within nuclear fractions compared
to cytoplasmic fractions and specifically at E18 and P1 compared to
P56 (p < 0.05). Within nuclear fractions, the 55 kDa protein was
significantly (p < 0.05) increased at P1 compared to P56. There were no
significant differences in nuclear and cytoplasmic expression for the
50 kDa band. Overall, the 35 kDa band was significantly (p < 0.05)
increased within cytoplasmic fractions compared to nuclear fractions
and specifically at E18 compared to P56 (p< 0.05). Within cytoplasmic
fractions, the 35 kDa protein was significantly increased (p < 0.05) at
E18, P1 and P7 compared to P56. Values represent mean ± standard
error. *p < 0.05 nuclear vs. cytoplasmic at E18 and P1. + p < 0.05 E18
vs. P56 (nuclear for 55 kDa bad, cytoplasmic for 35 kDa band). # p < 0.05
P1 vs. P56 (nuclear for 55 kDa band, cytoplasmic for 35 kDa band)
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time. C9ORF72 was detected prenatally, consistent with
previous studies looking at the protein in mouse tissue
[15]. C9ORF72 was also observed in adult as well as in
embryonic and larval stages in zebrafish [2, 15]. A tran-
scription expression study of the mouse ortholog of
C9orf72 found that it was only detectable from P1 in the
CNS where it increased gradually until P60 [32]. Koppers
[15] suggested these differences could be explained by a
failure of the heterozygous LacZ reporter mice used in this
study to detect the low levels of gene expression present
prenatally.
C9ORF72 isoforms were differentially expressed be-
tween the nucleus and cytoplasm. Western blot analysis
of nuclear and cytoplasmic protein fractions showed that
the 55 kDa band was predominantly nuclear, the 35 kDa
band was predominantly cytoplasmic and the 50 kDa
band was expressed similarly in both fractions. The ex-
pression of mRNA for isoform 1 was higher at P1 than
in adult tissue corresponding with higher protein expres-
sion of isoform 1 at P1. The higher expression of isoform
1 during these developmental timepoints is consistent
with the strong immunohistochemical labeling of
C9ORF72 in mouse tissue in postnatal tissue and the
localization of C9ORF72 to nuclei at P7. At P56 there was
an increase in isoform 2 mRNA compared to P1 and P7.
However, this increase in mRNA content was not reflected
at the protein level, where isoform 2 protein was signifi-
cantly higher at early timepoints. These discrepancies may
be explained by differences in mechanisms involved in the
post-transcriptional regulation, or repression of translation
of isoform 2 mRNA in adulthood. A recent study by Xiao
and colleagues [37] found differential localization of
human C9ORF72 isoforms. The human short isoform
(approximately 25 kDa) was localized to the nuclear mem-
brane and the long isoform (approximately 55 kDa) was lo-
calized to cytoplasm with diffuse and punctate expression.
The identity of the 110 kDa band labeled by C9ORF72
is unknown. These bands have been observed in previ-
ous studies [25] and also in our western blots from pri-
mary cell culture (data not shown). As the characteristic
labeling of C9ORF72 was reduced following preadsorb-
tion, we speculate that there is a possibility that it could
be a dimer of the 55 kDa band resistant to the reducing
agents used in the western blot protocol. Further studies
are required to investigate these bands.
Throughout all time points in the current study,
C9ORF72 had a punctate pattern of immunolabeling,
which is consistent with other studies describing expres-
sion of this protein. In mice, synaptogenesis ranges from
the first to third weeks of postnatal life [24]. It is there-
fore plausible that, in the current study, the presence of
strongly labeled puncta during this time and reports of
diffuse cytoplasmic and punctate labeling from other
studies [3, 13, 26, 28, 37] suggest involvement of
C9ORF72 at the synapse. Only the 55 kDa form of
C9ORF72 was in synaptic-rich fractions in the synapto-
some preparations, perhaps indicating a specific role of
isoform 1 at synapses. This is also consistent with higher
expression of isoform 1 at early postnatal timepoints.
It is unknown why specific populations of cells are vul-
nerable to degeneration in diseases such as FTLD and
ALS. In this study, we showed C9ORF72 expression in
neurites and the neuropil. Previous studies have found
C9ORF72 within dystrophic neurites within plaques of
AD brains and within swollen neurites in the hippocam-
pus of both AD and non-AD brains [26], suggesting that
Fig. 5 Expression of C9ORF72 in synaptosome preparations from mouse brains. Figure shows representative western blots with results from 2
animals for each marker (indicated by 1 and 2 on figure). The 55 kDa isoform of C9ORF72 was present in the combined F3/F4 fractions which
contain synaptosomes. C9ORF72 expression was low in fraction F1, containing membranes, and F2 containing myelin, membranes and glia.
Unfractionated brain at P56 was also included. Purity of fractions was determined by labeling with GFAP (F2) and synaptic markers,
synaptophysin, PSD-95 and GAD67 (F3/F4)
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it is present in neurites. Additionally, the protein is ob-
served within swollen axons in the spinal cord ventral
gray matter [30]. Motor deficits and abnormal motor
neuron axons have been described following knockdown
of C9orf72 in zebra-fish [2], although more recent stud-
ies in mice have found no effect of complete lack of
C9ORF72 on motor function [15]. Our results demon-
strate the presence of C9ORF72 as puncta throughout
the actin cytoskeleton, and the presence of the protein
in synaptic-rich fractions. There are a number of vesicles
known to be present in axons including those supplying
the synapse, those involved in membrane trafficking and
axon outgrowth, and vesicles containing RNA and sig-
naling vesicles [21]. Membrane trafficking is critical for
cell survival and defects in transport to the membrane are
common hallmarks of neurodegenerative diseases, includ-
ing FTLD [35]. In a similar line, we recently showed that
C9ORF72 is involved in endosomal trafficking via Rab-
dependent pathways [7]. When C9ORF72 expression was
knocked down, endocytosis and autophagy-related traf-
ficking were inhibited. Human C9ORF72 isoforms have
also been shown to interact with nuclear pore complex
components, suggesting a possible role in nucleocytoplas-
mic shuttling [37]. These studies, in combination with our
current results related to synaptosome preparations and
differential nuclear and cytoplasmic localization, may sug-
gest that C9ORF72 plays a role in trafficking and raises
the possibility that failure in such neuronal cellular trans-
port during ageing may be linked to neurodegeneration.
Like many other genetic causes of neurodegenerative
disorders, the repeat expansion found in the C9ORF72
gene is present at birth but does not cause disease until
later in life. If haploinsufficiency of the encoded protein,
C9ORF72, does contribute to disease then this suggests
Fig. 6 Localization of C9ORF72 over development in vitro. Immunofluorescence was carried out on primary cultured cortical neurons. a At 1 DIV,
C9ORF72 (red) labeling was present within cell bodies, excluding nuclei (DAPI, blue) and punctate localization was present in neurites and growth
cones (β-III tubulin, green). b Co-staining with phalloidin (green) at 3 DIV confirmed localization of C9ORF72 (red) labeling to growth cones and to
filopodia (arrows). c At 14 DIV, C9ORF72 (red) was localized to nuclei of a population of neurons (arrows) but was less intensely expressed in nuclei
of other neurons (arrowhead). Neurons indicated by MAP2 (green). Neurons with nuclear immunolabeling for C9ORF72 frequently had punctate
somal localization of this protein. Inset (c) shows C9ORF72 labeling in nuclei and in puncta in surrounding cytoplasm. Scale bar: A, 2.5 μm; B,
C, 10 μm
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that it is due to vulnerability caused by altered isoform
expression in ageing.
This study has been the first to give a detailed descrip-
tion of the expression of C9ORF72 in mice, including ex-
pression over development, and lays a foundation for
future studies examining the effects of altering C9ORF72
expression in rodent models, potentially providing insights
into how abnormal repeat expansion may be associated
with FTLD and ALS. The presence of C9ORF72 within
vesicular puncta also warrants further study. Identification
of these vesicles could be key to determining the role of
this protein within cells.
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Additional files
Additional file 1: Figure S1. Primer efficiency and melting curve
analysis. (a). The efficiency of the primer pairs for C9orf72 isoforms was
assessed by plotting the cycle threshold value (Ct) at each concentration
against the logarithm of the fold dilution of the sample. The slope of a
linear-regression trendline is indicative of primer efficiency. Primer efficiencies
were 1.86 for isoform 1 (a i), 1.94 for isoform 2 (a ii) and 1.97 for isoform
3 (a iii). (b) Representative melting curve analysis showing the specific
amplification of the C9orf72 isoform products. Melting peaks (plotted as
the negative derivative of fluorescence) revealed peaks at three different
temperatures which indicate the identity of amplified C9orf72 isoforms.
(TIFF 24326 kb)
Additional file 2: Figure S2. Preadsorbtion with C9ORF72 peptide. (a)
P56 tissue from C57/Bl6 mice or (b) 7 DIV cortical neurons cultured from
C57/Bl6 mice were labeled with C9ORF72 (sc-138763) antibody or
C9ORF72 (sc-138763) antibody preadsorbed with the C9ORF72 peptide
(sc-138763 P). Labeling was decreased in both preadsorbed samples.
Labeling of puncta (arrows) and nuclei (arrowheads) with C9ORF72
antibody was present in brain tissue and cultured neurons (panel 1, a, b).
In contrast, when labeled with preadsorbed C9ORF72 peptide, there was
no nuclei labeling and non-specific puncta present in brain samples
(arrows, panel 2, a), and in cultured samples there was faint non-specific
nuclear labeling and an absence of puncta (arrowhead, panel 2, b). Scale
bar: a, 12 μm; b, 10 μm. (TIFF 999 kb)
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